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Summary
Rats homozygous for a mutation in the agu gene display reduced ability to initiate 
movement and slow movement. The phenotype of these rats is of particular interest as 
they display the closest available non-human phenotype to Parkinson's Disease and other 
neurodegenerative diseases. The rats show rigidity of the hindlimbs resulting in a 
staggering gait and a tendency to fall over every few steps. The major characteristic of the 
disorder, which is progressive, is difficulty in initiating movement. The mutation leading 
to this phenotype is a recessive mutation in single autosomal gene, and displays full 
penetrance in backcross progeny. AS/AGU rats have a 30-35% reduction of neostriatal 
dopamine when compared to control AS rats. These animals respond well to L-Dopa 
treatment. This thesis presents progress towards the positional cloning of the agu gene. 
Since few informative markers were available in the region where agu is found to map in 
rat, new microsatellite markers were isolated from PI clones identified to contain rat genes 
from the interval or from regions of synteny in mouse and man. These novel microsatellite 
markers were used to refine the genetic interval containing agu. The 3' UTR of rat genes 
mapped to the interval containing the agu locus were also investigated for SSCPs. 
Microsatellite markers from the region of synteny in mouse were also investigated for 
strain differences between the rat strains used, to allow mapping. Novel markers 
identified from the PI clones were used in conjunction with published markers to position 
the agu gene within a region of approximately 10 cM. A marker was identified which 
maps less than 0.1 cM from the agu locus. This marker was identified within the 3’ UTR 
of a rat gene and was used in a screen of rat genomic PI and YAC libraries. Another 
probe designed to the 5’ UTR of this gene was also used in a screen of a rat PAC library. 
One PI clone, seven YAC and three PAC clones were isolated in this initial screen using 
the closest marker. The cloned end sequences of one of these PACs were then used in a 
further screen of the PAC library, resulting in seven PAC clones. All of these clones have 
been used to establish a genomic contig spanning at least 750 kb, thought to contain the 
agu gene.
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Chapter 1 
Introduction
1.1 Introduction
In this thesis I present work that has resulted in the definition and cloning of a region of 
the rat genome less than 1 Mb in length, that is very likely to contain the agu gene. Rats 
homozygous for a mutation in this gene have an interesting phenotype, with similarities to 
human Parkinson’s disease (PD). These rats display reduced ability to initiate movement 
and slow movement. They also display rigidity of the hindlimbs resulting in a staggering 
gait and a tendency to fall over every few steps. This interesting mutation could prove 
useful in the investigation of human Parkinson’s disease and other neurodegenerative 
disorders and the identification of the mutation is vital.
1.2 Parkinson's disease
Parkinson’s disease (PD) was first described in 1817 by James Parkinson in An Essay on 
the Shaking Palsy and to date the primary cause or causes of this debilitating disorder 
remains an enigma. PD affects one in 500 of the population in general and while the 
incidence is lower than that of other neurodegenerative diseases, such as Alzheimer's 
disease, it remains an illness of socio-economic importance (Jenner, 1992). In the UK, 
PD afflicts 100,000 individuals; it usually strikes in mid- to late life and has a duration 
which varies from 5-40 years. Parkinson's disease is characterised by three classical 
symptoms; muscle rigidity, movement disorders (akinesia and bradykinesia) and gait 
abnormality. The primary pathology of the disorder is the degeneration of pigmented 
dopamine-containing cells within the zona compacta of the substantia nigra, although many 
other neuronal systems in the brain are also affected. Cell death is accompanied by the 
appearance of eosinophilic inclusions termed "Lewy bodies". While dopamine 
replacement therapy with L-Dopa or dopamine agonist drugs is initially effective in 
relieving the symptoms of PD in the early stages of the illness, there is, at present, no 
means of preventing the progression of pathology There is no cure for PD and the 
underlying cause of neuronal death remains unknown.
1.2.1 Pathology of the nervous system in PD.
All cases of PD show moderately severe cell loss in the substantia nigra pars compacta 
associated with Lewy bodies in a portion of the remaining cells. Lewy bodies are 
intracellular cytoplasmic inclusions which are mostly eosinophilic. Lewy bodies always 
signify neuronal degeneration, and nerve cell loss in PD does not occur without them 
being found in some of the degenerating nerve cells. They appear at an early stage of the 
process, and because of their distinctive appearance, they can be readily found before 
significant cell loss is apparent (Gibb, 1992). The classical appearance of a Lewy body is
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of one or several spherical bodies with a dense core and a peripheral halo in the cytoplasm 
of a pigmented nerve cell (Fomo, 1996).
Lewy bodies are not unique to PD, but are seen in a wide variety of other 
neurodegenerative disorders e.g. Alzheimer's disease. This suggests that Lewy bodies 
might simply be a final common pathway in the neurodegenerative process. They are so 
characteristic of PD, however, that they may provide an insight into the pathogenesis of 
the disease.
The tight link between Lewy bodies and nerve cell degeneration means that their 
distribution in the nervous system maps out the territories involved in the degeneration. In 
addition to the substantia nigra, these sites are the locus coeruleus, ventral tegmental area, 
nucleus basalis of Meynert, raphe nuclei, thalamus, cerebral cortex, and the entire 
autonomic nervous system. All of these areas appear to be affected shortly after the onset 
of the disease process, and spread of Lewy bodies does not occur in new areas (Gibb, 
1992). As a rule, Lewy bodies are located in the cytoplasm of neurons in the substantia 
nigra, the locus coeruleus, the raphe nuclei and the cerebral cortex, and as elongated forms 
in nerve cell processes in the nucleus basalis of Meynert, the hypothalamic dorsal motor 
nucleus of the vagus and autonomic ganglia, but both forms can be found in any of these 
anatomical areas (Fomo, 1996).
In most cases of PD, the inclusions are numerous, easy to find and are usually present in 
one unilateral 7-pm section cut horizontally through the midbrain. The most important 
element which all Lewy bodies have in common is the filamentous cytoskeletal 
component, now considered to consist of neurofilaments which have undergone a number 
of alterations, including phosphorylation, ubiquitination, proteolysis, and cross-linking 
(Pollanen et.al., 1992). The exact mechanism leading to the formation of the Lewy body 
is unknown, but it is thought that they are formed in three over-lapping steps involving 
self-assembly and aggregation of protein, followed by posttranslational phosphorylation 
and, last, ubiquitination. Proteolysis is felt to be the last step. They are not known to 
contain abnormal proteins, as in the paired-helical filament of the Alzheimer tangle, and 
consequently they may result simply from the structural degradation of abnormal 
accumulations of the cytoskeleton. These accumulations could reflect deranged energy- 
dependent processes responsible for the normal transport of the cytoskeleton within the 
neurone. The Lewy body also contains neuromelanin, lipofuscin, mitochondria, dense 
core vesicles, and other organelles as well as electron dense granular or amorphous 
material, as observed by electron microscopy (EM) (Fomo, 1996).
A second type of nerve cell inclusion seen in PD is the pale body. It often lies close by or 
contiguous with the Lewy body and is restricted to the substantia nigra and locus
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coeruleus. It has a featureless ultrastructure comprising a mixed loose accumulation of 
granules, vesicles, and sparse filaments.
In Parkinson's disease (PD) neuronal loss within the substantia nigra shows a 
characteristic pattern with preferential degeneration of lightly melanised cells forming a 
ventral tier of the pars compacta and relative preservation of heavily melanised cells 
forming a dorsal tier, a marked difference to that seen in normal ageing (Gibb, 1992). The 
anatomical and functional significance of this division of the pars compacta is unknown.
1.2.2 Dopamine and Parkinson's Disease.
Parkinson's disease (PD) is an age-related disease, the primary cause of which is the 
degeneration of dopamine producing neurons within the substantia nigra pars compacta 
(SNpc) of the basal ganglia, giving rise to the characteristic disruption of normal 
movement. Since the discovery in 1960 that the primary neurotransmitter loss in PD was 
dopamine and the region of the brain most affected the substantia nigra, much research has 
been focused on the production and metabolism of dopamine and it's role in the function 
of the normal brain.
Synthesis o f dopamine.
Tyrosine is usually considered to be the starting point in the biosynthesis of dopamine and 
this amino acid is abundant in dietary proteins. Blood-borne tyrosine is taken up into the 
brain by a low-affinity amino acid transport system and subsequently from brain 
extracellular fluid into dopaminergic neurons by high- and low-affinity amino acid 
transporters. Once tyrosine has entered the neuron, it's conversion to 
dihydroxyphenylalanine (L-Dopa), driven by the cytosolic enzyme tyrosine hydroxylase, 
is normally the rate-limiting step in dopamine biosynthesis (Figure 1.1).
Tyrosine availability does not influence the rate of tyrosine hydroxylation in vivo under 
normal conditions (Elsworth and Roth, 1997). Short-term activation of tyrosine 
hydroxylase involves feedback inhibition, phosphorylation of the regulatory domain by 
protein kinases and possibly also alternate splicing. For example, in man the single 
tyrosine hydroxylase gene generates four different mRNA species through alternative 
splicing events, TH-1 and TH-2 being the predominant forms in the locus coeruleus and 
the substantia nigra. An additional residue in TH-2 for phosphorylation, generated 
through alternative splicing, leads to an increase in enzyme activity by giving rise to an 
increase in its affinity for the cofactor (Le Bourdelles et.al., 1991). The activated form of 
tyrosine hydroxylase is thought to have a lower Km for its cofactor, and a higher Ki for 
dopamine, which effectively reduces end-product inhibition. In primates, rodents and
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Drosophila, multiple tyrosine hydroxylase mRNAs are produced through alternative 
mRNA splicing from a single primary transcript, and it has been speculated that different 
isoforms of TH may occur in different brain regions or be expressed differentially during 
development (Laniece et.al, 1996).
OH
CH 2— CH —  NH2
L-Tvrosine
COOH
1TH(oxygen + tetrahydrobiopterin)
CH 2—  CH —  NH2 
COOH
L-Dopa
HO
AADC
I (pyridoxal 
f  phosphate)
C H 2— CH 2— NH2 Dopamine
Figure 1.1 The production of dopamine from tyrosine within the dopaminergic neuron. 
Adapted from Elsworth and Roth, 1997. TH=tyrosine hydroxylase, AADC=dopa 
decarboxylase. The enzyme cofactors are shown in brackets below each enzyme.
Aromatic amino acid decarboxylase (AADC, dopa decarboxylase) is the enzyme 
responsible for the cytosolic conversion of L-Dopa to dopamine. This enzyme so avidly 
decarboxylates L-Dopa that the levels of this amino acid in brain are very low under 
normal conditions (Elsworth and Roth, 1997).
Storage
In dopaminergic neurons, dopamine is transported from the cytoplasm into specialised 
storage vesicles. This is carried out by the vesicular monoamine transporter (VMAT) , 
which differs from the plasma membrane transporter (DAT) located on the outer membrane 
of the dopamine neuron and transports dopamine in an ATP-dependent and H+-driven 
manner. It appears that many of these vesicles are transported empty down the axon, 
gradually filling with neurotransmitter on their journey, as demonstrated by nerve ligature 
(Bradford, 1986). These particles accumulate on the proximal side of the ligature.
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Release
Upon arrival of an action potential, a change in membrane protein conformation allows the 
influx of calcium ions, which is a key part of the stimulus responsible for the fusion of 
vesicles with the neuronal membrane. By the process of exocytosis, the vesicles discharge 
their soluble contents into the synapse. Exocytosis is a carefully controlled and 
complicated process. The exocytosis/release of dopamine, or indeed any neurotransmitter, 
involves at least four key steps (Sudhof, 1995) (Figure 1.2):
1) Docking. Synaptic vesicles (S V) that are filled with neurotransmitter are predocked at a 
specialised area of the presynaptic membrane called the active zone. Docking is defined as 
the initial contact between the SV and the presynaptic membrane and occurs only at the 
active zone opposite to the synaptic cleft, indicating a targeting process.
2) Priming. After docking, SVs go through a maturation process that makes them 
competent for fast Ca2+-triggered membrane fusion. Such a priming step is suggested by 
three observations: first, the speed of Ca2+-triggered SV exocytosis occurs too fast for a 
complex multistep reaction; second, most of the docked SVs cannot be triggered to fuse by 
Ca2+ immediately and therefore appear to be not yet competent to fuse (Rastaad et.al., 
1992; Hessier et.al., 1993 and Rosenmund et.al., 1993); and third, during extensive 
repetitive stimulation, SV exocytosis slows down before the number of docked SVs 
declines. These results suggest that docking is not rate limiting and that SVs are not 
immediately competent to fuse after docking and need to go through a rate-limiting priming 
step. Priming may initiate exocytosis by executing a partial fusion process. At this point 
SVs arrest, awaiting a Ca2+ signal.
3) Fusion/Exocytosis. Primed SVs are stimulated for rapid fusion/exocytosis by a Ca2+ 
spike during an action potential.
4) Endocytosis. Empty SV membranes are rapidly internalised, probably by way of 
clathrin-coated pits which become coated vesicles.
As anticipated for a highly regulated, multistep pathway, the concerted action of a large 
number of gene products is required for neurosecretion. Mutated forms of these proteins 
are being studied in model organisms such as Drosophila, C. elegans and mouse, all of 
which allow the thorough investigation of the mutant phenotype. Some examples of these 
proteins are given in Table 1.1. A short example is then given of some of these proteins 
and the evidence for their action.
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Figure 1.2 The synaptic vesicle cycle in the presynaptic nerve terminal.
Adapted from (Sudhof, 1995). The four stages of vesicle exocytosis are 
described in Section 1.1.3 - dopamine release.
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Table 1.1 Examples of proteins identified to be involved in synaptic vesicle release. The 
proteins are grouped by the stage at which they are thought to act in exocytosis.
Results from biochemical and genetic studies allows formulation of a model which 
although, incomplete, may approximate the molecular events in synaptic vesicle 
exocytosis. According to this model, SVs dock and then proceed through a partial fusion 
reaction, priming, to make them competent for the final Ca2+-triggered step. During 
priming, a complex called the core complex is assembled by three abundant synaptic 
proteins, two from the plasma membrane (syntaxin and SNAP-25) and one from the SV 
(synaptobrevin). The core complex forms the anchor for a cascade of protein-protein 
interactions required for exocytosis to occur.
Syntaxin and SNAP-25 bind tightly to each other and form a high-affinity binding site for 
synaptobrevin. Under steady-state conditions, most syntaxin, synaptobrevin and SNAP- 
25 in the nerve terminal are not assembled together. Synaptobrevin is largely bound to 
synaptophysin, another SV protein. At least some of the syntaxin is bound to munc 18 
over the entire plasma membrane. Syntaxin binding protein 2 (Sxtb2) is the mammalian 
homologue of the proteins encoded by the C.elegans unc-18 and the Drosophila rop genes, 
mutations in which lead to severe synaptic defects, suggesting an essential function in SV 
exocytosis. One of the functions of the Sxtb2/syntaxin and the 
synaptophysin/synaptobrevin interactions may be to inhibit the formation of the synaptic 
core complex which would otherwise assemble spontaneously and indiscriminately outside 
the active zone (Siidhof, 1995). Binding of Sxtb2 to syntaxin inhibits its interaction with 
SNAP-25, and the interaction of synaptophysin with synaptobrevin is incompatible with 
the binding of synaptobrevin to the SNAP-25/syntaxin complex. This suggests that 
synaptophysin and Sxtb2 have to dissociate from synaptobrevin and syntaxin, 
respectively, before the core complex can assemble.
After SV docking, Sxtb2 probably dissociates from syntaxin, and synaptophysin from 
synaptobrevin, this allows assembly of the synaptic core complex. Sxtb2 may collaborate
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with rab3 and/or other rab proteins to ensure that the synaptic core complex is assembled 
only at the active zone (Siidhof, 1995). Once the trimeric core complex has assembled, it 
serves as a receptor for SNAP and NSF. NSF is a V-ethylmaleimide-sensitive ATPase 
with a universal function in membrane fusion, a-, p-, and y-SNAPs are soluble NSF- 
attachment proteins that are not related to SNAP-25. Synaptobrevin, syntaxin and SNAP- 
25 were affinity purified on immobilised a-SNAP, but individually bind only weakly to a- 
SNAP. Only their assembly into the core complex results in the formation of a high- 
affinity binding site for a-SNAP which in turn creates a receptor site for NSF. As a 
trimer, NSF then probably multermerises core complexes and disrupts them under ATP 
hydrolysis. Thus an ordered sequence of protein-protein interactions leads to the 
assembly of a multimeric complex that is then disrupted by the enzymatic activity of NSF 
(Siidhof, 1995).
Synaptotagmins
SVs are docked close to Ca2+ channels at the active zone. This arrangement facilitates 
rapid exocytosis by high local concentrations of Ca2+ during an action potential. 
However, signal transduction leading to exocytosis is inefficient. To trigger the final stage 
of the fusion reaction, a Ca2+ sensor is required at the site of exocytosis. This sensor 
must bind Ca2+ co-operatively and undergo a Ca2+-dependent conformational change. If 
this Ca2+ sensor could be identified, it would give the first mechanistic clue to the 
regulation of the fusion reaction. Five lines of evidence suggest that synaptotagmins 
function as such sensors in the final fusion step. 1) Biochemically, synaptotagmins are 
SV proteins that bind Ca2+ co-operatively and undergo a Ca2+-dependant conformational 
change. 2) In synaptotagmin-I knockout mice, Ca2+-dependent neurotransmitter release is 
severely impaired. The fast, synchronous component of Ca2+-triggered release is 
inhibited, but the slow, asynchronous component is unimpaired. 3) In the synaptotagmin- 
I knockouts, release can still be triggered normally by agents that act by Ca2+-independent 
mechanisms, such as hypertonic sucrose or a-latrotoxin. However, in nerve terminals 
poisoned by tetanus and botulinum A toxins, the response to hypertonic sucrose is 
blocked. This suggests that synaptotagmin I acts after the core complex that is inhibited by 
these toxins. 4) In squid nerve terminals injected with synaptotagmin peptides, release is 
inhibited and SVs accumulate at the active zone. This presumably results from competition 
by the peptides for synaptotagmin effectors. 5) Synaptotagmin mutants in Drosophila 
show a severe but incomplete block of neurotransmission with an altered Ca2+ dependence 
in some mutants. Similar changes are also observed with manipulations of synaptic 
transmission that are unrelated to the Ca2+ sensor, making an interpretation of such 
changes difficult.
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Re-uptake
Dopaminergic terminals possess Na+/Cl"-dependent transporter molecules (the dopamine 
transporter: DAT) that are critical in terminating transmitter action and in maintaining 
transmitter homeostasis (Lesch et.al., 1997). Under normal conditions, the transporter 
recycles dopamine that has been released into the synaptic cleft by actively pumping 
extracellular dopamine back into the nerve terminal. After its retrieval dopamine is either 
repackaged into synaptic vesicles or metabolised by mitochondria-associated monoamine 
oxidase (MAO) (Lesch et.al., 1997).
Vesicular and plasma membrane uptake of dopamine both play important roles in the 
neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), a drug that 
produces parkinsonism by inducing damage to dopaminergic nigrostriatal neurones 
(Langston et.al, 1983). While the vesicular uptake mechanism (through VMAT) can 
protect the cell from MPTP-induced toxicity, by sequestering the toxic species, MPP+, in 
vesicles, uptake of MPP+ by the plasma membrane uptake mechanism (through DAT) is 
actually a necessary step in the toxicity of MPTP. It is the relative expression of these 
transporters which make substantia nigra neurons more susceptible to MPTP toxicity.
Metabolism
The main pathways involved in dopamine metabolism are shown in Figure 1.3. As the 
relative abundance and activity of the enzymes vary according to the cell type, brain 
region, and species examined, these factors determine the relative concentration of a 
particular metabolite present in a given situation. The principal locations of these 
metabolising enzymes are given in Table 1.2 and it appears that it is possible for 3,4- 
dihydroxyphenylacetic acid (DOPAC) to be formed either intraneuronally or 
extraneuronally with respect to the dopamine terminal, whereas, because of the location of 
catechol-O-methyltransferase (COMT), homovanillic acid (HVA) is formed 
extraneuronally. In brain, dopamine is metabolised mainly to acidic (DOPAC, HVA) 
metabolites, with less formation of alcoholic metabolites (DOPET, MOPET). The major 
end product of dopamine metabolism in primate brain is unconjugated homovanillic acid 
(HVA), whereas in rat brain it is DOPAC, and a significant proportion of DOPAC in the 
rat brain is sulfate-conjugated. DOPAC sulfate is not a substrate for monoamine oxidase 
(MAO) or COMT, so that, once formed, it cannot be further metabolised by these enzymes 
(Elsworth and Roth, 1997).
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Enzyme Subtype Cellular location Subcellular
location
MAO A Dopamine and norepinephrine 
neurons
Mitochondria
MAO B Glia, serotonin neurons Mitochondria
COMT high Km Glia Soluble
COMT low Km Postsynaptic to dopamine neuron Membrane bound
PST M Postsynaptic to dopamine neuron Cytosolic
Table 1.2 Location of the major dopamine metabolising enzymes in the striatum. For 
abbreviations see text. Table taken from Elsworth and Roth, 1997.
Autoreceptors
A receptor which is sensitive to the transmitter that is secreted from the neuron on which 
the receptor is located is referred to as an autoreceptor. Activation of autoreceptors by 
released dopamine is thought to be one of the principal mechanisms responsible for 
regulation of dopaminergic neuronal function. Autoreceptors are present on the nerve 
terminals of dopamine neurons. Stimulation of dopamine autoreceptors in the nerve 
terminals results in an inhibition of dopamine synthesis and/or release (release- and 
synthesis-regulating autoreceptors). Thus, nerve terminal autoreceptors work to exert 
feedback regulatory effects on dopaminergic transmission. In general, all dopamine 
autoreceptors can be classified as D2-like dopamine receptors. Dopamine autoreceptors are 
more sensitive to the effects of dopamine than postsynaptic dopamine receptors (Elsworth 
and Roth, 1997).
Postsynaptic Receptors
There are now known to be at least six different forms of the dopamine receptor. The Di 
class of dopamine receptor has been divided into Di and D5 receptor subtypes, and the D2 
class comprises D2Short and D2iong, D3 and D4 receptor subtypes. When activated, the Di- 
like receptor subtypes stimulate adenylate cyclase activity, whereas the D2-like receptor 
subtypes inhibit adenylate cyclase activity. The pharmacological profile and regional 
distribution in the brain of each subtype is different, with the exception of D2short and 
D2 long> which appear identical in these respects (Seeman and Vantol, 1994).
It is now established that Di and D2 dopamine receptors act synergistically in the 
expression of certain behaviours and in certain electrophysiological and biochemical 
models. It appears that striatal Di receptors are principally located on the striatonigral
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projecting neurones ("direct pathway"), while D2 receptors are mainly located on 
striatopallidal neurones ("indirect pathway").
1.2.3 The action of dopamine in the basal ganglia.
While there is heterogeneity of dopamine loss within the nigrostriatal dopamine system, 
overt parkinsonism does not present until approximately 80% of dopamine loss has 
occurred. The basal ganglia appear to be able to suffer this loss because there is normally 
a large reserve of nigrostriatal dopamine neurons, which may be linked to the natural age- 
related loss of these neurons and/or the apparent susceptibility of nigrostriatal dopamine 
neurons to damage from various insults. However, surviving nigrostriatal dopamine 
neurons mount a compensatory response by increasing the rate of synthesis and release of 
dopamine.
Akinesia and slowed movement execution (bradykinesia) are the principal symptoms of 
PD. These motor deficits of PD result from dysfunction of the nigrostriatal dopaminergic 
pathway within the basal ganglia. The basal ganglia are several closely grouped neuronal 
nuclei situated below and on each side of the cerebral cortex; and they are concerned with 
movement control (Bradford, 1986). They include the neostriatum, consisting of the 
caudate nucleus and putamen, the two shells of the globus pallidus and the subthalamic 
nucleus. The substantia nigra, although more caudal in position and situated in the region 
of the brain stem, is included as a basal ganglion structure because of its close functional 
and anatomical relationships with the neostriatum. The pars compacta of the inner 
substantia nigra consists largely of dopamine-containing cell bodies whose dendrites 
penetrate into the outer, pars reticulata, layer of this nucleus (Bradford, 1986).
A working model of the functional organisation of the basal ganglia is based on the 
concept of disinhibitory mechanisms regulating the GABAergic output neurons of the 
basal ganglia (Figure 1.4). According this scheme, SNR (i.e. Gpi) neurons are tonically 
active, providing a tonic inhibition to their target areas in the thalamus, superior colliculus, 
and pedunculopontine nucleus. Cortical activity results in activity in the striatonigral 
pathway, which is inhibitory and results in phasic pauses in the output of nigral neurons. 
That such disinhibition is responsible for specific movements was elegantly demonstrated 
by Hikosaka and Wurtz (1983), who demonstrated that phasic pauses in nigral neurons are 
directly correlated with eye movements, generated by activity in the superior colliculus. 
Similar findings are reported for activity of the internal segment of the globus pallidus in 
primates related to arm movements. Here the disinhibitory mechanisms are suggested to 
modulated thalamocortical feedback loops to premotor and motor cortical areas. The basal 
ganglia thus appear to affect motor behaviour by way of cortically generated activity of
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Figure 1.4 Schematic representation of the main connections in a basal ganglia- 
thalamocortical circuit. A. Normal status: The two output routes (“indirect” and 
“direct”) are in balance at the level of the output structures. B. Presumed 
disturbances in Parkinson’s disease: Depletion of dopamine in the striatum leads 
to an imbalance in the two output routes and a suppresion of thalamocortical activity. 
The large black cross indicates the depletion of the dopamine neurons in the 
substantia nigra.
ENK = enkephalin, GP = globus pallidus, GPE = external segment of GP, GPI = 
internal segement of the GP, MD = mediodorsal thalamic nucleus, SNR = pars 
reticulata of the substantia nigra, SNC = pars compacta of the substantia nigra,
SP = substance P, STN = subthalamic nucleus, VA/VL = ventral anterial/ventral 
lateral thalamic nuclei.
striatal output pathways that regulate the activity of neurons in the substantia nigra (and the 
internal segment of the globus pallidus) (Gerfen and Engber, 1992).
There are two major output pathways from the striatum, the direct and the indirect, which 
are responsible for smooth and well co-ordinated movement. The two pathways, which 
converge in the internal segment of the globus pallidus and in the substantia nigra, have 
opposing effects: the direct pathway causes disinhibition of the thalamocortical neurons 
while the indirect pathway causes inhibition of these neurons. Since the glutamatergic 
thalamocortical neurons facilitate the stimulation of movement via the cortex, the net result 
of the indirect pathway is to reduce movement while the direct pathway increases it 
(Gerfen, 1992).
The pars compacta of the substantia nigra (SNpc) projects to the striatum (caudate 
putamen) using dopamine as a neurotransmitter. At least two dopaminergic receptor types 
exist within the striatum that respond differently when presented with dopamine. Striatal 
neurons projecting directly to the internal segment of the globus pallidus (Gpi) contain 
receptors (Di type) that cause net excitation (the "direct" pathway), and striatal neurons 
projecting to the external segment of the globus pallidus (Gpe) contain receptors (D2 type) 
that cause net inhibition when dopamine is present the "indirect pathway"). Activation of 
the direct pathway results in inhibition of Gpi, whereas activation of the indirect pathway 
leads to excitation of the Gpi. The Gpi is the major outflow structure of the basal ganglia 
related to movement control, and it exerts tonic inhibitory influence on the thalamus (Watts 
et.al., 1992).
Depletion of dopamine in the striatum results in increased activity of the striatopallidal 
pathway and decreased activity in the striatonigral pathway (Figure 1.4). The functional 
consequence of the alteration in the balance in activity in the striatal output systems that 
occurs in the dopamine deafferented striatum results from the disinhibition of the 
subthalamic nucleus, which coupled with decreased activity in the striatonigral pathway 
results in increased tonic activity of the GABAergic neurons of the output nuclei of the 
basal ganglia, the substantia nigra , and the internal segment of the globus pallidus (Gerfen 
and Engber, 1992). The bradykinesia of PD has been suggested to result from an increase 
in the inhibitory outputs of these nuclei (Albin et.al., 1989).
The striatal neurons of these pathways constitute over 90% of all neurons in the striatum 
and are characterised by their medium size (a diameter of approximately 1 0 pm) and spiny 
dendrites. These are the major output neurons of the striatum and although both groups of 
neurons (i.e. those of the direct and the indirect pathways) release GABA, they can be 
distinguished by the neuropeptides they express: the striato-Gpe neurons of the indirect
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pathway contain enkephalin while the striato-Gpi/nigral neurons of the direct pathway 
contain substance P and dynorphin. These striatal neurons, which receive massive 
excitatory inputs from the cortex and thalamus, are controlled by inhibitory feedback from 
recurrent collatral axons. Other influences on these neurons include dopamine (released 
from the nigrostriatal neurons that die in PD) and modulators intrinsic to the striatum 
including acetylcholine (ACh), which is released from a group of striatal intemeurons.
1.2.4 Aetiology of PD.
The cause of the degeneration of dopamine-containing cells and the appearance of Lewy 
bodies in the zona compacta of the substantia nigra in patients with Parkinson's disease 
remains unknown. At present little can be done to prevent or slow the progression of the 
pathological changes because the nature of the degenerative process involved also remains 
unsolved. The theories postulated on the mechanism leading to this disorder are 
numerous. In the early twentieth century much weight was given to the theory of a 
causative environmental agent, mainly due to a pandemic of postencephalitic parkinsonism 
which occurred between 1918 and 1920 and which appeared to indicate a viral cause of the 
disease. While it is now clear that postencephalitic parkinsonism is different from 
idiopathic PD, the possibility that the idiopathic disease might have a viral origin has 
continued to interest researchers right to the present time. Another discovery which 
indicated an external factor in the cause of PD was the discovery that l-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP), a contaminant of a synthetic pethidine analogue sold 
as a street drug, produced a condition resembling Parkinson's disease (Langston et.al, 
1983). The idea that little or no genetic factors contributed to PD was strengthened by a 
series of twin studies during the 1980's (Duvoisin et.al., 1981; Ward et.al., 1983; Marttila 
et.al., 1988) that failed to demonstrate increased concordance rates for PD in monozygotic 
versus dizygotic twins.
However, in recent years there has been a re-emergence of interest in the genetic causes of 
idiopathic PD. As a result, there is currently much more research investigating the role of 
hereditary factors and gene-environment interactions in causing PD.
MPTP induced Parkinsonism.
MPTP was shown to cause a selective destruction of nigrostriatal dopaminergic neurons in 
primates and some other animal species, and this stimulated a great deal of work on the 
mechanisms involved in its neurotoxic effects and their possible relationships to idiopathic 
PD. The selective toxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) 
toward nigral dopamine-containing cells in humans (Langston et.al, 1983) provided the 
first substantial evidence for toxin involvement in Parkinson's disease. The compound
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enters the brain where it is converted by the action of the B form of monoamine oxidase 
(MAO B) to the l-methyl-4-phenylpyridinium ion (MPP+), which is the effective 
neurotoxin (Heikkila et.al., 1984; Javitch et.al., 1985). Since MAO B is not present 
within dopaminergic neurons but within glia, MPTP must be oxidised to MPP+ within glia 
and not within the dopamine neuron, itself. MPP+ is a substrate for the presynaptic 
dopamine uptake system (dopamine transporter, DAT) and the toxicity of MPP+ and 
MPTP can be prevented by prior administration of inhibitors of presynaptic dopamine 
uptake. In contrast, MPP+ is a poorer substrate for the noradrenergic and serotonergic 
presynaptic uptake carriers and the selectivity of MPTP as a toxin to dopaminergic neurons 
can be explained by this energy-dependent concentration within these neurons. This local 
concentration effect is the critical process for toxicity and is enhanced further by the 
binding of MPP+ to neuromelanin. Melanised dopaminergic neurones have been shown to 
be more susceptible to neurodegeneration in PD and MPTP neurotoxicity.
MPP+ is a potent inhibitor of mitochondrial oxidation of NAD+-linked substrates. The 
cessation of respiration brought about by this blockade leads to rapid depletion of ATP and 
consequent loss of membrane potential, which in turn, leads to nigrostriatal nerve cell 
death by mechanisms that may involve altered calcium homeostasis, and perhaps, free 
radical formation (Tipton and Singer, 1993). The inhibition of mitochondrial respiration is 
the result of a chain of events, starting with the rapid and extensive accumulation of MPP+ 
inside the mitochondrial matrix, driven by the electrochemical potential of the membrane. 
MPP+ must be concentrated within the mitochondria in order to be effective (Tipton and 
Singer, 1993), and this accumulation appears not to be mediated by a carrier because the 
initial rate is non-saturable (Davey et.al., 1992). The concentration within the 
mitochondria is followed by a gradual penetration of the compound into a hydrophobic 
binding region. As a consequence, reducing equivalents from NADH dehydrogenase do 
not reach ubiquinone [coenzyme Q(CoQ)] and, thus, oxidative phosphorylation is halted. 
Direct intrastriatal injection of the complex I inhibitor rotenone also results in 
neurotoxicity, demonstrating that the inhibition of mitochondrial NADH oxidation is 
sufficient, on its own, to cause nigrostriatal cell death.
Because the inhibitory effects of MPP+ on mitochondria are not organ-specific, affecting 
that organelle in all mammalian cells, the selective neurotoxic action may be the result of 
the specific ability of the nigrostriatal dopaminergic nerve terminals to take up MPP+ and 
retain it at sufficiently high concentrations to cause neuronal cell death. The selectivity of 
the toxic effects may be enhanced further by the binding of MPP+ by neuromelanin 
associated with the dopaminergic neurons (Tipton and Singer, 1993).
The involvement of MPTP in producing a parkinsonian syndrome lead researchers to 
believe that there was an environmental toxin which produced PD. However, this toxin
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would have to be world wide as the disease shows no localisation to any distinct areas, 
also recent evidence indicates that there may be some genetic contribution to the risk of PD 
(see section Genetic factors influencing PD). Such a genetic factor may affect the activity 
of one or more of the enzymes involved in drug detoxification.
Several lines of evidence have been interpreted as indicating the involvement of an 
environmental factor in the development of PD, but the data are confusing and often 
apparently contradictory (Tanner, 1989). The structural resemblance of paraquat to MPTP 
might suggest an involvement, as it is widely used in agriculture. However, the toxic 
actions of paraquat are restricted to the periphery, because, like MPP+, it does not 
penetrate the brain. Also paraquat is a relatively new chemical, predated by PD. It has 
been suggested that tetrahydroisoquinoline or its derivatives may be endogenous 
compounds giving rise to PD by a mechanism similar to MPTP. Several groups have 
reported tetrahydroisoquinoline and its 1,3-dimethyl derivative induce a condition 
resembling PD (Booth et.al., 1989; Makowski and Ordonez, 1981). They have been 
shown be present in human brain caudate and frontal lobe (Makino et.al., 1990) but there 
were no significant differences between its concentrations in normal and parkinsonian 
brains.
Oxidative stress and the pathogenesis o f PD.
Another current concept of the cause of PD is that dopamine cell death is due to the 
excessive formation of oxygen radical species. Oxidative stress refers to the cytologic 
consequences of a mismatch between the production of free radicals (a free radical is any 
molecular species with an unpaired electron) and the ability of the cell to defend against 
them. Powerful oxidising agents cause extensive injury and even cell death through 
multiple mechanisms including damage to nucleic acids, oxidation of proteins and lipid 
peroxidation. Two types of protective mechanisms are present in cells to combat these 
changes: cellular antioxidants e.g. tocopherol (vitamin E) and ascorbate (vitamin C), which 
react with the free radical and stop the chain reaction. Also enzymes such as superoxide 
dismutase (SOD), glutathione peroxidase and catalase, which catalyse the removal of 
reactive species. The presence of oxidative stress is indicated by: 1) the loss of reducing 
substances e.g. tocopherol, ascorbate and glutathione, 2 ) the decreased activity of 
protective enzymes e.g. SOD, 3) an altered redox status of cells e.g. an increased ratio of 
the oxidised compared with the reduced form of glutathione and 4) the appearance of 
molecular damage e.g. peroxidized lipids, oxidized proteins and damaged DNA.
The idea that PD may involve either an endogenous or an environmental toxin or toxic 
process has propagated the concept that excessive formation of reactive oxygen species 
and the onset of oxidative stress are key components of the pathogenesis of PD. The
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hypothesis that reactive oxygen species and oxidative stress contribute to the pathogenesis 
of PD originates from two main sources. The discovery that MPTP is selectively toxic to 
nigrostriatal dopaminergic neurones provided an important model of parkinsonism and 
clues to the possible pathogenic mechanism in PD. Oxidation of MPTP to MPP+ and its 
subsequent ability to impair mitochondrial function and generate oxidant stress are the key 
components of the toxic process initiated by this agent (Singer et.al., 1987). Impairment 
of mitochondrial function can itself give rise to excessive formation of reactive oxygen 
species, but in addition, MPTP and its metabolites (MPP+ and l-methyl-4-pheny 1-2,3- 
dihydropyridinium ion [MPDP+]) can interact directly with biomolecules to form free 
radical species (Adams and Odunze, 1991). MPTP toxicity could also be due to inhibition 
of ATP formation through an impairment of mitochondrial function coupled with the 
generation of reactive oxygen species capable of exerting neurotoxicity. The discovery of 
MPTP toxicity led to the discovery of many analogues of MPTP, some of which also exert 
toxicity of the substantia nigra. Furthermore, several naturally occurring molecules e.g. 
isoquinolines and p-carbolines can exert MPTP-like toxicity and can be found in food and 
others may be generated by the brain itself. These, however, are relatively weak 
neurotoxins, and their relevance to PD is unknown, although it is possible that long-term 
exposure may lead to progressive neurodegeneration.
Oxidative stress in PD may also arise from the metabolism of dopamine itself by both 
chemical and enzymatic mechanisms. The autoxidation of dopamine leads to the 
production of semiquinones, which are themselves toxic and which may also lead to the 
generation of reactive oxygen species (Olanow, 1990). The semiquinone cascade leads to 
polymerisation and the formation of neuromelanin, although there is no evidence that 
increased dopamine oxidation or melanin formation occurs in individuals who develop PD. 
The enzymatic metabolism of dopamine leads not only to the deaminated metabolites 
homovanillic acid (HVA) and 3,4-dihydroxyphenlyacetic acid (DOPAC) but also to the 
generation of H2O2 . Based on this concept, a theoretical scheme for the excess formation 
of the oxidant species H2O2 and OH* formation has been devised. Increased dopamine 
turnover in the early stages of PD might generate excessive H2O2 , which would normally 
be inactivated by glutathione (GSH) in a reaction catalysed by glutathione peroxidase. 
However, if the GSH system is impaired or deficient, H2O2 might be converted by the 
iron-mediated Fenton reaction to form highly reactive OH*, so initiating lipid peroxidation 
and cell death. Indeed the experimental elevation of dopamine turnover can lead to 
increased oxidative stress as determined by a rise in the formation of oxidised glutathione 
(GSSG) (Spina and Cohen, 1989).
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Evidence for oxidative stress in Parkinson's disease.
Oxidative stress could be produced by several processes that take place in dopaminergic 
cells as well as in other monoaminergic cells (Feldman et.al., 1996). First, hydrogen 
peroxide is one of the products of MAO deamination. Thus, every molecule of dopamine 
catabolised within the cell gives rise to a molecule of hydrogen peroxide (which can be 
converted to dangerous hydroxyl radicals). Second, catecholamines can undergo
nonenzymatic auto-oxidation in the presence of molecular oxygen. This process gives rise 
to toxic quinones as well as hydrogen peroxide and oxyradicals as by-products. 
Moreover, DA auto-oxidation is considered to be the mechanism of neuromelanin 
formation. Hence, auto-oxidation may play a role in the particularly severe loss of 
melanised neurons in PD.
Finally, there is much interest in the possible role of iron in generating hydroxyl radicals. 
The formation of hydroxyl radicals from hydrogen peroxide can be catalysed
nonenzymatically by ferrous ions in a so-called Fenton-type reaction. A by-product of this 
reaction is the oxidation of ferrous (Fe2+) to ferric (Fe3+) ions. Rats administered Fe2+ 
intracerebrally show increased lipid peroxidation (Triggs and Willmore, 1984). The 
substantia nigra contains a high concentration of iron, and neuromelanin appears to be 
capable of reducing Fe3+ to Fe2+, thereby driving the Fenton reaction. There is general 
agreement that iron levels within the substantia nigra are elevated in PD (Dexter et.al.,
1989; Sofic et.al., 1991; Gorell et.al., 1995 and Gerlach et.al., 1994) and this may
mediate the formation of reactive oxygen species if the excess iron is in a reactive form. It 
has also been demonstrated that infusion of iron into the substantia nigra leads to a dose- 
related and progressive reduction in nigral neurons and striatal dopamine (Sengstock et.al., 
1993 and Ben-Schachar et.al., 1991). However, there is dispute over whether the 
increased iron load in PD is in a reactive form. Much of this centres on whether iron is or 
is not bound to ferritin, since in a ferritin-bound form, iron is much less reactive. One 
study of the brain-specific ferritin isoforms indicates that neuronal ferritin levels are low in 
PD, but have failed to undergo the expected upregulation that would normally occur in the 
presence of increased levels of iron (Connor et.al., 1995). Thus, it has not been 
ascertained whether the increased iron levels in PD exceeds the binding capacity of ferritin, 
and whether free iron is present in the substantia nigra. Therefore, the capacity of iron to 
generate reactive oxygen species in PD remains unknown. Even if the iron in the 
substantia nigra of patients with PD is in the reactive form, this may occur as a late and/or 
secondary change. A recent study demonstrated that iron secondarily accumulates within 
the substantia nigra following remote lesions of the nigrostriatal tract (Oestreicher et.al.,
1994). In addition increased iron levels may not be specific to PD and may occur in other 
basal ganglia degenerative disorders e.g. Alzheimer's disease (AD).
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A further key to the pathogenesis of PD relates to alterations in mitochondrial function. 
The critical observation is the finding of impaired complex I function in the substantia 
nigra of PD patients in the absence of changes in any of the other mitochondrial complexes 
(Schapira et.al, 1989; Mizuno et.al, 1989). The deficit in complex I activity is specific to 
the substantia nigra in PD and is not found in other neurodegenerative disorders. 
Interestingly, it is exactly the same mitochondrial defect as occurs with MPP+ toxicity. At 
the present time, however, the cause of this impairment is unknown. Studies on human 
PD fibroblasts indicate that complex II of the mitochondria is unaffected and it is thought 
that forcing metabolism through complex II increases free radical formation and the 
likelihood of developing oxidative stress. Thus complex I inhibition could lead to the 
generation of reactive oxygen species, but there is as yet no evidence that this mechanism 
is directly responsible for cell death in PD.
Nigral cell loss based on the concept of oxidative stress implies that antioxidant defence 
mechanisms in the PD brains may be impaired or inadequate. Many of the major 
antioxidant defences appear unimpaired e.g. catalase, vitamin C. However, there are 
changes in superoxide dismutase (SOD) and reduced glutathione. The activity of SOD in 
the substantia nigra pars compacta (SNc) in PD is increased (Marttila et.al, 1988). This 
does not occur in other areas of the PD brain, but alterations in SOD have been described 
in other neurodegenerative disorders, including AD and amyotrophic lateral sclerosis 
(ALS). Whether the increase in SOD activity is associated with the inducible Mn- 
dependent mitochondrial form of the enzyme or the constitutive Cu/Zn-dependent cytosolic 
form is debated. Studies of the cerebrospinal fluid support an elevation of the Mn- 
dependent form in PD. Since the Mn-dependent form is found in mitochondrial 
membranes, this would be compatible with an impairment of mitochondrial function 
leading to over-production of superoxide radical with consequent induction of Mn-SOD 
activity. Increased SOD levels may be neuroprotective since transfection of the gene for 
SOD production protects nigral cells from MPTP toxicity, and leads to increased survival 
of transplanted foetal ventral mesencephalic cells.
Hydrogen peroxide is removed from the cell by its metabolism to water by either catalase 
or glutathione peroxidase. In the latter reaction, reduced glutathione (GSH) is converted to 
its oxidised form (GSSG) by glutathione peroxidase, a by-product of which is water, and 
GSSG can be returned to its reduced state by glutathione reductase. There is general 
agreement that levels of the total and the reduced species of GSH in the PD brain are 
decreased (Perry et.al., 1982 and Sofic et.al, 1992) and that there is no corresponding 
increase in the level of oxidised glutathione (GSSG). The loss of GSH is specific to the 
SNc and has not been demonstrated in other areas or in other degenerative diseases 
affecting the basal ganglia. Impairment of the GSH system may reduce the clearance of 
H2O2 and promote the formation of OH* in a reaction catalysed by excess iron in the
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substantia nigra. The decrease of GSH also appears to be an early component of the 
disease. In patients with incidental Lewy body disease (ILB, possible presymptomatic 
PD), levels of GSH are reduced to approximately the same degree as in patients with PD 
(Hirsch et.al., 1991). In contrast, in ILB patients there is no change in iron concentration 
or in levels of mitochondrial complex I. Thus, a fall in GSH may be the earliest 
biochemical marker associated with nigral degeneration. Why GSH levels are decreased in 
PD remains unknown. Oxidative stress or mitochondrial abnormalities might deplete 
glutathione irreversibly, but this has not yet been established.
While measurements of iron levels, mitochondrial function and GSH content in the 
substantia nigra suggest increased formation of reactive oxygen species and that the SNc is 
in a state of oxidative stress in PD, they provide only an indirect measurement of free 
radical involvement.
The free radical hypothesis of the cause of PD is based on the concept that constant 
oxidation of dopamine may be deleterious to the nigrostriatal system, since the products of 
this oxidation may lead to oxidative stress and eventually neuronal damage. Yet all 
humans are exposed to this process throughout their lifetimes but only a small percentage 
develop PD. If dopamine oxidation is the key, then why does the pathologic process in 
PD spread well beyond the dopaminergic system to areas such as the locus coeruleus and 
the nucleus basalis of Meynert? And why doesn't everyone get the disease? A hypothesis 
which would answer the second question is that there is a genetic predisposition in certain 
individuals to PD. Environmental agents may also have a part to play in the aetiology and 
may contribute to oxidative stress.
Genetic factors influencing PD.
Although viral encephalitis or an environmental toxin such as MPTP are clearly capable of 
damaging the substantia nigra, the 1990s have seen a re-emergence of interest in the 
genetic causes of idiopathic PD. Familial clustering of PD was observed a century ago 
when 10-15% of PD patients were reported to have a positive family history (Nussbaum 
and Polymeropoulos, 1997). Accurate measurement of the frequency of PD among 
relatives of affected patients is made very difficult by the inaccuracy of diagnosis of PD 
from history, the variability in age of onset, and the rarity of autopsy data required for 
making the diagnosis of diffuse Lewy body disease in relatives reported to have PD. 
During the 1980's, a genetic contribution to PD was thought unlikely when a series of 
twin studies failed to demonstrate an increased concordance for PD in monozygotic versus 
dizygotic twins (Duvoisin et.al., 1981; Ward et.al., 1983; Marttila et.al., 1988). As has 
been pointed out (Zimmerman et.al., 1991), however, these studies are not easily 
interpretable because the number of twins studied and the duration of the observation to
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either support or reject a genetic contribution to PD were inadequate. As nearly 80% of the 
function of dopaminergic neurones of the substantia nigra must be lost before symptoms 
occur, reliance on clinical diagnosis alone and a lack of follow-up makes a determination 
of concordance extremely insensitive. The use of positron emission topography can be 
used to measure 18fluorodopa uptake into basal ganglia and to diagnose preclinical 
dysfunction of the substantia nigra. When this was carried out an increased concordance 
rate was observed among monozygotic twins when compared to dizygotic twins (Bum 
et.al., 1992). As a result, the lack of increased concordance in twin studies cannot be 
taken as evidence that no genetic factors are involved in PD.
More recently, a number of epidemiological studies with differing methodological 
approaches and study populations have been published and found to support a familial 
contribution to PD (Duvoisin, 1992; Golbe, 1993; Johnson, 1991; Marder et.al., 1996). 
In case control studies, positive family history was found to be the single greatest risk for 
PD. In family studies a family history for PD was found in 10-24% of patients. In the 
largest of these studies, the frequency of PD was 2% in 1458 first degree relatives of 233 
PD patients, a significantly higher frequency than the 1% seen in the 7834 first degree 
relatives of 1172 age-matched controls (Marder et.al., 1996).
In an attempt to integrate our current knowledge of the familial nature of PD, the possible 
role of defects in energy metabolism in causing the disease, the toxicity of MPTP and the 
role of dopamine metabolism in PD, there have been three major lines of research : 1) 
investigation of the mitochondrial genome for mutations in PD patients 2) looking for 
linkage of polymorphism’s in drug metabolising enzymes in affected individuals 3) 
attempts at identifying linkage between PD and polymorphism’s in genes involved in 
dopamine synthesis and breakdown. There have been several reports of deficiencies 
arising in complex I of the electron transport chain (Mizuno et.al., 1989; Schapira et.al., 
1989 and more recently Shoffner et.al., 1993; Brown et.al., 1996) in patients with PD but 
whether these abnormalities are primary or secondary to the disease process is unknown. 
It is interesting, however, that the action of MPTP also involves inhibition of complex I 
activity. A few small studies have suggested a significant association of certain 
mitochondrial DNA polymorphism’s with PD but the sample sizes were small and 
replication is ongoing (Shoffner et.al., 1993; Brown et.al., 1996). Thus, there appears to 
be some consistent abnormalities in oxidative phosphorylation, particularly of complex I, 
in PD but a direct causative role for inherited or acquired mutation of the mitochondrial 
genome remains unproved.
In view of the possible involvement of neurotoxins in PD (e.g. MPTP), research has also 
been directed towards identifying variation in certain drug metabolising enzymes that might 
predispose certain individuals to greater toxicity from environmental agents. Association
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studies in PD have focused on polymorphism’s in drug metabolising enzymes such as 
cytochrome P450IA1 (encoded by the CYPIA1 gene) and the debrisoquine 4-hydroxylase 
cytochrome P450 (encoded by the CYP2D6 gene), as well as the monoamine oxidase A 
and B enzymes (encoded by MAO A and MAOB). A number of studies have suggested 
significant association between PD and loci encoding cytochrome P450 enzymes and 
monoamine oxidase. Association studies with the CYP2D6 gene revealed a highly 
significant 4-fold increased risk among patients with disease onset before age 50 in a 
Spanish population although no such association was seen in the United States and British 
samples (Sandy et.al., 1996). Many studies have indicated association between the 
CYP2D6 allele and early-onset PD (Agundez et.al., 1995) but no association with late- 
onset PD (Diederich et.al., 1995). A particular haplotype at the MAO A locus was found to 
be 3-fold more common among PD patients as compared to controls while another 
haplotype was 3-fold less common among affected patients (Hotamisligil et.al., 1994). 
No such associations were found at the MAOB locus (Ho et.al., 1995). Thus, there is 
some evidence for a modest association for certain alleles at these loci with PD but, as with 
many association studies, replication of these findings is difficult and requires larger, 
carefully controlled studies before they can be accepted as definite.
Allelic association between genes involved in dopaminergic transmission and PD has also 
been investigated. No association was seen with a polymorphism in the gene encoding the 
dopamine transporter (Taussig et.al., 1995 and Tanaka et.al., 1993), but evidence of 
allelic association for the dopamine D2 receptor was detected among sporadic PD patients 
(Taussig et.al., 1995) indicating a possible role in PD. However, these were preliminary 
data with a small number of individuals, and this allele association will have to be 
investigated further. Interestingly mice lacking dopamine D2 receptors show symptoms 
similar to PD: lack of spontaneous movement, akinesia and abnormal gait (Balk et.al.,
1995).
A genetic contribution to PD has received substantial support from the identification of a 
number of families in which PD with diffuse Lewy body disease was inherited as an 
autosomal dominant trait (Lazzarini et.al., 1994; Dwork et.al., 1993; Payami et.al., 1995; 
Golbe et.al., 1996 and Denson et.al., 1997). Penetrance appeared to be age-dependent, 
rising from 43% early in adulthood to 85% after age 70. In one such family, from the 
town of Contursi near Salerno in Italy (Golbe et.al., 1996), linkage analysis was carried 
out and the gene for PD mapped to chromosome 4 at 4q21-q23 (Polymeropoulos et.al.,
1996). Linkage mapping of a PD gene to 4q21-q23 in the Contursi pedigree suggested a 
number of candidate genes for PD which mapped to this region. One of them, a- 
synuclein, was a particularly good candidate. The protein is a neuron-specific presynaptic 
membrane protein (Iwai et.al., 1995) that was originally identified as the peptide named 
NACP, (non-Ap protein component of AD amyloid), isolated from plaques in AD.
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Sequencing of the a-synuclein gene in affected individuals from the Contursi kindred 
revealed that affected members were heterozygous for a missense mutation, changing 
alanine->threonine at amino acid 53 of the protein, that segregated with PD in this family 
(Polymeropoulos et.al., 1997). The same missense mutation was found in three additional 
unrelated PD families of Greek origin but was absent in 314 chromosomes from control 
European populations, including 200 chromosomes obtained from random controls from 
the area near Contursi itself. The evidence that this mutation causes PD is based entirely 
on finding the mutation in four unrelated families and finding it absent in a large set of 
controls. Definitive proof requires elucidation of the mechanism by which this mutation 
causes the disease e.g creation of a knock-out mouse for this gene.
Over the last few years, a major shift in thinking and focus for PD research has resulted in 
renewed interest in the genetic basis of this fascinating disease. This change in attitudes 
has already proved beneficial with the identification of one gene in which a particular 
missense mutation predisposes to PD.
1.2.5 Animal Models of Parkinson’s Disease.
Animal models of human diseases are useful in two respects, they allow the development 
and testing of new therapeutic strategies and they can also provide insight into the specific 
cause of the disorder. Clearly an animal model of Parkinson's disease would be a valuable 
tool in both of these aspects of this disorder.
1.2.5.1 Chemically-induced animal models ofPD.
MPTP
Within a year after the discovery that MPTP could cause parkinsonism-like symptoms in 
humans (Langston et.al, 1983) and monkeys (Bums et.al., 1983), repeated injections of 
MPTP in mice (Heikkila et.al., 1984) were shown to cause prolonged depletion of striatal 
dopamine apparently via a neurotoxic mechanism. Clinically, the animals became akinetic 
and bradykinetic, flexed and rigid, and some had tremor. Histopathological examination 
of the brain revealed extensive degeneration of the substantia nigra zona compacta, and 
biochemically dopamine and its metabolites were profoundly depleted in the striatum of 
these animals. Also squirrel monkeys treated with MPTP, particularly in older animals, 
eosinophilic inclusions have been seen that are reminiscent of human Lewy bodies 
(Langston, 1996). In monkey and mice, MPTP causes degeneration of a similar 
population of nucleus A8 , A9 and A10 neurons of the midbrain (the retrorubal field, the 
substantia nigra and the ventral tegmental area, respectively) as in human PD. There 
appears to be a large scale of MPTP sensitivity among the species tested. Primates appear
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to be the most vulnerable of the species so far tested, to MPTP toxicity. Rats appear to be 
the least affected, exhibiting transient behavioural deficits after acute MPTP administration 
but are relatively resistant to the toxic effects of repeated drug treatment. Mice appear to 
fall some where in the middle. There are thought to be three main reasons for the 
difference in species sensitivity: MPP+ is cleared from primate brains slower than any 
other, activity of MAO-B the capillary endothelium, in rats is high and converts most of 
the MPTP to MPP+ at this site. Due to ionisation MPP+ is unable to cross the endothelial 
cell membrane and gain access to nerve cells. Finally, the substantia nigra in primates 
appears to have a high concentration of neuromelanin which concentrates MPP+ in these 
cells. However, recent evidence indicates that the relative insensitivity of rats to MPTP 
neurotoxicity is not accounted for by these mechanisms (Sundstrom and Samuelsson,
1997). Pretreatment of rats with deprenyl to prevent MAO-B-mediated oxidation in the 
capillary did not increase toxicity in the striatum. Synaptosomal uptake was also studied 
and was found to be no different in mouse and rat (Sundstrom and Samuelsson, 1997). 
Therefore, the lack of effect of MPTP in rats is not due to mechanisms specific for MPTP 
but probably to the ability of rat catecholamine neurons to cope with, and survive, 
impaired energy metabolism (Sundstrom and Samuelsson, 1997).
However, MPTP-induced parkinsonism differs from human PD in many respects. For 
example, noradrenergic and sertonergic systems may be less severely damaged (if not 
damage at all) than in idiopathic PD. Neurochemical differences were also found between 
MPTP-induced parkinsonism and PD e.g. equal losses of DA in the caudate and putamen 
of MPTP-treated animals (Bums, 1983), which differs from PD, in which the putamen is 
more severely affected. More recent work has demonstrated that appropriate drug 
treatment regimes can bring about neurochemical effects closely resembling those in PD 
and even the slow evolution of clinical symptoms (Bezard et.al., 1997).
The 6-OHDA model.
The catecholamine neurotoxin 6 -hydroxydopamine (6 -OHDA) is transported into the cell 
bodies and fibres of dopaminergic and noradrenergic neurons. This leads to massive 
degeneration of the nerve terminals and can also affect the cell bodies, particularly when 
administered to cell body regions. Reasonable selectivity for the substantia nigra can be 
obtained by pre-treatment with despiramine, a noradrenergic transporter blocker that 
inhibits 6 -OHDA uptake into the adrenergic neurons. Better selectivity can also be 
obtained when the toxin is injected directly into the striatum, substantia nigra or the medial 
forebrain bundle, which contains the axons.
The most widely used model is that of animals with unilateral lesions. The phenotype of 
these animals is normal but when challenged with amphetamine rotational behaviour is
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elicited, ipsilateral to the side of the lesion. When L-Dopa is administered contralateral 
rotation is obtained. Animals which have received bilateral lesions more closely resemble 
PD, they display severe bradykinesia and L-Dopa is seen to enhance their motor function 
(Sakai and Gash, 1994). However, not many studies are carried out on animals treated in 
this way, as after lesioning the animals have difficulty in eating, drinking and are difficult 
to maintain.
Intrastriatal application of 6 -OHDA initiates a delayed and progressive loss of nigral 
dopaminergic neurons and may resemble the slow developing neuropathology of PD. 
Studies carried out by Zigmond (Zigmond et.al., 1990) investigated the characteristics of 
the 6 -OHDA model when compared to human PD. Extracellular levels of dopamine in the 
striatum as measured by microdialysis do not decrease until tissue dopamine depletion 
exceeds 80% and behavioural impairment is observed only after severe (bilateral) damage. 
Therefore, some compensatory mechanisms may under he the disparity between total 
tissue dopamine and extracellular dopamine levels including increased firing by the 
remaining neurons and increase in the amount of dopamine released per action potential. 
This mirrors human PD where symptoms do not appear until striatal dopamine loss 
reaches 80% and the remaining nigral cells show increased firing and dopamine turnover.
The mechanism by which 6 -OHDA acts as a neurotoxin in still unknown but several 
hypotheses have been put forward. 6 -OHDA can generate highly cytotoxic free radicals 
(i.e. hydrogen peroxide and the hydroxyl radical). Peroxidative membrane damage 
probably due to free radical generation has been observed after intrastriatal injection of 6 - 
OHDA (Kumar, 1995). It has also been shown that 6 -OHDA, similar to MPTP is a potent 
inhibitor of respiratory chain enzymes, suggesting a neurotoxic pathway for 6 -OHDA not 
primarily involving oxidation products (Glinka and Youdim, 1995). In addition, 
disturbance of intracellular calcium homeostasis by excessive entry of calcium and/or 
release from intracellular storage sites either may be a causal factor for neurotoxin- 
mediated cell death or may represent a common final pathway involving other mechanisms 
(Gerlach, 1996). Specifically, it is not clear whether intrastriatal 6 -OHDA acts directly on 
the nigral cell bodies (following specific uptake and retrograde transport) or whether the 
toxin mediates a rapid destruction of striatal DA terminals and the progressive nigral cell 
degeneration is caused by another mechanism (e.g. lack of a target-derived neurotrophic 
factor).
These chemically-induced models of PD do, to some degree resemble the human condition 
but as yet no spontaneous occurring models of PD have been observed in animals.
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1.2.5.2 A genetic model o f PD.
The Weaver mouse
The principal phenotype of the weaver mouse is a weaving gait that is due, in part, to a 
severe hypoplasia of the cerebellum marked by a near total loss of midline granule cells 
(the most numerous cell type in the CNS). However, it is not only the cerebellum which 
is affected in the weaver phenotype, a progressive loss of dopaminergic cells from the 
substantia nigra pars compacta is also observed. This was particularly interesting as these 
are the type of cells lost in PD . In Parkinson's disease and weaver mice, the involvement 
of dopaminergic mesencephalic neurons is heterogeneous: it is prominent in the substantia 
nigra (SN) (A9), especially in the lateral areas, but less marked in the retrorubral area (A8 ) 
and the ventral tegmental area (A 10) (Triarhou et.al., 1988). It has also been shown that 
calbindin-D28k positive neurons are relatively spared in the SN in both PD patients and 
weaver mice (Gaspar et.al., 1994). Calbindin-D28k is thought to reduce free intracellular 
calcium levels and neurons expressing this protein are better protected against 
excitotoxicity.
The weaver mouse mutation was shown to be a single-base substitution in GIRK2 which 
encodes a inward rectifying potassium channel (Patil et.al., 1995). The base change leads 
to a substitution of amino acids in the pore region of the protein, which is thought to block 
the channel, leading to increased excitotoxic stress and resulting in nigral cell death 
(Bandmann et.al., 1996). Excitotoxic stress may cause increased radical production and 
impaired mitochondrial metabolism both of which have been described in PD (Jenner, 
1992). It was therefore thought that abnormalities of the channel may contribute to the 
aetiology of PD (Goldowitz and Smeyne, 1995). A study of the GIRK2 gene was carried 
out by Bandmann and colleagues (1996) in idiopathic and sporadic cases of PD to evaluate 
the possibility of a shared genetic defect in weaver mice and PD, but the sequence was 
normal in all cases. This suggested a different aetiology of nigral cell loss in PD and 
weaver mice. There are many other differences between PD and the weaver mouse which 
suggested a different aetiology: behaviourally, weaver mice differ from the akinetic-rigid 
features seen in PD in that they display ataxia and fine tremor, this is due to severe 
involvement of the cerebellum with profound cell loss of granule cells. In PD, the 
cerebellum is spared (Gibb, 1992). Other frequently affected areas in PD such as the 
nucleus raphe dorsalis or the locus coeruleus (Gibb, 1992) are normal in weaver mice 
(Lane et.al., 1977). Thus, the limited damage of the nigrostriatal system in weaver mice 
does not match the distribution and extent of the widespread morphological and 
biochemical changes seen in PD.
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1.3 The AS/AGU rat.
Rats homozygous for a mutation in the agu gene display movement abnormalities similar 
to those seen in human patients with Parkinson's disease (PD). Phenotypically these rats 
are characterised by a reduced ability to initiate movement, an abnormally wide gait of the 
hind paws, rigidity of the hindlimbs resulting in a staggering gait and a tendency to fall 
over every few steps (Clarke and Payne, 1994, Campbell et.al., 1996). A series of 
locomotor tests have been carried out to investigate the exact phenotype of these animals 
including mid-air righting, rate of movement within a defined area and balancing; animals 
homozygous for the agu mutation show reduced abilities in all of these tests. The 
phenotype can be detected as early as postnatal day 1 0  through a combination of clumsy 
gait, high stepping, tail elevation and slight whole body tremor. In older rats the fully 
developed condition includes difficulty in initiating movement. Injection of L-Dopa and 
fetal midbrain grafts are observed to increase performance in the described motor tests 
(Payne et.al., in press). The agu mutation arose spontaneously within a closed breeding 
population of Albino-Swiss rats at the Department of Anatomy, at the University of 
Glasgow (Clarke and Payne, 1994).
1.3.1 Anatomy o f the AS/AGU rat.
Anatomical investigations of the AS/AGU rat brain were carried out in an attempt to 
determine the basis of this disorder. No gross abnormalities were observed in any CNS 
structures and the cerebellum and cerebral hemispheres appeared normal and were the 
appropriate size and orientation. The substantia nigra appeared smaller, with a distorted 
shape and the pars compacta was thinner than normal (Clarke and Payne, 1994). Tyrosine 
hydroxylase (TH) immunostaining revealed that there were major deficits in the number of 
TH-immunoreactive cells in mesencephalic regions, particularly the substantia nigra 
(Figure 1.5). Counts of TH immunoreactive neurons were carried out on the substantia 
nigra in nine mutant strain rats and in three controls of the parent strain (Albino Swiss), 
mean deficits of 20% were seen in the numbers on TH-immunoreactive neurons in this 
region (Clarke and Payne, 1994).
1.3.2 Pharmacology o f the AS/AGU rat.
The reduction in size of the substantia nigra and the general phenotype of AS/AGU rats 
suggested an involvement of the neurotransmitter, dopamine in the production of the 
phenotype. Investigations were therefore carried out to determine the effect the agu 
mutation has on dopamine levels in the neostriatum, the target of nigrostriatal 
dopaminergic neurons (Albin et.al., 1989 and Beckstead et.al., 1979). At 12 months 
dopamine levels in the caudate-putamen (CPU) of the corpus striatum were determined.
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AS/AGU rats had lower levels of neostriatal dopamine than control AS rats, with the 
greatest discrepancy in the dorsal CPU which showed a reduction of 30-35%, moderate 
loss in the lateral CPU and small losses in the ventral CPU. Differential patterns of 
dopamine loss within the striatum are also observed in PD brains, where dopamine loss is 
reported to be most pronounced in the dorsal and intermediate regions (Kish et.a l, 1988).
The deficits in striatal dopamine levels were detectable from about 6  months (Campbell 
et.al, 1997), suggesting that locomotor disorders which develop in the mutant AS/AGU 
animals before six months are due not to a gross reduction in levels of dopamine, but does 
not rule out some other deficiency in dopaminergic function. However, micropunch- 
derived data cannot distinguish between intra- and extra-cellular levels of transmitters, 
therefore a study was carried out to measure the extracellular levels of dopamine and its 
metabolite 3,4-dihydroxy-phenylacetic acid (DOPAC) in the dorsal caudate putamen of 
conscious AS (control) and AS/AGU rats. At all ages, microdialysis levels of dopamine 
were 8-10 fold lower in AS/AGU rats than in the AS strain. However, levels of DOPAC 
were 2.5-5 fold higher in AS/AGU than in AS (Campbell et.al., 1998). These results can 
even be detected at 3 months, in the absence of a detectable loss of whole tissue dopamine 
(Campbell et.al., 1997). Extracellular dopamine in the dorsal-caudate putamen of 
conscious animals was reduced to 1 0 -2 0 % of control levels.
Age Dopamine (pg/sample) DOPAC (pg/sample)
3 months
AS(n=6 ) 105.7 ± 26.5 20.2 ± 1.3
AS/AGU (n=6 ) 16.2 ± 1.4 48.6 ± 3.2
P < 0 .0 1 < 0 .0 1
6 months
AS (n=6 ) 37.3 ± 1.3 7.2 ± 0.9
AS/AGU 4.1 ±0.5 25.2 ± 6.3
P < 0 .0 1 < 0 .0 1
9 months
AS (n=6 ) 27.4 ± 1.8 3.6 ± 0.9
AS/AGU (n=6 ) 2.3 ± 0.5 16.7 ± 2.7
P < 0 .0 1 < 0 .0 1
Table 1.3 Concentrations of extracellular dopamine and DOPAC in striatal dialysis of 
AS and AS/AGU rats. The data are taken from Campbell et.al., 1998.
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Other aminergic systems are also depleted in PD, including the number of serotonergic cell 
bodies in the dorsal raphe and the locus coerulus, a study was undertaken to see if similar 
deficits occur in AS/AGU rats. There are modest decreases in dopamine in the ventral 
tegmental area (-40%) and the locus coerulus, while the locus subcoeruleus was unaffected 
(Scott et.al, 1994). There was wide variation in the number of serotonergic cell bodies in 
both the median and dorsal raphe and the locus coerulus of AS/AGU rats. HPLC-ECD 
measurements of biogenic amines reveal overall depletion’s of serotonin in AS/AGU rats 
in a ventral tegmental area containing the median raphe nuclei (-70%) and in a dorsal 
tegmental area containing the dorsal raphe nuclei (-50). The data suggests that, as in 
human PD aminergic deficits are not confined to dopaminergic systems.
Significant depletion of glucose utilisation is also observed in the substantia nigra pars 
compacta, subthalamic nucleus and ventrolateral thalamus (Lam et.al., in press) of 
AS/AGU rats.
The agu mutation produced a very interesting phenotype in the rat which could prove a 
useful tool in the investigation of basal ganglia disorders e.g. Parkinson's disease. The 
obvious similarities between the human phenotype and pathology of Parkinson's disease 
and the phenotype and pathology observed in the AS/AGU rat made the investigation of 
the mutation an interesting possibility.
1.3.3 Genetic investigation of the agu mutation.
AS/AGU rats were originally crossed to AS animals and all of the FI progeny had normal 
locomotion. The FI progeny were then backcrossed to AS/AGU and the progeny of the 
backcross fell into two phenotypic classes; those with normal locomotion (50%) and those 
with abnormal locomotion (50%). The ratio of 1:1 for affected and non-affected progeny 
indicated the involvement of a single locus and the mutation was seen to be recessive and 
fully penetrant in backcross progeny. There did not appear to be maternal or X-linked 
patterns of inheritance, indicating that this gene was contained on an autosomal 
chromosome, rather than a sex or mitochondrial chromosome. The karyotype of AS/AGU 
rats appeared normal and there were no gross chromosomal abnormalities.
Using a large rat backcross to map agu.
The mutation within the agu gene which gives rise to this phenotype will be identified by 
what is termed positional cloning (Collins, 1992). There are two stages to this process: 
the first stage is the use of formal linkage analysis to find flanking DNA markers that must 
lie very close to the gene of interest. Using these markers, the second stage of the process
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involves cloning across the region that contains the gene responsible for the phenotype, 
and then identifying the gene itself.
The first stage of this process requires fine genetic mapping of the agu gene. Genetic 
linkage is a direct consequence of the physical linkage of two or more loci within the same 
pair of DNA molecules that define a particular set of chromosome homologs within the 
diploid genome (Silver, 1995). To map a mutationally defined locus, one will have to 
generate progeny in which segregation of the mutant and wild-type alleles can be followed 
phenotypically in animals prior to DNA preparation for marker locus typing. This could 
be performed to map the agu mutation, as the phenotype could be followed easily in off­
spring.
A decision was made to use a backcross to produce offspring which would allow mapping 
of the agu gene. The first mating in this scheme is always an outcross between the mutant 
strain and a inbred strain. Once Fi hybrid animals are obtained, they are subsequently 
bred to the mutant strain. In the backcross, therefore the Fi hybrid animal will be 
heterozygous at both two linked loci, which results in two complimentary sets of coupled 
alleles-A B and a b. The genotype of this animal is therefore, AB/ab. In the absence of 
crossing over between homologues during meiosis, one or the other coupled set-either A B 
or a b will be transmitted to each gamete, producing offspring either AB/ab or ab/ab after 
mating with the homozygous (ab) mutant strain. However, if a cross-over event does 
occur between the A and B loci, a non-parental combination of alleles will be transmitted to 
each gamete. The frequency of recombination between loci A and B can be calculated 
directly by determining the percentage of offspring formed from gametes that contain one 
of the two non-parental, or recombinant, combination of alleles (Silver, 1995).
To a degree, crossing over occurs at random sites along all of the chromosomes in the 
genome. A direct consequence of this randomness is that the farther apart two linked loci 
are from each other, the more likely it is that a crossover event will occur somewhere 
within the length of chromosome which lies between them. Thus, the frequency of 
recombination provides a relative estimate of the genetic distance. Genetic distances are 
measured in centimorgans (cM) with 1 cM defined as the distance between two loci that 
recombine with a frequency of 1%. 1 cM is taken to be approximately 2 Megabase (Mb) 
in physical distance in the mouse genome but unfortunately not known in rat. However, it 
is important to be aware that the rate of equivalence can vary due to genetic interference, 
gender-specific differences in rates of recombination, recombination hotspots and the 
region of chromosome under investigation. Although the frequency of recombination 
between two loci is roughly proportional to the length of DNA that separates them, when 
this length becomes too large, the frequency will approach 50%, which is 
indistinguishable from that expected from unlinked loci.
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The analysis of backcross data is very straightforward, and when all loci are known to 
map on the same chromosome, it is possible to derive linkage relationships. By looking at 
an ordered set of markers, one can visualise the actual meiotic products contributed by the 
Fi parent in the form of individual haplotypes. Every recombination event between the 
mutation locus and a marker can be detected and the frequency of recombination can be 
easily determined. The major disadvantage with the backcross is that it is not universally 
applicable to all genetic problems. In particular, it cannot be used to map loci defined only 
by recessive phenotypes that interfere with viability or absolute fecundity in both males 
and females (Silver, 1995).
1.3.4 Choosing the inbred strain and number o f animals for a backcross.
Upon commencing a new linkage study, a decision will have to be made concerning the 
two parental rat strains that will be used to establish the backcross. Obviously in the 
backcross situation one of these strains is already determined i.e. the mutation carrying 
strain. The most important consideration for the choice of the other strain will be the 
degree of polymorphism that exists between the two parental strains, and the ease with 
which they, and their offspring, can be bred to produce a large panel of second-generation 
animals for DNA typing. Backcross construction is significantly more difficult in the rat 
than in the mouse in one important respect. Genetic mapping in the mouse can exploit 
crosses with different subspecies or species (e.g. M.castaneus and M.spretus) that have 
SSR polymorphism rates with laboratory strains of about 90%, rather than intraspecific 
crosses in which the polymorphism rate is only about 50% (Jacob et.al., 1995). Because 
similarly distant rat strains are not available, at best only about half of the SSR markers 
isolated are informative in any given mapping cross. An informative marker is defined as 
a marker which displays a polymorphism between the individuals or species being tested.
To determine the inbred strain to be used in the backcross a set of 73 microsatellite loci 
were typed in the AS, PVG, F344 and BN rat strains to determine the strain with the 
highest level of polymorphism with AS (the agu mutation arose within the AS strain, and 
would presumably only differ from the AS strain at the agu locus). These strains were 
chosen as they were among the most common used in mapping studies. The microsatellite 
loci typed were optimised and covered the entire rat genome, and would prove useful at a 
later date. AS differed from BN, F344 and PVG at 62%, 47% and 43% of loci, 
respectively (Shiels et.al., 1995) (work carried out by Miss M.B. Duran Alonso and 
Dr.P.Shiels). As BN and F344 displayed the largest rates of polymorphism with AS they 
were both selected to be used to establish a backcross with AS/AGU.
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The number of animals produced in a backcross determines the level of resolution obtained 
from that backcross. The greater number of animals produced, the greater number of 
recombination events which can be identified. Assuming random sites of recombination, 
the average distance in centimorgans, between crossover events observed among the 
offspring of a backcross can be calculated using the simple formula (100/N), where N is 
the number of meiotic events that are typed (Silver, 1995). With 1,000 meiotic events, the 
average distance will be only 0.1 cM. Therefore, it was decided that a resolution of 0.05 
cM would be useful, meaning 2000 progeny from each backcross would have to be 
produced. This would produce a physical distance resolution of approximately 50 kb. 
However, as mentioned previously crossover events do not always occur randomly and 
this figure is an approximation.
1.4 Genetic mapping in rat.
The laboratory rat, Rattus norvegicus, was the original mammalian species used in 
scientific research but has fallen behind the mouse as the choice of animal for genetic 
studies for many reasons: the smaller size of the mouse simplified housing requirements 
and many behavioural mutants were available. As a result, the range of genetic markers 
identified within the rat genome has been sparse when compared with that of mouse. In 
the last five years this situation has improved slowly. The recent convergence of 
molecular genetics with physiology and the availability of a wide array of rat strains has 
made the rat the species of choice in the study of many complex genetic disorders. 
Identifying genomic loci which influence traits that exhibit continuous or quantitative 
variation in organisms amenable to breeding experiments has become the focal point of a 
great deal of research. The rat has become the organism of choice in the investigation of 
quantitative trait loci (QTL) which influence many complex phenotypes e.g.. hypertension 
(Gu et.al., 1996), diabetes (Gaugier et.al., 1996), arthritis blood pressure and stroke. As 
the rat is utilised more frequently as a model for such disorders complete genetic linkage 
maps are required.
The first construction of a rat genetic map was reported by Serikawa and colleagues in 
1992 who isolated one hundred and seventy-four rat loci which contained short tandem 
repeat sequences. This was followed by Jacobs et.al.( 1995) who reported the first 
complete genetic linkage map of the laboratory rat consisting of 432 SSLPs with an 
average spacing of 3.7 cM. From then onwards an increasing number of rat genetic 
mapping studies have been published concerning nearly every chromosome of the rat. The 
most recent rat genetic map (September, 1997) from the Whitehead Institute/MIT Centre 
for Genome Research contains 2,275 markers, bringing the total on all of their maps to 
3,139 SSLP markers (WIBR/MIT CGR version 2.0).
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Another area of improvement where genetic mapping of the rat genome is concerned is the 
availability of genomic libraries. Rat genomic libraries rat are important when a novel gene 
is to be isolated which corresponds to an observable phenotype, in the process known as 
positional cloning. The absence of libraries also limited mapping of the rat genome, in 
particular physical mapping of small areas. The only genomic library available before 
1997 was a PI library constructed by Southard-Smith (1994), when compared to the many 
different libraries available for mouse and man it is evident why the rat has lagged behind 
these two species in mapping projects. In 1997, however, three rat genomic libraries 
became available, the first a Yeast Artificial Chromosome library constructed by Cai et.al., 
(1997) followed by another YAC library (Haldi et.al., 1997) and finally a PI Artificial 
(PAC) library constructed by The Roswell Park Cancer Institute. This is a moderate start 
for rat genomic mapping resources, but as more and more genetic mapping studies are 
carried out within the rat for such diseases as hypertension etc., the demand for resources 
will increase, as will the available resources.
1.5 DNA Markers
There are three criteria that define the perfect DNA marker. First, they should be 
extremely variable to provide a good possibility that any two chromosome homologues in 
a species will carry different alleles. Second, they should be easily identified so that one 
can develop a set of markers for the analysis of any species. Finally, they should be easy 
to genotype rapidly in large numbers of individuals. A large number of types of markers 
have been identified that fulfil all of these criteria. However, experience within our 
laboratory has shown that detection of variation by PCR at microsatellites and by 
identifying an SSCP (single-strand conformational polymorphism), are the most efficient 
ways of genotyping large numbers of backcross progeny.
1.5.1 Microsatellites
Microsatellites fulfil all of the criteria above for DNA markers and have been utilised 
extensively in recent years for mapping projects in nearly all species. Microsatellites can 
be defined as relatively short (<100 bp) runs of tandemly repeated DNA with repeat unit 
lengths of 6  bp or less. Microsatellites are used extensively as markers for establishment 
of linkage maps of all eukaryote genomes as they occur at high frequency throughout 
genomes (approximately 50,000-10,000 copies/haploid genome, Sun et al., (1996), tend 
to be highly polymorphic and are easily assayed by the polymerase chain reaction (PCR). 
A microsatellite (also known as a simple sequence repeat - SSR) is a genomic element that 
consists of a mono-, di-, tri- or tetrameric sequence repeated multiple times in a tandem 
array. Allelic variation is based entirely on differences in the number of repeats present in 
the tandem array rather than specific basepair changes. Thus, the only way in which
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alleles can be distinguished is by measuring the total length of the PCR product containing 
the microsatellite.
Novel microsatellites can be identified within genomic clones by hybridisation with repeat 
sequence oligonucleotides. The most common repeat sequence observed in the rat genome 
in a database survey carried out by Beckman and Weber (1992), was the (CA)n repeat 
element, accounting for 36% of all microsatellites surveyed. It was estimated during an 
investigation of the Genbank database that a (CA)n repeat element where n> 6  occurred 
approximately every 21 kb within the rat genome (Stallings e t.a l, 1991). Therefore, this 
oligonucleotide should always be utilised first in the search for new microsatellites in the 
rat. Sedkawa observed that dinucleotides in the rat tend to be variable in length once a 
threshold size of 20 bp has been reached (Serikawa et.al, 1992). PCR primers can then 
be generated flanking the novel microsatellite and used to identify repeat length differences 
within this sequence between our different rat strains, and subsequently used for mapping 
relative to the agu mutation.
The properties of microsatellites make them useful tools in all mapping projects and they 
will be extremely useful in mapping the agu gene.
1.5.2 SSCP
Single strand conformation polymorphism (SSCP) takes advantage of the fact that even 
single nucleotide changes can alter the three-dimensional equilibrium conformation that 
single strands will assume at low temperatures (Orita et.al., 1989). If a sample of DNA is 
denatured at high temperature and then quickly placed on ice, reformation of DNA hybrids 
will be inhibited. Instead, each single strand will collapse onto itself in what is often called 
a random coil. In fact, it is now clear that each single strand will assume a most-favoured 
conformation based on the lowest free energy state. Even a single base change could 
conceivably disrupt the previous most favoured state and promote a different one, which, 
if different enough, would run with an altered mobility on a gel, allowing the detection of a 
strain difference which can be used for mapping.
1.6 Positional Cloning
Positional cloning is a powerful strategy for identifying disease genes with unknown 
biological function (Collins, 1994). Application of this approach relies upon initially 
determining the chromosomal localisation of the responsible gene followed by additional 
fine mapping carried out to narrow down the responsible region (Figure 1.5), however 
this is generally limited by the number of informative meioses available. In general in 
human mapping studies, about 1 0 0  events are available, so fine mapping is often limited to 
genetic intervals of about 1 cM. Mapping studies in mouse and rat have an advantage as
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the number of meioses generated is determined only by limitations on animal numbers. 
Fine mapping of the region is followed by an examination of the transcripts in the area, 
with the aim of identifying a gene that contains a mutation. After the correct disease gene 
has been cloned, a biochemical analysis then ensues to understand the encoded protein and 
its function.
The development of a clone-based contig map encompassing the critical region bridges the 
gap between genetic studies and transcript (cDNA) identification. Previously, YAC clones 
were isolated for this purpose, since they contained large inserts, simplifying and 
accelerating the coverage of extensive stretches of the genome. However, it has become 
preferable to use PI, PAC or BAC clones to establish a contig, as problems such as 
chimaerism and instability can arise in YAC cloning. Chromosome Walking is the name 
given to a systematic process which allows the isolation of large (greater than 100, 000 bp) 
regions of complex genomes in an ordered array of overlapping recombinant DNA clones 
(Cross et.al., 1986). Chromosome walking is typically performed using YAC, BAC, 
PAC or cosmid clones. Typically, fragments from both ends of the insert of the “founder” 
clone are isolated and used as hybridisation probes to screen a library for over-lapping 
clones. This approach assumes that the new clones will extend bilaterally, significantly 
beyond the founder clone. The walk then proceeds in a linear fashion in steps by isolation 
of new end probes from the new clones and repeating the process. However, 
chromosome walking is a laborious and time consuming procedure, no walk can proceed 
faster than the speed and length it takes to make each individual step, and this has limited 
its general application and also restricted the length of walk that can be contemplated. This 
is the disadvantage of using clones with relatively small inserts e.g. PI clones and BACs, 
as short distances will only be taken at each step, when compared to large insert YAC 
clones.
The clones identified by chromosome walking then provide an important resource of easily 
manipulable DNA, suitable for generating markers to refine genetic maps. These clones 
can also easily be used for fingerprinting to allow overlaps between clones to be 
established.
Following this, strategies for rapidly identifying transcripts directly from cosmid, YAC, 
PAC, BAC and PI clones are utilised, such as exon-trapping and cDNA selection 
techniques (Lovett et.al, 1991; Kom et.al., 1992).
1.7 Progress in mapping the agu mutation.
Genetic and physical mapping of a gene locus, identification of the gene and eventually 
identification of a mutation in the gene which gives rise to a specific phenotype is termed
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reverse genetics (Collins, 1992) or positional cloning. This process involves a set of 
defined steps as detailed previously. The first step involved decisions made on a breeding 
scheme, rat strains involved etc., this work was detailed previously. Two backcrosses 
were initiated between F344 and AS/AGU and BN and AS/AGU with both to eventually 
comprise 2000 offspring each.
The next step involved a chromosomal localisation of the agu locus. To accomplish this 
the set of 73 microsatellite markers, used in determining the rat strains to be used for the 
backcross, were used in a genome wide scan for linkage. This involved typing at least one 
informative marker per rat chromosome, with the exception of chromosomes 9 and X 
which did not have any informative markers, being assayed for linkage with the agu 
mutation. Linkage was observed with the marker R33 (Serikawa et.al, 1992) which was 
localised to chromosome 1 (work carried out by Dr.P.Shiels and Miss M.B.Duran 
Alonso). This marker mapped approximately 30 cM from agu and therefore defined a 
region of genome of approximately 50 cM from R33 which contained agu.
1.8 Aims of current study.
The aim of the work detailed in this thesis is to establish a physical (DNA) map of a 
defined, small region of the rat genome that contains the agu gene. The situation at the 
beginning of my work has been outlined in Section 1.7. Therefore, the experimental work 
presented here has two major components:
- Identification of new genetic markers to allow fine mapping of the agu gene in a genetic 
interval of < 1 cM.
- Establishment of a genomic clone based contig of this region by chromosome walking.
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Chapter 2 
Materials and Methods
2 .1  Basic Molecular Techniques
2.1.1 Gel Electrophoresis o f DNA
DNA was visualised and resolved in multi-purpose agarose from Boehringer Mannheim in 
IX TBE. Conditions such as voltage and length of time of DNA resolution were adjusted 
to suit the purpose of the gel and the samples to be resolved. All agarose gels are loaded 
with 200 pg of lkb ladder from GibcoBRL and DNA was visualised by adding ethidium 
bromide ( 1 0  mg/ml) to the molten agarose.
2.1.2 Bacterial strains utilised
Bacterial Strain Genotype of strain Reference
TG-1 SupE hsdA5 thiA (lac- proAB) F  [tra D36 
pro AB+ lac M Lac ZAM15]
Gibson et. 
al., 1984
DH10B F- mcrA A(mrr hsdRMS- mcrBC) <))80d lac
Z AM15 AlacX74 deoR recAl endAl
araA139 D(ara, leu) 7697 gal U gal K Ar 
rpsL nupG
Grant et. al., 
1990
NS3529 recA- mcrA- A(hsdR hsdM mcrB mrr) (A 
imml LPI) (A imm434-Pl; Cre+)
Pierce et. al., 
1992
F3 DH10B [F::Tnl0d-Cam] Kimmerly et. 
al., 1994
INV a F F  endAl recAl hsdR17(rk-,mk+) supE44 
thi-1 gyrA96 relAl (|)801acZAM15 
A(lacZYA-argF) U169 Ar
Invitrogen® 
Version B 
150626 
25-0024
Table 2.1 Bacterial strains utilised in this study
2.1.3 Production o f Competent E.coli Cells
An overnight culture of the bacterial strain TG-1 was grown from a single colony in 
2XYT. The following day 100 mis of 2XYT was inoculated with 1 ml from the overnight 
culture. The cells were grown for approximately 2 hours until the OD5 9 5nm was 
approximately 0.6. The cells were then pelleted at 3, 000 rpm for 5 minutes. The pellet 
was resuspended in 25 mis of ice cold 50 mM calcium chloride and incubated on ice for 20 
minutes. The cells were centrifuged again and resuspended in 5 mis of ice cold 50 mM 
calcium chloride. The cells were then kept on ice until required.
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2.1.4 Transformation o f competent E.coli cells
100 j l l I  of cells, prepared as above, were utilised in all transformations. DNA or ligation 
reactions at the appropriate concentration were incubated along with the E.coli cells for 30 
minutes on ice. The DNA was then transformed into the cells by performing a heat shock 
at 42°C for 2 minutes. The cells were then placed back on ice for 2 minutes. 250 pi of 
2XYT is then added and the cells allowed to recover at 37°C for 1 hour. 100 pi of cells 
were then plated onto an agar plate containing antibiotic.
2.1.5 Small scale preparation o f plasmid DNA
Small scale preparation of plasmid DNA (mini-prep) was carried out using the Promega™ 
SV Wizard mini-prep® kit as described by the manufacturer.
2.1.6 Large scale preparation o f plasmid DNA
Large scale preparation of plasmid DNA was carried out using the Qiagen™ tip 100 kit 
(Qiagen) as described by the manufacturer.
2.1.7 Transfer o f DNA to Nitrocellulose (Southern blotting)
DNA was transferred from agarose gels onto nitrocellulose (MSI) as the method described 
in Sambrook et. a l , (1989). The agarose gel was soaked in denaturing solution for 20 
minutes, followed by 20 minutes in neutralising solution. The gel was then briefly rinsed 
in 2X SSC. Nitrocellulose and 3 sheets of 3MM Whatmann paper were cut to size and 
soaked in 2X SSC before use. The blotting apparatus was then assembled as Sambrook 
et.al., (1989). The gel was kept in contact with the nitrocellulose for 16 hours to allow 
DNA transfer by cappillary action. The nitrocellulose was then washed with 2X SSC to 
remove traces of agarose and baked at 80°C for 2 hours to fix the DNA to nitrocellulose.
2.1.8 Automated Sequencing
2.1.8.1 Preparation o f plasmid templates fo r  sequencing
Plasmid DNA was prepared using the standard Bimboim and Doly alkaline lysis technique 
(1979), followed by chloroform extraction and PEG precipitation as follows : bacterial 
cells from a 3 ml culture were pelleted and resuspended in 200pl GTE buffer (50 mM 
glucose, 25 mM Tris pH 8.0, 10 mM EDTA pH 8.0). The cells were lysed by the 
addition of 300 pi of 0.2 M NaOH, 1% SDS and inverted gently. 300 pi of neutralising 
solution was then added (3 M potassium acetate pH 5.5). The solution was centrifuged at
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14, 000 rpm for 10 minutes and the supernatant removed to a new tube. The supernatant 
was treated with RNaseA at a final concentration of 1 mg/ml. The supernatant was then 
chloroform extracted using an equal volume of chloroform/isoamyl alcohol 24:1. To the 
aqueous phase was added an equal volume of isopropanol and centrifuged at 14, 000 rpm 
for 10 minutes. The pellet was then washed with 70% ethanol and allowed to air dry. The 
pellet was then resuspended in 32 pis of dH2 0  and 48 pis of a PEG salt mixture (8  pi 4M 
NaCl + 40 pi 13% PEG 8000). This mixture was vortexed briefly and incubated on ice 
for 20 minutes. The mixture was then centrifuged at 14, 000 rpm for 20 minutes at 4°C. 
The pellet was washed in 70% ethanol, allowed to dry and resuspended in 20 pi. The 
DNA was visualised on a agarose gel to estimate concentration.
2.1.8.2 Preparation o f PCR products fo r  sequencing
PCR products were sequenced directly without prior cloning. The PCR reaction was 
carried out as in Section 2.2, in a total reaction volume of 50 pi. The PCR reaction was 
then passed through a MicroSpin™ S-400 HR Sephadex column (Pharmacia) to remove 
excess primers. The sequencing reaction was then carried out as described 2.I.8.C.
2.1.8.3 Sequencing Reactions
Sequencing reactions were carried out in a 20 pi reaction volume containing 3.2 pmoles of 
primer, approximately 0.5 pg of template DNA and 8 pi of the Amersham dye- terminator 
cycle sequencing Thermosequenase mix (Amersham). The reactions were carried out in a 
Perkin Elmer Gene Amp PCR System 9600 (Perkin Elmer) as follows : 96°C 2 mins, 25 
cycles of 94°C 10 secs, 50°C 5 seconds and 60°C 4 mins. Any excess primer, or dNTP 
mix were then removed by precipitating the reaction using 2.5 volumes of 95% ethanol 
and l/10th volume 3 M sodium acetate, washed with 70% ethanol and allowed to dry 
completely. The pellet was then resuspended in 4 pi of formamide stop buffer.
Primer Sequence of primer 5’->3'
T7P1 CCGCTAATACGACTCACTATAGGG
SP6  PI GGCCGTCGACATTTAGGTGACAC
T7 T AAT ACGACTC ACT AT AGGG
T3 ATTAACCCTCACTAAAGGG
M13 Forward CATTTTGCTGCCGGTCA
M13 Reverse GGAAACAGCTATGACCATG
Table 2.2 Sequencing primers used in this study.
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2.1.8.4 Electrophoresis o f  sequencing reactions
All sequencing reactions were resolved on the ABI 373 stretch automatic sequencing 
machine and analysed with software provided by ABI.
2.1.9 Transfer o f DNA from bacterial colonies to nitrocellulose
Bacterial colonies can be transferred from agar plates onto nitrocellulose to allow colony 
hybridisation with radioactive probes. Nitrocellulose filters (MSI) were laid on top of the 
bacterial colonies for thirty seconds and marked with asymmetric dots to allow orientation 
after hybridisation. The nitrocellulose was then removed and placed DNA/colony side up 
on a denaturing solution for 5 minutes. The nitrocellulose was then transferred onto a 
neutralising solution for 5 minutes. The nitrocellulose filters were then washed for 20 
minutes in 2X SSC to remove bacterial cell debris. Bacterial colonies were always colony 
lifted in duplicate. Nitrocellulose filters were then baked at 80°C for 2 hours to bind DNA 
to the filter.
2.1.10 Hybridising Southern Blots with Oligonucleotides
Oligonucleotides (synthesised by GibcoBRL) were radiolabelled with y-32P dATP (NEN 
DuPont, 3000 Ci/mmol) using T4 polynucleotide kinase (Promega). The total reaction 
volume of 30 pi contained 50 pmoles of oligonucleotide, IX kinase buffer, 50 pCi of y- 
32P, 20U of T4 polynucleotide kinase and dH2 0 . The reaction was incubated at 37°C for 1 
hour and the enzyme heat killed at 65°C for 20 mins. After labelling the probe was 
purified in Sephadex™ columns. Filters for probing were incubated at 42°C for 1 hour in 
a solution of IX Demhardts, 5X SSC, 50 mM sodium phosphate, 1 mM sodium 
pyrophosphate, 0.1 mg/ml salmon sperm DNA and 20% formamide previous to addition 
of the probe. The probe was then added to the pre-hybridisation solution and incubated 
overnight at 42°C. Filters were washed at room temperature in 2X SSC, 0.1% SDS for 15 
mins, followed by two washes in IX SSC, 0.1% SDS for 15 mins at room temperature. 
The filters were then exposed to X-ray film (Fuji) at -70°C for approximately 15 hours.
2.2 Polymerase Chain Reaction (PCR)
All PCR reactions were performed in a reaction containing IX magnesium free Thermo 
buffer (Promega), 1 mM magnesium chloride (Promega) and each dNTP at 125 fiM 
(Promega). All primers for PCR were synthesised by GibcoBRL™ and each primer was 
added at a final concentration of 5 ng/pl. Table 2.3. contains the sequence of all PCR 
primers utilised and the conditions at which they were optimal. Template was usually 
added to final concentration of 10 ng/pl. Samples were heated to 99°C for 5 mins before
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the addition of 1U Taq (Promega) at 80°C. This was followed by 25 or 30 cycles of 
denaturation at 94°C for 15 secs, annealing for 30 secs and an extension step at 72°C for 
30 secs. These were followed by a final extension step of 72°C for 2 mins. The reactions 
were carried out in a Perkin Elmer Gene Amp PCR System 9600 (Perkin Elmer). PCR 
reactions were generally visualised on a 2% TBE/agarose gel stained with ethidium 
bromide (10 mg/ml) (Sigma) and visualised by Ultra Violet. The primer pairs are designed 
with the forward primer (F) designed 5’ to 3’ and the reverse (R) primer designed 3’ to 5’.
Positive control for the PCR reaction were generally carried out on Brown Norway 
genomic DNA at a final concentration at 10 ng/pl. Negative controls were carried out 
which did not contain any DNA. PCR contamination problems were eliminated by 
dispensing PCR solutions and aliquoting these within a laminar flow hood. A clean set of 
pipettes was also used and oil over laid onto the PCR reaction to prevent air bome 
contamination.
PCR
A ssay
Gene Primers Sequences 5' to 3* PCR parameters
GU100 Bgp2 F - GCATTCCAGATTCTCTGTCACGG 55°C/25 cylces
R - GGCTCC AGG AT AC ACCTTTTCTTC
GU101 Atp4a F- CATAGTCCCACACCCAGGAAAGTAC 55°C/25 cycles
R- AACCCTCTTGTCCAGATGGAGTC
GUI 02 SCNIB F- GCATGATGGGTGAAGCAATATGG 55°C/30 cycles
R - TAGGAGGTGTCACAGGAAGGGAAC
GUI 03 GRIK5 F - CAGTTTCTGGTGAAGTCCAAGCC 60°C/30 cycles
R - AAGTGTGGAGAGCCGTGTCAAG
GU104 GRIK5 F- CAGTTTCTGGTGAAGTCCAAGCC 55°C/27 cycle s
R - AAGTGTGGAGAGCCGTGTCAAG
GUI 06 SSR F - CACCGTCTTTGTCTCTGTCTT 60°C/25 cycles
R - GCTTGTCCAGTCTGTCAGTG
GU10 SSR F - CAAAGATCCTGAGGAAACTGGC 55°C/32 cycles
R - CCTGCGGAGATGAAAGAGGAAAGG
KSP6 End PI F - AT AC A AAGTG AGTTCC AGGG 58°C/30 cylces
cloneK R - CCTTCTCCTTGTGTGGCTGC
F20 SSR F - GTTGGACTAGAAGCACCCAGC 65°C/30 cycles
R - TTGTTCAGGCCTGCTGGGTCC
F34 SSR F - GGCAGAGGTAGACAGAGTTCG 62°C/30 cycles +
R - TCCTCATTCGCTATTCTTGG 5% formamide
F61 SSR F - GTGTGAATTCTCACTGCAGC 55°C/30 cycles
R - CCTGTTCTGTCTTGTTCTACC
F101 SSR F - GCCCACATGTCCATCAATTGATGG 60°C/33 cycles
R - TTAGCACAGCATGCTGACCTCC
FI 10 SSR F - TAGGAAGTGGCCCACATGTCC 65°C/30 cycles
R - GCATGCTGACCTCCAGTCCCTCC
H31T SSR F - CCTGTCTTCTGCATAGATCACTG 68°C/30 cycles
R - GTAAAGATCAGGTGTGCATGCG
H31C SSR F - CGCATGCACACCTGATCTTTAC 69°C/30 cycles
R - GC AAGGTG AGG A AATACCTGTGG
KSP62 End PI F - CC ATC ACTGTT AC AC AC AG A A ACCC 54°C/32 cycles
cloneK R - TCCATAAATCCACGGCACTCC
R158 marker F- AGAACCCTTCACTGCTGCTCACC 60°C/30 cycles
R - AGAAAGTCCCAGAAAGTGGC
NCA Atp] F - CTGCCAGTGACGATTTCAGCC 57°C/30 cycles
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R - GCTGCTCCACAGACACATGAATAG
KT7 End PI F - GTTTCTGAGGGGCAGTAATGGCGG 67°C/27 cycles
cloneK R - GCTGC AC A ACTGGGGT ACTGTGGC
K66 SSR F - GATTCCCAACACCCATACCAGG 65°C/30 cycles
R - GAGCAACGCCAAATGCTTCTTCC
K100 SSR F - GACTCCCACACTTGACTTCAGACC 65°C/30 cycles
R - CTCTGACCACAACACATGTGTGCC
K106 SSR F - TTGGGCTCCCACCTTGCTTTTCC 65°C/30 cycles
R - CTGGAAGTCAGATTTCTGGTCTCC
K3 3' UTR F - ATGTAATCTC ATCTGCTGCCGC 55°C/30 cycles
of PKC R - TTCTACAACTGAAGTGGAGG
GU 9 Ferittin F - TGACTTCTTGGAAAGCCACTTCC 65°C/30 cycles
light
chain
R - AAGAGATACTCGCCCAGAGATGCC
K5 5' UTR F - CAGTAGTTCTCCGTTGCGTTCC 54°C/30 cycles
of PKC R- AGGTTTCCTCTCTTGAGTTCCTCC
SRY F - CAAGTTGGCTCAACAGAATCCCAG 55°C/27 cycles
R - GGCACTTTAACCCTTCGATGAGG
D1 Mgh7 SSR F - CCACACTATGTCCATGTGTACAA 50°C/25 cycles
R - GGAAACTCAAAGGTAGACAAAACA
D7 Mit 178 SSR F - ACCTCTGATTTCAGAACCCTTG 50°C/32 cycles
R -TAGAGAGCCACTAGCATATCATAAC
D7 Mit243 SSR F - TTCCCTTC ACTC ATG ATGT A AG A 48°C/30 cycles
R - GGCTGCCATACTGTTGAACA
D7 Mit75 SSR F - AAAGATGTGGTGACCATGATTG -
R - CCTTT AC AC ATGC AT AC AC AT AC A
D7 Mit 168 SSR F - CCCAAAACATTTAAAAAGCCA -
R - GCT ATGGC AC ATGC AC A AGT
D7 Mit 152 SSR F - GCCTAGCACACGCCAAAG 50°C/32 cycles
R - CCTTGTGCATGGTTGCTATG
D7 Mit 153 SSR F - TGGTTTGAATTTCTATTTGATTTCC -
R - AT AG AAAGGC ATGGGTGTGTG
D7 Mit76 SSR F - CATGAGCACGTGGAGAAAGA 50°C/32 cycles
R - CGTGGAAACCTGATAAACTGA
D7 Mit 190 SSR F - TGTG ATT AC AC ACTC AT A ATC AC AC A 50°C/32 cycles
R - GGCC AGGGTC AGT AAC A A A A
D7 Mit56 SSR F - A ATG A AG AT ACCC AC AG AAGCTG 50°C/32 cycles
R - GATGGGAACTGGGAACTTAGC
D7 Mit65 SSR F - T AATTG AAT AGTGTGCTGTG ACC A 50°C/32 cycles
R - CATGGCTTTGAAGAATTGTGTT
D7 Mitl91 SSR F - TTGGGTTTGTACTACCTAG ATACCTC 50°C/32 cycles
R - CCTCTAGGGCTCTTGCACAC
D7 MU244 SSR F - CATGCATACACATGTGCCCT 50°C/32 cycles
R - ATGCCT ATC A AA AAG A ATG AGTG
Table 2.3 PCR primers utilised, the sequence and annealing temperature and cycle 
number used in routine PCR from rat genomic DNA.
2.3 Analysis of backcross progeny
2.3.1 Isolation o f  DNA from  backcross progeny
DNA was isolated from the spleens of animals produced from both backcrosses. DNA 
was isolated as the technique described by Davis et.al., (1980). This protocol has been
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adapted to produce a genomic DNA isolation kit by Puregene (Gentra). After isolation of 
the DNA a spectrophotomic reading was taken at OD26O to ascertain the concentration of 
the DNA. The DNA was then diluted to 100 ng/pl for PCR and 1 pi used in the PCR 
reaction.
2.3.2 Genotyping backcross progeny
2.3.2.1 Genotyping PCR products on Metaphor gels
PCR reactions were carried out as described for the standard reaction, any modifications 
made are cited within Table 2.3. Metaphor™ (Flowgen) gels were prepared as the 
manufacturer's specifications in IX TBE buffer. The total PCR reaction volume was 
loaded onto a 4% TBE/Metaphor gel in IX TBE and 125V were applied to the gel for 
approximately 4 hours. The gel was then stained with ethidium bromide (10 mg/ml) and 
visualised by Ultra Violet.
2.3.2.2 Genotyping o f Radioactively-labelled PCR products
The PCR primer radioactive-labelling reaction was carried out as performed for 
hybridisation with oligonucleotides, containing 50 ng of forward primer to be used in the 
PCR reaction. A PCR reaction was performed as standard with the addition of the 
radioactively-labelled primer in a ratio of 1:300 to the forward primer which was not 
labelled. The PCR reaction was then carried out under mineral oil (Sigma) in a Perkin 
Elmer Cetus DNA Thermal Cycler. Again Taq (Promega) was added after an initial 
denaturing step at 99°C for 10 mins. The PCR reactions were then carried out as above. 
After the PCR has been performed 2 pi of formamide stop buffer was added to the reaction 
and 4 pi of this was loaded on to a 6% acrylamide denaturing gel. The PCR products were 
resolved on the gel at 60W for approximately 2 hours depending on size. The gel was 
then dried and exposed to X-ray film (Fuji) overnight at room temperature.
2,4 Utilisation of the PI library
The PI library was provided in groups of PI clones, containing between 300-1500 clones, 
named superpools. These superpools were provided as glycerol stocks. The library was 
kindly provided by Dr.R. Mac Donald (University of Texas) and described in Southard- 
Smith et.al, (1994).
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2.4.1 M aking lysates o f  PI Superpools
A small scraping was taken with a toothpick from the superpool glycerol stock into 100 pis 
of (IH2O and boiled for 20 mins at 99°C. These lysates were stored at -20°C and 1 pi used 
in a PCR reaction.
2.4.2 Screening superpool lysates
The PI library was screened by PCR. Firstly the 209 superpools were screened always 
performing 30 cycles in the PCR reaction. The PCR reactions were carried out as before, 
with a positive and neagtive control as described (Section 2.2). The products were then 
resolved on a 2% TBE/agarose gel. Once a positive superpool had been identified, a 
scraping was taken from the top of the glycerol stock of that pool and was placed into 3 
mis of L-Broth. The superpool was then plated onto L-agar plates containing kanamycin 
at a final concentration of 25 pg/ml. The plates were incubated overnight at 37°C. Single 
colonies from these plates were then picked into 100 pis of dH2 0  and screened by PCR as 
batches of 10 colonies. These batches of 10 were boiled for 20 mins before PCR carried 
out. While these colonies were being picked they were also streaked again as single 
colonies onto a gridded L-agar plate containing kanamycin (25 pg/ml). The PCR reactions 
were then carried out as before containing 1 pi of the lysate. The reactions were resolved 
as before. Once a positive batch of 10 had been identified the 10 colonies contained within 
this were picked on toothpicks into a PCR reaction as before.
2.4.3 Isolation o f PI DNA
Three methods of isolating DNA from PI clones were tested within in our laboratory.
2.4.3.1 Qiagen™
A PI clone single colony was grown in 50 mis of LB culture containing 25 pg/ml 
kanamycin and 5% sucrose. The following day 500 mis of 2X YT containing kanamycin 
was inoculated with 500 pi of the overnight culture. The culture was then incubated for 4 
hours at 37°C. After this time 5 mis of 0.1 MIPTG was added and the culture grown for a 
further 3 hours or until the OD550 was 0.8. The cells were then harvested at 5K for 10 
minutes. The supernatant was removed and the cell pellet resuspended in 8  mis of the 
Qiagen PI buffer (GTE). 8  mis of buffer P2 (0.2 M NaOH, 1% SDS) was then added, 
mixed gently and incubated at room temperature for 5 mins. Chilled buffer P3 (3 M 
Potassium acetate, pH 5.5) was then added, mixed gently and incubated on ice for 15 
minutes. This was then centrifuged at 4°C for 30 minutes at 15,000 rpm and the 
supernatant removed promptly. The Qiagen-tip 100 was equilibrated with 4 mis of buffer
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QBT and the column allowed to empty by gravity flow. The supernatant was then applied 
to the column and allowed to enter the resin. The Qiagen column was then washed with 
40 mis of buffer QC. The DNA was eluted with warmed (47°C) QF buffer. The DNA 
was precipitated with 0.7 volumes of isopropanol and centrifuged at 4°C at 12, 000 rpm 
for 30 minutes. The DNA was washed with 5 mis of 70% ethanol and allowed to air dry 
for 5 minutes. It was then re dissolved in 250 pi of TE.
2.4.3.2 Nucleon kit
The Nucleon I kit (Scotlab bioscience) was used to isolate genomic DNA from cultured 
cells, tissue and blood. To isolate PI clone DNA 3 mis of culture was pelleted and 
resuspended in 340 pi 400 mM Tris-HCl (pH 8.0), 60 mM EDTA, 150 mM NaCl and 1% 
SDS. The resulting solution was treated with RNaseA. To remove proteins the solution 
was shaken for 20 minutes at 37°C after the addition of 100 pi of 5M sodium perchlorate. 
Then incubated at 65°C for 20 minutes. The DNA was extracted using chloroform, 
shaking at room temperature for 20 minutes. The DNA was then precipitated.
2.4.3.3 Caesium chloride
This method is described in detail in the paper by Kimmerly et.al., 1994. A single colony 
of a PI clone was inoculated into 15 mis L-Broth containing kanamycin (25 pg/ml) and 
grown overnight at 37°C. The cells were collected and lysed as standard Bimbiom and 
Doly lysis (Bimboim and Doly, 1979). After lysis the DNA was precipitated using an 
equal volume of isopropanol. The pellet was then resuspended in 3.5 ml of TE buffer (10 
mM Tris, pH 8.0 and 1 mM EDTA) and then 4g CsCl and 100 pi 10 mg/ml ethidium 
bromide were added. The CsCl-DNA solution was transferred to Beckman Quick Seal 
tubes, heat sealed and then centrifuged in the VTi65.2 rotor (45 krpm, 20 hours, 18°C). 
PI DNA was removed from the gradient using a 1ml syringe. Ethidium bromide was 
removed from the sample by multiple extractions with isopropanol saturated with 20X 
SSPE buffer (3.6 M sodium chloride, 0.2 M sodium phosphate and 10 mM EDTA, pH
7.0). Finally the sample was precipitated with ethanol and suspended in sterile water.
2.4.3.4 Phenol/chloroform
50 ml culture of a PI clone was grown overnight at 37°C containing 25 pg/ml kanamycin. 
The cells were pelleted, suspended in 2 mis of GTE and incubated at room temperature for 
5 minutes. 3 mis of 0.2 M sodium hydroxide, 1% SDS was added, inverted gently and 
incubated on ice for 10 minutes. 3mls of 3 M potassium acetate, pH 5.5 were added 
inverted gently and incubated on ice for 10 minutes. This was followed by centrifugation 
at 15, 000 rpm for 15 minutes. The liquid was removed with a pipette and an equal
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volume of phenol/chloroform 1:1 was added and inverted gently. This was centrifuged 
again at 15, 000 rpm for 15 minutes. The aqueous phase was removed and precipitated 
with 2 volumes of absolute ethanol. The pellet was washed with 2 mis of 70% ethanol 
and allowed to dry. Then resuspended in 500 pis of dH2 0 . This was then treated with 
RNAse at a final concentration of 1 mg/ml.
2.4.4 Transfer o f PI clones into DH10B
This method was carried out by the method conceived by Kimmerly et.al., 1994. A single 
colony of the PI clone was picked from a kanamycin plate, as this clone was isolated from 
the library it was contained within the bacterial strain NS3529. A single colony was also 
picked from a plate containing the bacterial strain F3 (provided by Dr. W. Kimmerly). 
Both of these were grown overnight at 37°C. The 1 ml culture containing the PI clone 
contained 50 pg/ml of kanamycin and the 5ml culture containing the F3 strain contained 
chloramphenicol at 10 pg/ml. The next day 100 pis of the F3 overnight was added to 100 
pis of the PI clone overnight and added to 1.8 mis of L-Broth in a glass 50 ml test tube. 
This was incubated at 37°C in a shaking water bath at 30 rpm to allow bacterial conjugation 
to occur. This mixture was then diluted approximately 1/1000 and 30 pis plated onto L- 
agar plates containing 50 pg/ml kanamycin and 10 pg/ml chloramphenicol. As a control 5 
ml of F3 and of each PI clone were spotted onto a agar plate containing 50 pg/ml 
kanamycin and 10 pg/ml chloramphenicol. The plates were then incubated overnight at 
37°C.
For the second round mating a single colony was picked into 1 ml L-Broth + 50 pg/ml 
kanamycin and 10 pg/ml chloramphenicol and grown overnight at 37°C. A single colony 
was also picked from a plate containing the bacterial strain DH10B into 5 mis of L-Broth 
and grown overnight. The second round matings were carried out as before with 100 pi of 
DH10B and 100 pi from the culture obtained from mating round 1. The mixture was then 
diluted as before and plated onto L-agar plates containing kanamycin, chloramphenicol and 
streptomycin at 100 pg/ml. As a control 5 pis of DH10B and of each F/Pl donor were 
spotted onto a L-agar plate containing kanamycin, chloramphenicol and streptomycin.
2.4.5 Isolation o f PI DNA from Superpools
A scraping was taken from the top of the glycerol stock as for making lysates into 3 mis of 
L-Broth and 100 pis plated out onto L-agar plates containing kanamycin at 25 pg/ml and 
5% sucrose. The number of colonies plated was calculated to give at least a 95% coverage 
of the original superpool. After incubation overnight at 37°C the colonies were washed 
from the plates with 3 mis of L-Broth. 1 ml was taken from this to make two DNA
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preparations and 800 pis used to make a new glycerol stock. DNA was isolated by the 
standard Bumboim and Doly followed by two phenol/chloroform extractions. DNA was 
resuspended in 200 pis of dH2 0 . These DNA preps were used to make megapools for 
screening. Again PCR reactions carried out as before.
2.4.6 Southern Blotting o f PI DNA
500 ng of DNA was digested at 37°C for 1.5 hours in the standard buffers for each 
enzyme (Promega). The digestion products were generally resolved overnight on a 0.5% 
TBE/agarose gel. Prior to blotting the gel was treated with 0.25 M hydrochloric acid to 
depurinate the DNA, which was then transferred onto nitro-cellulose membranes (MSI) by 
standard Southern blotting. (Sambrook et.al, 1989)
2.4.7 Sub-cloning o f PI clones
PI DNA (500 ng) was digested for 1.5 hours at 37°C with Sau 3AI in IX React 4 Buffer 
(GibcoBRL), lU/pl of enzyme and dH2 0 . 200 ng of pUC18 DNA was also digested with 
Bam HI using the conditions as above containing IX React 3 buffer (GibcoBRL). The 
digested vector fragment was then band isolated from a 1% TBE/agarose gel using the 
QiaexII gel extraction system(Qiagen) or the Qiaquick gel extraction kit (Qiagen). Ligation 
reactions were performed in IX ligase buffer (Promega), 1 mM ATP, 3U/pl of ligase 
(Promega) 10 ng of vector and insert at concentrations ranging between 10 ng and 20 ng. 
Ligations were generally performed overnight at 16°C. Half of the ligation was then 
transformed into the E.coli strain TG-1, previously made competent using CaCl. The cells 
were plated out onto L-agar plates containing 100 pg/ml ampicillin, 2% X-gal and 20 
mg/ml IPTG. The plates were then incubated overnight at 37°C. White colonies were 
picked onto a gridded plate, in duplicate, and were again incubated overnight. Bacterial 
colonies were then transferred onto nitro-cellulose (Sambrook et.al., 1989) for 
hybridisation. Hybridisation with oligonucleotides was carried out as the conditions for 
Southern Blots.
2.4.8 Identification o f novel SSRs
The PI clone from which the simple sequence repeats (SSRs) were to be isolated was 
shot-gun cloned into pUC18, as described for the sub-cloning of PI clones (see previous 
methods) using Sau3AI. pUC18 was digested with BamHI and treated with 1U of 
shrimp alkaline phosphatase (Amersham Life Science) for 10 minutes at the end of the 
digestion. The digest was then resolved on a 1.0% agarose gel and the vector band was 
isolated from the gel prior to ligation. Ligations were carried out in the presence of 3U of 
ligase (Promega), IX ligase buffer and 1 mM ATP at 16°C overnight. Half of the ligation 
is then transformed into the E.coli strain TG-1 competent cells. The transformed cells
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were then plated onto L-agar plates containing ampicillin, 5-bromo-4-chloro-3-indolyl-p- 
D-galactoside (X-gal) and isopropyl-p-D-thiogalactosidase (IPTG) for blue/white 
selection. The plates were incubated overnight at 37°C. The bacterial colonies were then 
transferred onto nitro-cellulose, in duplicate, for hybridisation as previously described. 
Colonies were screened using a (CA)io repeat oligonucleotide (synthesised by
GibcoBRL). The oligonucleotide was radioactively-labelled with y-32p dATP (NEN 
DuPont, 3000 Ci/mmol) using T4 polynucleotide kinase (Promega). To a total reaction 
volume of 30 pi is added 50 pmoles of oligonucleotide, 10X kinase buffer, 50 pCi of y-
32p? 20U of T4 polynucleotide kinase and dH20. The reaction was incubated at 37°C for 
1 hour and then the enzyme heat killed at 65°C for 20 mins. After labelling the probe was 
purified in Sephadex™ G25. Filters for probing were incubated at 42°C for 1 hour in a 
solution of IX Demhardts, 5X SSC, 50 mM sodium phosphate, ImM sodium 
pyrophosphate, 0.1 mg/ml salmon sperm DNA and 20% formamide previous to addition 
of the probe. The probe was then added to the pre-hybridisation solution and incubated 
overnight at42°C. Filters were then washed at room temperature in 2X SSC, 0.1% SDS 
for 15 mins, followed by one wash in IX SSC, 0.1% SDS for 15 mins at room 
temperature. The filters were then exposed to X-ray film at -70°C for approximately 15 
hours. Colonies containing repeat sequences were identified and picked into L-Broth 
containing ampicillin and incubated overnight at 37°C. DNA was isolated using the mini- 
prep method previously described. Sequencing was then carried out on the positive clones 
using M13 forward and reverse primers. Once the repeat sequence had been identified 
PCR primers were designed to the region of sequence flanking the repeat and prior to 
ordering these primers were submitted to the BLAST programme (NCBI) to verify that 
they do not match any repetitive element within the genome e.g. LINE elements. The 
primers were then synthesised by GibcoBRL. The repeats were investigated for alleleic 
variation by the techniques previously described.
2.4.9 Identification o f end sequences in a PI clone
There are two ways of sequencing the end sequences of PI clones to allow "walking" : a) 
direct sequencing from the PI clone b) sub-cloning the end fragment and sequencing.
2.4.9.1 Direct sequencing from the PI clone
DNA template for sequencing was isolated as the phenol/chloroform extraction method for 
the isolation of PI clone DNA. Once the template had been made it was best if the 
sequencing reaction was carried out as soon as possible. Sequencing reactions were 
carried out as described with 2 pg of PI DNA.
66
2.4.9.2 Sub-cloning PI ends
Shot gun sub-cloning of the PI clone was carried out as described and the white colonies 
transferred to nitrocellulose as described. The membranes were then probed with the 
T7P1 and SP6P1 oligonucleotides which flank the cloning site in the PI vector. After 
preparation of DNA from sub-clones sequencing of the insert can then be performed with 
the original oligonucleotide used for probing or the M 13 forward and reverse primers.
2.5 Identification of YAC clones
2.5.1 Screening o f the YAC library
The Harvard/EC/HGF rat yeast artificial chromosome (YAC) library was obtained from 
Research Genetics. The library was supplied in twenty-four 96-well microtiter plates as 
DNA ready for PCR screening. The library is arrayed in 67 superpools of DNA which 
allows the location of a positive superpool in 67 PCR reactions. An additional 28 PCR 
reactions are then carried out resulting in the plate, row and column address of a single 
YAC clone. The library was screened by PCR as before, a 10 pi reaction was performed 
and 2 pi of template used from the library. However, in some cases the reaction volume of 
the PCR has to be increased to 25 pi and 5 pi of template, this is generally dependent on 
the primers. A positive control containing rat genomic DNA was included (Section 2.2) 
and a negative containing yeast genomic DNA and a negative containing no DNA. After 
the identification of the address of a particular clone the YAC clone was obtained from 
Research Genetics.
2.5.2 Growth o f YAC clones
Individual YAC clones were streaked onto SD plates (2% glucose, 0.072% CSM -trp, - 
ura, 0.67% yeast nitrogen base) minus uracil and tryptophan. The colonies were grown 
on plates at 30°C for 2 days. YAC clones were originally grown in culture in SD medium, 
as above. YAC clones can also be grown in a culture of AHC medium containing 0.17% 
yeast nitrogen base without amino acids and (NH4 )S0 4 , 0.5% (NH4)2S04 and 0.1% 
acid-hydrolyzed caesin (Unitied States Bio) and lmg/ml adenine hemisulfate (Sigma), 
supplemented with 1% glucose. The cultures are grown at 30°C for approximately 2 days 
or until a slight pink colour is observed in the culture.
2.5.3 Identification o f the correct YAC clones
Four single colonies were picked from each of the original streaked clone plates and were 
streaked onto SD plates minus uracil and tryptophan, to allow further purification. After a
67
further 2 days grown on plates “whole cell PCR” was carried on a single colony from each 
of the streaks to identify the correct YAC clone. A single colony from each of the 4 
streaks for each clone was picked into 500 jxl of dH2 0  and 10 pi of this was used in a 25 pi 
volume PCR. The PCR was then carried out as standard. Once the correct colony had 
been identified the yeast clone was grown in liquid culture, SD -ura, - tryp, for 2 days in a 
shaking incubator at 30°C. A glycerol stock was made from the liquid culture in a final 
concentration of 20% glycerol and stored at -70°C.
2.5.4 Isolation o f DNA from YAC clones
Crude DNA for PCR can be isolated from the YAC clones. Cells were pelleted from 100 
pi of yeast culture by centrifugation for 10 minutes at 2, 000 rpm. The cells were 
resuspended in 50 pi of SCE (1 M sorbitol, 0.1 M sodium citrate and 0.06 M EDTA pH
7.0) and then pelleted again. After removal of the supernatant 25 pi of Lyticase solution (4 
mg Lyticase - 5,000-20,000 U/mg protein (Sigma), 100 pi of 100 mM dithiothreitol and 
900 pi of SCE)were added and incubated for 1 hour at 37°C. 60 pi of 0.14 N NaOH was 
then added and incubated for 10 minutes at room temperature. 60 pi of 1M Tris-HCl pH
8.0 was then added and the sample can then be frozen at -20°C. lpl from this is then used 
in a PCR reaction.
2.5.5 Production o f YAC DNA in agarose plugs fo r CHEF gel analysis.
Agarose plugs containing YAC clones were made in the following way : a 10 ml culture of 
yeast was pelleted at 3, 000 rpm for 10 minutes. The cell pellet was then washed in 10 
mM Tris-HCl and 50 mM EDTA pH7.5. The pellet was then washed in SCE (see above). 
The cell pellet was then resuspended in 40 pi of SCE for each block to be made. To this 
Novozyme (Novo Biolals) at a final concentration of 8  mg/ml was added and incubated at 
room temperature for 10 minutes. The yeast cells were then briefly incubated at 50°C 
before the addition of an equal volume of 1.5% Low Melting Point agarose (Seaplaque® 
GTG® agarose, Flowgen) in SCE. The mixture was quickly mixed and then pipetted into 
previously chilled block formers. These were then incubated on ice for 15-30 minutes. 
The plugs were pushed out of the formers and into a solution of 0.4 M EDTA, 1% 
Sarkosyl (BDH) and 2 mg/ml proteinase K (Sigma). The plugs were then incubated for 
24-48 hours at 50°C. Following this the plugs were washed in 10 mM Tris-HCl and 50 
mM EDTA (2X 30 minutes) and can be stored at 4°C. Prior to loading onto a gel the plugs 
were equilibrated in 0.5X TBE for 2 hours.
2.5.6 CHEF Gel Analysis o f YAC clones.
All CHEF analysis was carried out on the CHEF-DR® II system from Bio-rad. The 
analysis was carried out in Low Melting Point agarose (Seaplaque® GTG® agarose,
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Flowgen). For conditions used for CHEF gel electrophoresis see chapter X. Markers 
utilised in CHEF electrophoresis were Promega-Markers® Yeast Chromosomal DNA and 
Promega-Markers ® Lambda ladder.
2.6 Mouse Primers
Mouse MapPairs™ were supplied by Research Genetics. The PCR reactions were carried 
out as for a standard reaction, with some modifications. The PCR primers were used at a 
final concentration of 0.1139gM as per the protocol supplied by Research Genetics. The 
reactions were carried out as follows: 4 minutes at 94°C, 1U of Taq added at 80°C, at least 
30 cycles of 94°C for 15 secs, 50°C for 2 minutes, 72°C for 2 minutes followed by a final 
extension time of 7 minutes. The primer sequence and conditions for PCR from rat 
genomic DNA are given in Table 2.3.
2.7 SSCP Analysis
SSCP analysis was performed using PCR reactions as stated in Section 2.2. The PCR 
reaction was carried out using a final concentration of 5 ng/pl of primers, 20 mM dNTPs 
and 20 ng of template. The Thermo buffer and magnesium were at the concentrations as 
standard PCR. Again a hot start was performed and 1U of Taq added at 80°C. PCR 
reactions were carried out for 25 cycles on the Perkin Elmer Cetus DNA Thermal Cycler. 
After PCR 2 pi of the reaction was diluted into 30 pi 20 mM EDTA, 0.1% SDS. 2 pi from 
this is then diluted into 2 pi formamide stop buffer and loaded onto the SSCP gel. SSCP 
gels used were 6 % non-denaturing acrylamide gels containing 10% glycerol, 0.5X TBE. 
Acrylamide (Anachem) was used in two forms 19:1 or 34.5:1 acrylamide to bis-acrylamide 
ratio depending on SSCP to be resolved. The SSCP was resolved at 30 watts for 4.5 
hours at 4°C in IX TBE.
2.8 Utilisation of a PAC Library
The PAC library is avaliable from Dr. P. De Jong at B AC/P AC resources, The Roswell 
Centre (Buffalo, N.J.). The library construction and ordering details can be found on the 
World Wide Web homepage : http://bacpac.med.buffalo.edu.
2.8.1 Screening the PAC library
Screening of the PAC library was carried out by hybridisation. The colony filters were 
firstly incubated at 65°C in approximately 20 mis of 5X Demhardts, 5% dextran sulphate, 
5X SSC, 0.5% SDS with 100 pg/ml Herring Sperm DNA. The PCR product used in 
screening was band isolated from a 2% agarose gel using the QiaexU gel extraction kit
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(Qiagen). After band extraction 4 jxl was resolved on a 2% agarose gel to determine 
concentration. 20 ng of DNA was then denatured in 47 pi of dH2 0 , chilled and finally 
added to the Ready-to-Go DNA labelling kit (Pharmacia). 30 pCi of a 32P dCTP (NEN 
DuPont, 3000 Ci/mmol) was then added and the reaction incubated at 37°C for 30 minutes. 
The probe was then purified using a G50 Sephadex™ column (Pharmacia). Escherichia 
coli DNA was also isolated from the bacterial strain DH10B and labelled using the Ready- 
to-Go DNA labelling kit as before. After purification the probes were both added to the 
pre-hybridisation solution at cpm/ml and incubated overnight at 65°C. The filters were 
then washed at 50°C for 30 minutes in 2X SSC, 0.1% SDS, followed by a final wash in 
IX SSC, 0.1% SDS at 50°C. The filters were then exposed to X-ray film at room 
temperature overnight.
2.8.2 Utilisation o f PAC clones
Protocols involving the growth of PAC clones and the isolation of DNA are citied on the 
World Wide Web homepage : http://bacpac.med.buffalo.edu.
2.9 Cloning in T-vector
PCR product cloning was carried out using the TA cloning kit (Invitrogen). 10 ng of PCR 
product to be cloned was incubated overnight at 16°C with IX ligation buffer, 50 ng of the 
pCR™ II vector, sterile dH2 0  and 4 units of T4 DNA ligase. 2 pi of the ligation was then 
transformed into INV ocF cells in the presence of 0.5 M p-mercaptoethanol, as for normal 
bacterial transformations and then incubated in SOC medium before plating. The 
transformants were plated onto ampicillin plates containing 20 mg/ml IPTG and 2% X-gal.
2.10 Computer Programs
PCR primers were designed using the MacVector software. Sequence alignments were 
performed using the Gene Jockey II Software from Biosoft.
2.11 Internet Resources
Sequence verification and identification are carried out by submitting any sequence to the 
National Centre of Biotechnology Information (NCBI) Basic Local Alignment Sequence 
Tool (BLAST-BLASTN) programme (Altschul et.al, 1990) on the World Wide Web 
(http://www.ncbi.nlm.nih.gov.). The RepeatMasker programme can be found at the 
WWW site http://www.genome.washington.edu. Loci from mouse and rat chromomes 1 
and 7 were found at the Mouse Genome Database (http://www.informatics.jax.org/) and 
the RATMAP (http://ratmap.gen.gu.se/) WWW homepages.
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2.12 Somatic Cell Hybrid Panel
The somatic cell hybrid panel was supplied by Dr. C. Spirzer. The mouse and rat species 
used in the construction of the panel are BWTg3 and HRSRD, respectively. The Somatic 
cell hybrid panel was analysed by PCR. All PCR reactions were as standard. Reactions 
were firstly tested on the mouse and rat templates to ascertain that a difference can be 
observed between the two strains, if a difference was seen i.e. a length difference 
observed in the PCR product or no signal seen in the mouse. PCR was then carried out on 
the panel using approximately 100 ng of template DNA. The reactions were resolved on a 
2 % agarose gel and scored for the presence of the rat specific band.
2.13 Production of Rat Genomic Southern Blots
10 pg of Brown Norway genomic DNA was isolated as described previously and digested 
using 5U of BamHl, BgBl and EcoBl. The DNA was then loaded onto a 0.7 % agarose 
gel and resolved overnight at 10V. The gel was treated with 0.25 M HC1 for 20 minutes. 
Before treatment with denaturing and neutralising solutions for 20 minutes. Then 
transferred to nitrocellulose by Southern blotting overnight.
Solutions
SOC medium 
litre)
10XTBE(1 litre) 20XSSC
2 % tryptone 108g Tris 175g NaCl
0.5% yeast extract 55g Boric acid 8 8 .2g Na citrate
lOmMNaCl 7.4g EDTA Make to 1 litre
2.5 mM KC1 Make to 1 litre with dH2 0 .
10 mM MgCl2
10 mM MgSC>4
20 mM glucose (dextrose)
with dH2 0
2XYT (1 litre) LB(Luria-Bertani) medium and plates
16 g bacto-tryptone 1 .0 % tryptone
lOg bacto-yeast extract 0.5% yeast extract
5g NaCl 1.0% NaCl
pH 7.0 pH 7.0
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Denhardt's reagent(50X) TE
5g Ficoll
5g polyvinylpyrroliodone 
5g bovine serum albumin
10 mM Tris-HCl (pH 7.4) 
1 mM EDTA (pH 8.0) 
pH 7.4
Add dH2 0  to 500 ml and filter.
AHC medium
1.7 gm yeast nitrogen base without amino acids and (NH4 )2S0 4
(Difco#0335-15)
5.0 gm (NH4 )2 S 0 4
10 gm acid-hydrolysed caesin (U.S. Biochem. Corp., Cat#12852, low 
salt)
20 mg adenine hemisulphate (Sigma #A-9126)
Bring to 1 litre with dH20 and adjust pH to 5.8
Chapter 3
Identification of new genetic markers to allow more precise 
mapping of the agu locus, by isolation of microsatellite markers 
from PI clones of rat genomic DNA.
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Section 1 - Identification o f new genetic markers from PI clones o f rat 
genomic DNA, isolated to contain the genes encoding GRIK5 and ATP4A.
3.1 Introduction
3.1.1 Identifying new genetic marker loci for mapping
The initial localisation of the agu gene to a genetic region of approximately 10 cM had 
involved the use of all the informative markers published to date for rat (Figure 3.1). As 
discussed previously (Chapter 1, Section 1.3), coverage of the rat genome with genetic 
markers was inadequate when compared to mouse and man. Localisation of agu to 
chromosome 1 was based on very few mapping marker loci. Therefore, further markers 
from within this interval of chromosome 1 in the rat were required to establish a map 
position and allow finer mapping of agu. Therefore much of the work carried out at this 
time was focused on the identification of new genetic markers from this region of rat 
chromosome 1 .
1
3 cM R191
agu
30 cM
Kallikrein/R33
Figure 3.1 Markers and genes mapped flanking the agu locus on rat 
chromosome 1 (data as October, 1995). The Figure shows markers and genes 
shown by mapping to be the closest flanking marker loci to the agu locus in October, 
1995. The markers were identified by Serikawa et.al., 1992 and Jacob et.al., 1995 and 
mapped on the F344/AS/AGU and BN/AS/AGU backcrosses. The black circle represents 
the centromere.
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Three approaches for the identification of new genetic markers were followed: 1) 
identification of microsatellite sequences in PI clones isolated from the interval containing 
agu in rat, 2 ) investigation of rat genes which had previously been shown to map within 
the interval, for strain differences using SSCP and 3) investigation of genetic marker loci 
previously mapped in the syntenic chromosome in mouse, for strain differences in rat.
The work described in this chapter concerns the identification of novel microsatellite 
sequences from PI clones containing genes considered likely to map within the relevant 
interval. The bacteriophage PI system permits cloning of DNA fragments of 75-100 kb as 
plasmids (Pierce et.al., 1992; Sternberg, 1994). This system has three main advantages 
over other cloning systems ; the DNA can be faithfully replicated as a low copy number 
plasmid in E.coli (thus minimising rearrangements) but can be amplified to high-copy 
number using IPTG, cloning efficiency in the PI system is better than in YAC clones 
(Sternberg, 1994) and DNA can be readily isolated as supercoiled circles by standard 
techniques. PI clones were isolated using PCR primers designed by the Mac Vector 
programme (Chapter 2, Section 2.10) to these genes and microsatellite sequences 
identified from within the clone. Microsatellite sequences are identified by hybridisation to 
oligonucleotides synthesised as dinucleotide repeat units e.g. repeat (CA)]0. PCR primers 
are then designed to sequence flanking the microsatellite.
3.1.2 Genes identified for investigation.
Four genes were chosen for investigation in view of their positions within conserved 
regions of syteny between mouse, man and rat chromosome 1. The interval of rat 
chromosome 1 thought to contain the agu locus was syntenic to a region of mouse 
chromosome 7 and human 19ql3.2 -13.4 (Yamada et.al., 1994; The Mouse Genome 
Database (October 1995); and Stubbs et.al., 1996; Figure 3.2 and 3.3). The genes 
encoding GRIK5, ATP4A, ferritin light chain (FTL) and ATPL were chosen for 
investigation. The investigation of the genes encoding ATP4A, FTL AND ATPL is 
described in Section 2, work on GRIK5 follows.
3.1.2.1 GR1K5
The rat gene GRIK5 encodes the kainate-preferring glutamate receptor subunit KA2. It 
was previously located to chromosome 1 in rat using a rat X mouse somatic cell hybrid 
panel (Szpirer et.al., 1994) but had not been mapped to a specific region within this rat 
chromosome. The authors also reported the mapping of the mouse gene in interspecific 
backcrosses to the proximal region of mouse chromosome 7 and to human chromosome 
19ql3.2 by fluorescence in situ hybridisation (FISH). These regions had previously been
75
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reported to be syntenic to the region of chromosome 1 in the rat within which the agu gene 
was contained (Fig.3.3) (Yamada et.al., 1994; Cavanna et.al, 1990).
3.1.2.2 Atp4A
The rat gene Atp4A encodes the rat stomach (H+ and K+)-ATPase (Shull et.al., 1986) and 
was mapped at 9 cM on mouse chromosome 7 and to human chromosome 19ql3.1 (Malo 
et.al, 1993), placing it within the a conserved region of sytenys for rat chromosome 1. 
The gene encoding the 16 kDa subunit of V-ATPases (Atpl) was mapped in the mouse to < 
1 cM from the gene encoding protein kinase C gamma (Pkcc) and mapped to 
approximately 5 cM from the gene encoding GRIK5 on mouse chromosome 7 (Figure 
3.3).
The justification for choosing the genes encoding ATPL and ferritin light chain (FTL) and 
the work carried out on them, are detailed in Chapter 3, Section 2.
Three other members of the research group (Dr.P.Shiels, Miss M. B.Duran Alonso and 
Mr M. Canhan) were also involved in the isolation of PI clones and new microsatellites 
from this interval. Most of these genes e.g. Cypel encoding cytochrome P450e, Cea 1-5 
encoding the CEA gene family of proteins and Atpla3 encoding Na+K+ transporting, alpha 
3 polypepetide, had previously been mapped to the correct interval in the rat genetic map 
(Serikawa et al., 1992, Jacob et al., 1995 and Gu et.al., 1996). However, all the 
published markers proved to show not detectable allelic differences between the rat strains 
BN, AS/AGU and F344.
3.2. Results
3.2,1. Screening the PI library fo r  the pools o f clones containing the  
GRIK5 gene
The cDNA sequence of the GRIK5 gene was retrieved from the National Centre for 
Biotechnology (NCBI) nucleotide database (Accession number : U08258) and the 
MacVector programme was used to design PCR primers to the cDNA. The primer pair 
GUI03 forward and reverse were designed to amplify a PCR product of 224 bp from the 
GRIK5 gene. These primers were synthesised and optimised using rat genomic DNA 
(strain BN). The PCR product obtained was sequenced to verify that the correct product 
was obtained. Once this had been ascertained the PCR primer pair GUI03 forward and 
reverse were used to screen the rat PI library superpool lysates for the presence of the 
GRIK5 gene. Initially only the first 50 pools were tested as this had been shown to be 
sufficient to locate a clone (P. Shiels, personal communication). A PCR product of the 
correct size was observed in the pool of clones number 47 (Figure 3.4).
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Size in bp
500 —
344 —
154 —
75 —
Figure 3.4 Identification of a positive PI superpool with GU103
The +ve control was BN DNA and the -ve lacked DNA. Superpool 47 
was the only strong positive signal.The marker (MAR) is 1 kb ladder.
3.2.2 Identification o f a PI clone containing the rat GRIK5 gene.
As a preliminary experiment pool number 47 was grown in liquid culture from the glycerol 
stock and plated onto agar plates containing kanamycin and 5% sucrose to select against 
vector without an insert. Superpool 47 contains 950 clones and approximately 2500 
colonies were replica-plated and grown overnight to provide two identical sets of 15 
plates. The bacterial colonies were washed from one set of plates and a PCR assay for 
GRIK5 carried out on dilutions of the wash containing the colonies. This procedure twice 
failed to detect a positive signal for GRIK5.
In this experiment, clones contained within the superpool were passed through three 
rounds of growth, the first in liquid culture. If the PI clone for GRIK5 is at a growth 
disadvantage compared to other clones in the superpool then it may be have been competed 
out. Alternatively, the PI clone insert may be unstable. Southard-Smith et.al., 1994 
reported one clone which was unstable and had to be purified in a single round of growth. 
However, this was only a preliminary experiment and the numbers of colonies screened 
were too small to be positive of these conclusions. A new system for isolating PI clones 
was therefore devised.
Superpool lvsate
oc
19
A scraping was taken from the frozen glycerol stock of superpool 47 and was diluted in L- 
Broth medium, before plating onto agar plates with kanamycin and sucrose. Single 
colonies were picked, streaked onto another plate in grid formation and grown overnight. 
Samples of ten colonies at a time from the grid were picked into dH2 0  to make lysates. 
These lysates of ten colonies were then screened for GRIK5. This new procedure reduced 
the number of times the colonies were grown before they were screened for a gene and 
only allowed clones to grow as isolated colonies on an agar plate, thus reducing 
competition between clones. In this way 560 colonies from pool number 47 were tested 
for the presence of the GRIK5 gene using the primers GUI03 forward and reverse. A 
positive signal was obtained from lysate 54 (colonies 531-540) (Figure 3.5 a). These 
colonies were picked from the gridded plate and tested individually for GRIK5. A positive 
signal in the PCR was obtained from colony 534 (Figure 3.5 b). This PI clone was 
named GRIK5/P1/1.
3.2.3 Isolation o f plasmid DNA from PI clones
Various methods of isolating DNA from PI clones were evaluated within the laboratory: 
Qiagen kit, tip 100 purification of DNA, phenol/chloroform extraction after alkaline lysis, 
Wizard mini-prep and caesium chloride gradient purification. The Qiagen kit was initially 
used to isolate PI DNA. This involves a standard bacterial cell lysis technique followed 
by purification of the DNA on a resin column. The plasmid copy number was increased 
by growing the bacterial culture in the presence of IPTG. The Qiagen protocol was 
modified by adding double the volume of solutions PI, P2, P3 and QC from the kit. 
However, the DNA yield was low (2.5 gg of DNA from 500 ml of culture) and of poor 
quality; some shearing of the DNA was observed (Figure 3.6 a) and some preparations 
were resistant to restriction enzymes. The problems encountered could be a result of 
purifying large plasmid DNA using resin columns; a large volume of bacterial cell culture 
is required for high DNA yield, and the resulting bacterial debris in the column could be 
reducing the efficiency of the purification.
Caesium chloride gradient purification gave high quantities of good quality DNA. 
However, the method is lengthy and expensive, and the yield and quality of DNA was 
comparable with standard alkaline lysis followed by phenol/chloroform extraction of the 
DNA. This procedure produced relatively large quantities of DNA (20 gg of DNA from 
50 ml of culture) which was readily digestible. Shearing was reduced by using pipette tips 
with cut ends (Figure 3.6 b). This method was adopted as the standard procedure for 
extracting DNA of PI clones.
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Fig. 3.5 PCR assay for GRIK5 in a screen of PI library superpool 47.
Colonies were in batches of ten and the mixed template was screened by PCR.
a) PCR tests of batches 41-56. A positive signal was seen for batch 54.
b) PCR tests colonies 531-540, from batch 54. The +ve control was a PCR reaction 
carried out in the presence of BN genomic DNA as template. The negative control 
(-ve) is a PCR reaction without DNA. The marker (M) was a 1 kb ladder (Materials 
and Methods, Section 2.1.1).
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Figure 3.6 Digestion patterns of DNA from GRIK5/P1/1 isolated by 
two different methods.
a) The Qiagen kit using the tip 100. 1/10 of the final yield of DNA 
was digested.
b) NCI DNA isolated by the phenol/chloroform extraction method. 
1/50 of the final yield was digested. DNA fragments were resolved 
on a 0.5% agarose gel. The marker (M) was a 1 kb ladder.
3.2.4 Identification o f  novel SSRs in the PI clone GRIK5/P1/1.
DNA isolated for GRIK5/P1/1 using the phenol/chloroform purification method was 
digested with Bam HI, Bgl II and Eco RI and the digestion products resolved on a 0.5% 
agarose gel. (Figure 3.7 a) The gel was Southern blotted and the blot probed with a 22P 
labelled (CA)io oligonucleotide the most frequent repeat in the rat genome (Beckmann and 
Weber, 1992). At least five different (CA)n repeats were identified in clone GRIK5/P1/1 
(Figure 3.7 b), which corresponded to the number expected if repeats occur on average 
every 21 kb of genomic DNA (Stallings et.al., 1991), and the average PI clone contains 
an insert of 75-100 kb.
F igure 3.7 a) PI clone GRIK5/P1/1 cut with Bam HI, Bgl II and
Eco RI and the digests resolved on a 0.5% agarose gel. The marker was 
1 kb ladder.
b)This gel was Southern blotted and the blot probed with a 
radioactively-labelled (CA)10 oligonucleotide. At least 5 bands were 
identified in the Bam HI digestion products.
The Bam HI digestion products from GRIK5/P1/1 were shot-gun cloned into pUC18, 
because on Southern blots the size range of fragments with (CA)n repeats were smallest 
when digested with Bam HI. DNA from the resulting colonies was screened by
hybridisation for (CA)„ repeats. Five positive clones were identified, with insert sizes 
between 1.8 and 7 kb (T l .l ,  T1.3, T l . l l ,  T1.13, T1.16) (Figure 3.8).
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Figure 3.8 Comparison of digested sub-clones from 
GRIK5/P1/1 containing (CA) repeats compared to the 
digest of the PI clone. The cloned inserts were digested 
from sub-clones with Pst I and Xba I and compared to 
digested bands from GRIK5/P1/1 digested with Bam HI. 
The marker was a lkb ladder.
Clone T1.16 (Figure 3.8) had the smallest insert (1.8 kb), and a (CA)2 i repeat was found 
when it was sequenced (Figure 3.10). This sequence enabled me to specify the primer 
G U 106 forward on one flank of the repeat but it was necessary to sub-clone the repeat to 
obtain quality data from the other flank. A 900 bp Sst I fragment was shown to contain 
this repeat (Figure 3.9) and was sub-cloned into pBluescript. Sequencing from GU106 
and from the M13 reverse primer yielded acceptable sequence from which a pair of PCR 
primers (GU106 forward and reverse) were designed (Figure 3.10). PCR products 
amplified with G U I06 forward and reverse showed no length variation between F344, 
AS/AGU and BN.
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Figure 3.9 Subcloning of a m icrosatellite, a) Double digest of T l: 16 with Bam 
HI and a second enzyme, as indicated, to identify a smaller fragment containing the (CA) 
repeat in order to allow sequencing. The marker was a 1 kb ladder, b) A Southern blot of 
the gel (a) was probed with a (CA)10 oligonucleotide. A 900 bp fragment containing the 
(CA) repeat was detected in the Bam HI/S.st I digest.
G U I 0 6  F -------------------------------
1 5 1  CCTTGCTCCC AGCACTCAGC GTCGCCTGCC T T C A C C G T C T  T T C T C T C T G T
2 0 1  C T T T C T T T C C  CATTTTCTTC TCCCTTCCCC CTGCCCCTGG CCTTCTGGTC
2 5 1  ACTCTTCTCT GGTCCCAGTG AGTGCCTCGT CAGCCACTGA CAGAACCAGA
3 0 1  CACACACACA CACACACACA CACACACACA CACACACACA CAGGAGACAT
 G U I 0 6  R
3  5 1  A A G G A T G G A C  A A A C A G G C C C  A G A T A C A G A A  A T G G T T A A A C  A C T G A C A G A C
4 0 1  T G G A C A A G C A  G A G A G A G G G A  C A C A C T G A C A  A A T G C A G A C T  G A T A G A C A C A
4 5 1  G C T C C T C T G A  G A
Figure 3.10 Identification of sequence flanking the repeat in T 1 .16 . This 
allowed the primer pair G U I06 forward (F) and reverse (R) to be specified to amplify the 
repeat. The (CA) 2\ sequence is shown in italics and the primers shown in bold.
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Considerable time was expended on clone T1.16, the first clone containing a repeat to be 
investigated, without finding a useful marker for mapping. It was therefore important to 
increase the rate of experimentation. I therefore adopted the strategy of digesting the entire 
NCI PI clone with Sau 3A. This yielded smaller fragments which required fewer rounds 
o f sub-cloning in pUC 18. The resulting colonies were screened by colony hybridisation 
with the oligonucleotide (CA)io (Figure 3.11). Four positive clones were identified 
(T3:39, T3:40 T3:42, T3:60), all having inserts around 600 bp, which can be completely 
sequenced using the vector primers. Sequence analysis showed that sub-clones T3:40 and 
T 1:16 contained the same repeat. T3:39 contained a (CA)is repeat, which the primer pair 
G UI 11 forward and reverse was designed to amplify. T3:40 was observed to contain a 
(CA)i6 repeat.
+ve control +ve control
Figure 3.11. Hybridisation blots of colonies resulting from a sub-clon ing  
of GRIK5/P1/1, with a radioactive (C A )10 oligonucleotide. Colonies were 
gridded, each streaked in the shape of a cross, onto agar plates. Duplicate plates were also 
streaked in this way. The positive control was a T1.16 colony streaked onto the plate. 
The positive colonies T3.39 and T3.60 are indicated by arrows.
3.2.5 Mapping o f  a new marker from  clone GRIK5/P1/1
A (CA)20 repeat followed by an interrupted (CA)n repeat of 144 bp was identified in the 
sub-clone T1.13 when it was sequenced with the M13 forward primer (Figure 3.12). 
PCR primers (GU10 forward and reverse) were used to amplify the repeat and the
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products were assessed for length variations between the rat strains BN, AS/AGU and 
F344.
G U 1 0 F ----------------------------►
1 GGGGATCCAG GGCATCAAAG ATCCTGAGAA ACTGGCCATC TGGTCTACAC 
5 1  A C A C A C A C A C  A C A C A C A C A C  A C A C A C A C A C  A C A C A C A C G C  A C G C A C G C G C  
101 A C A C A C A C A C  A C G C A C A C A C  G C A C G C A C A T  G C A C G C A C G C  A C A C G C A C A C  
151 A C A C A C G C A C  A C A C A C A C T C  A T G T A C G C A C  G C A C A C A C G C  A C G C A C G C A C  
201 A C A C A C A C A G  G C A C G C A C G C  G C A C A C G C A C  A C AGCCAATA TAATAAATCT 
251 TCCGTGTCCC CTTTCCTCTT TCATCTCCGC AGGCCCA
-  ------------------------------GU10 R
Figure 3.12 Identification of a (CA) repeat within sub-clone T1.13. T1.13
DNA was sequenced using the M13 forward primer. The PCR primers (GU10) were 
designed to amplify the repeat and are indicated by arrows and shown in bold. The repeat 
is shown in italics.
PCR reactions were resolved on 4% Metaphor gels, an agarose which can resolve a 
difference of 2% in the length of a product in the size range of 200 to 800 bp. A length 
difference was observed with the primer pair GU10 forward and reverse, with 
AS/AGU > F344 (Figure 3.13). The primer pair GU10 forward and reverse was then 
used to genotype 205 progeny from the F344/AS/AGU backcross (Appendix 2). An 
example of the mapping data is given in Table 3.1. The resulting recombination fraction 
between GRIK5 (GU10) and agu was 0.06 (12 recombinant animals from 205 backcross 
progeny typed). This placed GRIK5 and the marker GU10 approximately 6 ± 1.6cM 
from the agu mutation using the Kosambi estimate of map distance (Kosambi, 1944). 
PCR products from the rat strains were cloned into the PCR II cloning vector and 
sequenced to identify the length variation between the three strains: the F344 PCR product 
was 12 bp smaller than the AS/AGU PCR product and the BN PCR product (BN = 
AS/AGU > F344) (Fig.3.14).
However, other markers isolated from the PI clone NCI were non-informative in these rat 
strains on 4% metaphor ; they were not resolved on 6% acrylamide which is capable of 
resolving differences of a single repeat unit (i.e. 2 base pairs).
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Animal num ber Phenotype of 
animal
Genotype at the 
locus GU10
G enotype
F671-95 Ataxic Heterozygote Recom binant
F672-95 Ataxic Homozygote Parental
F673-95 Ataxic Homozygote Parental
F674-95 Ataxic Heterozygote Recom binant
F675-95 Normal Heterozygote Parental
F676-95 Ataxic Homozygote Parental
F677-95 Normal Heterozygote Parental
F678-95 Ataxic Homozygote Parental
F679-95 Normal Heterozygote Parental
F680-95 Ataxic Homozygote Parental
Table 3.1 Sample mapping data of the agu gene relative to m arker GU10.
Figure 3.13 Typing of F344 backcross progeny with the m arker GU10.
a) Resolution of the PCR products from the primer pair GU10 forward and reverse, on 
4% Metaphor agarose. The PCR products display a difference of AS/AGU > F344, as 
shown on the gel. The B/A and F/A animals are heterozygote animals from each 
backcross. The marker (M) was 1 kb ladder.
b) Resolution of the PCR products from the primer pair GU10 forward and reverse, on a 
6% acrylamide gel. One of the primers was labelled and the PCR product resolved on an 
acrylamide gel. The samples shown are backcross progeny from the F344 backcross; the 
animal numbers are indicated at the top of the gel.
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Figure 3 .14 . Sequence alignment of PCR products obtained from the 
strains BN, F344 and AS/AGU using the prim ers GU10 forw ard and 
reverse. Strain F344 has a deletion of 12 bp between bases 165 and 178 as indicated by a 
dashed line.
3.2.6 Screening the PI library fo r  a clone containing the gene encoding  
A tp  4 A.
PCR primers (GU101 F and R) were designed to the cDNA for the rat Atp4A gene 
(Accession number: J02649). Once optimised to give a PCR product of approximately 
228 bp, the primers were used in a screen of the rat PI library pool lysates. A PCR signal 
was obtained from library pool number 45 (Figure 3.15) which contained approximately 
950 clones. 1400 colonies from this pool were plated out onto four agar plates. Colonies 
were picked into pools of ten and these screened by PCR, as described for the PI clone 
screened for the GRIK5 gene (Section 3.2.2). However, after a total of 820 colonies had
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been screened in this way, no positive signals were obtained. GU10, identified from a PI 
clone containing the gene encoding GRIK5, had been mapped 6 cM from agu and as the 
gene Atp4A mapped centromere distal to Grik5 on mouse chromosome 7 and was 
therefore expected to be located distal to agu than GU10 in the rat. No further work was 
carried out on this gene.
Superpool lvsate
M  + 4 13 14 22 35 45 M
Figure 3.15 Screening of selected P I library pool lysates with prim er pair 
GU101 forw ard and reverse, for the gene encoding Atp4A. The pool lysates 
(numbered above the gel lanes) had previously been tested and had shown faint signals; 
this experiment showed the result to be reproducible. The positive control (+ve) contained 
BN DNA and the negative (-ve), no DNA. The marker (M) was 1 kb ladder.
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Section 2 - Identification o f new genetic markers from PI clones o f rat 
genomic DNA, isolated to contain the genes encoding ATPL and FTL.
3.3 Introduction
Chronologically the work carried presented in this chapter was carried out after the 
mapping of markers R158 (Section 5.2) and GU10 (Section 3.2.5), but as the work 
detailed also involves isolation of markers from PI clones, I will describe the work within 
this chapter. Mapping of markers from within our original region of study e.g. 
GRIK5/GU10 and R158, produced a narrower field for investigation. Further genes, 
previously mapped within the mouse genome, were also identified, as the region of 
synteny between mouse and rat became clearer. Genes were identified for study from 
genetic mapping within the mouse which were observed to map close (< 1 cM) to the 
closest marker to agu, R158. Therefore, the genes encoding Atpl and ferritin light chain 
(ftl) were chosen because in mouse they map within 1 cM of Pkcc i.e. R158 (MGD). Also 
the gene encoding ferritin light chain was considered a putative candidate gene and had 
been mapped to the conserved region of syteny in man.
3.3.1 Atpl
The cDNA encoding the 16 kDa subunit of vacuolar H+-ATPase was cloned from rat liver 
by Nezu et.al., (1992). Vacuolar H+-ATPases are distributed in membrane systems of 
eukaryotic cells e.g. vacuoles, Golgi apparatus and plasma membrane. V-ATPases 
function as a proton pump coupled with ATP hydrolysis and maintain the interior acidic 
pH of these organelles. The gene encoding the 16 kDa subunit of V-ATPases {Atpl) was 
mapped in the mouse to < 1 cM from the gene encoding protein kinase C gamma {Pkcc). 
Both of these genes were identified to be approximately 5 cM centromere proximal from 
GRIK5 on mouse chromosome 7 (Figure 3.3 and 3.16). Isolation of a PI clone 
containing the rat Atpl gene and mapping of new microsatellites would allow mapping of 
the rat gene and facilitate further mapping of agu.
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Mouse chromosome 7
1 cM
2 cM
5 cM
Pkcc Atpl
Grik5
Figure 3.16 Mouse genetic map of chromosome 7. Taken from The Mouse 
Genome Database.
3.3.2 FTL
Ferritin is the major intracellular iron store in all organisms. Increasing evidence indicates 
that iron-induced oxidative stress may participate in the cascade of events leading to nerve 
cell death in Parkinson’s disease (PD). Levels of iron in the substantia nigra are increased 
from 35% to 77% in PD cases compared to normal controls (Dexter et.al., 1989, Hirsch 
et.al., 1991 and Sofic et.al., 1991). The expression of ferritin is regulated by the 
intracellular iron concentration, and when iron levels are high ferritin mRNA is translated 
leading to iron storage. It could be expected that the expression of the ferritin protein is 
affected in the substantia nigra of PD brains leading to excessive levels of iron within the 
brain. Mammalian liver and spleen ferritin consist of 24 subunits of two species, the 
heavy and light subunits. Brown et.al. (1983) presented evidence that in the rat, the two 
species of subunits are coded by separate mRNAs. By studying human/Chinese hamster 
hybrid cells and use of a radioimmunoassay specific for human ferritin, Caskey et.al. 
(1983) showed that human chromosome 19 encodes the structural gene for ferritin. By 
study of hamster-human and mouse-human hybrid cells, some with translocations 
involving chromosome 19, Worwood et.al. (1985) concluded that light subunits of ferritin 
are coded by a gene in the segment 19q 13.3. The gene encoding ferritin light chain 
therefore mapped to the region of the human genome syntenic to the rat genomic region 
containing the agu mutation and was considered a likely candidate gene to contain the agu 
mutation.
3.4 Results
3.4.1. Identification o f a new genetic marker from  a PI clone containing  
DNA sequence from  the rat Atpl gene.
PCR primers were designed with the aid of the Mac-Vector software, to the rat cDNA 
encoding the 16 kDa subunit of the vacuolar H+-ATPase (Accession numbers : D 10874
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and DO 1244). The primers (NCA forward and reverse) were designed to the 3’ 
untranslated region of the cDNA and were optimised to produce a 149 bp product from rat 
genomic DNA (strain BN). These primers were used to screen the PI library supeipool 
lysates. Library pool number 65 produced a PCR product of the correct size (Figure 3.17) 
and contained 950 clones. A slightly different strategy was then used to identify the PI 
clone containing the ATPL gene sequence: 5,000 colonies from the supeipool were plated 
onto agar plates containing kanamycin and the plate divided into quarters and the colonies 
scraped into L-Broth. PCR was then carried out on lysates of these quarters to identify 
one containing the sequence encoding ATPL. One quarter was identified as positive from 
this PCR (Figure 3.18) and the clones from this were plated out. These colonies were 
picked into lysates containing ten colonies and were screened by PCR. 720 colonies were 
screened from this positive quarter and a positive lysate identified, the single colonies were 
tested and one positive obtained. This clone was called ATPL/P1/2.
bp
1,000
506 
344
220 
154
Figure 3.17 Identification of a superpool (S65) containing the gene 
encoding ATPL by PCR. The supeipool 49 (S49) also gave a weak signal. The 
marker (M) was a 1 kb ladder.
Quarters
1 2  3 4 > MI
bp
506 
344 
201 
154
Figure 3.18 Identification of a positive quarter taken from a plate 
containing colonies from superpool 65. Quarter four was the only positive. The 
marker (M) was a 1 kb ladder.
ATPL/P1/2 DNA was cut, electrophoresed, Southern blotted and probed with a 
radioactively-labelled (CA)jo oligonucleotide to identify the microsatellite repeats within 
this clone. Two positive fragments were identified from ATPL/P1/2. PI clone 
ATPL/P1/2 was restricted with Sau 3A and shot-gun cloned into pUC 18. Colony
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hybridisation was performed on the resulting blot from the colonies with the radioactively- 
labelled (CA)jo repeat probe to identify sub-clones containing this microsatellite. One was 
identified. The positive sub-clone was sequenced using the M13 forward and reverse 
primers and a (CA)22 repeat identified within the sub-clone (Figure 3.19). This sub-clone 
also contained a (TA )24 repeat. The PCR primer pairs (H31C and H31T forward and 
reverse, respectively) were designed to amplify a PCR product containing both of these 
repeat structures (Figure 3.19).
F  ►
CTAGAGTCGA CCTGCAGGCA TGCAAGCTTT C C T G T C T T C T  G C A T A G A T C A  
CTGTTTTCTC AAATGTGATA ATTTAATATT AAACACACAC CCACCTGCTT 
ATTTTCATAT ATATATATAT ATATATATAT ATATATGTAT ATATATATAT  
ATATATTCAC ACAGAAACAC ATACATATAC ACAGACACAC ACACTCACAC
-------------------------►  F+R
ACACAGACGC ATGCACACCT GATCTTTACT TCAAATTTAC TTACTTACTT 
AC AAC C CA CA CACATACACA CACACACACA CACACACACA CACACACACA 
CCTGCTTCTT ACCTTCATGT AGACTTAGTT ATATTCATAG TTATTTGTTT 
ATTTATTCAC TTTACCTGCT GCACACTGCC CCCCTCCAGT TCACCCCTCT 
CACAAGCCTT CCCCCAGTCC TTTCTCCTCT GAGTAAGAGA AGACCCACAG
----------------------R
G T A T T T C C T C  A C C T T G C C TA TGTATCTCTG TGATCACATC CTCTGCTACT
Figure 3.19 Sequence identified from a sub-clone from A TPL/P1/2 
containing (CA)17 and (TA) 24 microsatellites (shown in italics). The PCR primers 
are shown in bold.
The PCR products produced from the primer pairs H 31C and H31T forward and reverse 
were assessed for length differences between PCR products containing these repeats. 
Both sets of PCR products were resolved on 6% acrylamide gels and H31T displayed a 
length polymorphism (BN>AS/AGU). This marker was then used to genotype progeny 
from the BN/AS/AGU backcross. The marker produced from H31T forward and reverse 
was shown to be unlinked to agu (it displayed >50% recombination between the marker 
and agu p = > 0.1), however, only a small number of animals was tested (n = 20). 
Subsequent testing with the primers H31T forward and reverse on a somatic cell hybrid 
panel indicated that this marker mapped to rat chromosome 4 (Figure 3.20 and Table 3.2)
H31T
H31C
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344500
150
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150
Figure 3.20 Analysis carried out on the somatic cell hybrid panel. (Section 
2.12) with H31T forward and reverse (Atpl). BWTG3 is the mouse strain and HRSD the 
rat strain used in the construction of the panel. The other lanes contain hybrids from the 
panel. The marker (M) was a 1 kb ladder.
H31T
Chromosome 4
+ -
+ 9 0
- 0 3
Table 3.2 Contingency table for H31T showing localisation on 
chrom osom e 4.
3.4.2. Mapping o f a rat ferritin light chain gene.
PCR primers, GU9 forward and reverse, were designed to amplify a fragment from exon 
four of the rat ferritin light chain gene (Accession number : J02741). The primers were 
used to screen the PI library and identified a positive clone, F16 from superpool 39. This 
PI clone was digested with Sau 3A and shot-gun cloned into pUC 18; the resulting 
colonies were screened for (CA) microsatellites by hybridisation to colony blots with a 
radioactively-labelled (CA )10 repeat oligonucleotide. Five colonies were identified that 
contained this microsatellite (Figure 3.21). The cloned DNA inserts were sequenced using 
the M13 forward and reverse primers and the microsatellites within these clones were 
identified (Figure 3.22). PCR primers were designed to the sequence flanking the 
microsatellite (Table 3.3).
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Figure 3.21 Shot-gun subclones from F16 probed with a rad ioactively- 
labelled (C A )10 repeat oligonucleotide. The positive control (+ve) is a colony from 
a sub-clone from GRIK5 known to contain a (CA)n microsatellite by sequencing. The 
colonies F20, F34 and F61 are positive.
M arker M icrosatellite Strain difference M apping
F20 (GT)19 No -
F34 (CA)27 BN>AS/AGU 22/52 = 42.3 ± 6.8
F61 (CA)i7 No PCR product -
F101 (CA),2 BN>AS/AGU -
FI 10 (CA)i3 No -
Table 3.3 Summary of microsatellite m arkers identified from F I 6. F I 6 is a
PI clone containing the ferritin light chain.
The genetic marker amplified by the primers F34 forward and reverse displayed a strain 
difference between BN and AS/AGU (BN > AS/AGU) and was used to genotype 52 
BN/AS/AGU backcross progeny to 42.3 ± 6.8 cM from agu.
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1  A A G T G A A G C C  T G T C T T A G G A  A C A C A C T G T C  T T C A C A T A G A  A A G T T G G A C T  p
5 1  A G A A G C A C C C  A G C T G G T G T C  C A C T T T A G A A  C C A G T T G C T A  G G T G T T G T G T
1 0 1  A A G G A N A C A C  C C C A C A C A C T  N C G T T T T G T G  C G T G C G T G T G  T G T G T G T G T G
1 5 1  T G T G T G T G T G  T G T G T G T G T G  T G T G T N N G C A  A A A T T G A T A N  T A T G T A G G A A
2 0 1  A A A C T G T G A N  T T T G G T T T C C  G G G G A C C C A G  C A G G C C T G A A  C A A A C T C C T T  R
1  G C A G G T C G A C  T C T A G A G G A T  C C C A G C A C T C  T A G A G G C A G A  G G T A G A C A G A  p
5 1  G T T C G A G G A C  A G C T G G G G C T  A C A C A A T G A A  A C T C T G T C T C  A A A A C A C A C A
1 0 1  C A C A C A C A C A  C A C A C A C A C A  C A C A C A C A C A  C A C A C A C A C A  C A C A C A C A C G
1 5 1  A G A C A A A G A A  A A A G T A A A C A  G C T A G T A T T C  A A T A A A C A A G  A A C A G A T A A C
2 0 1  A G A A A G T G G G  G A A A C T G A T T  T T T C A G T T A T  C C T A T A T T A C  A A T T G T C A A A
2 5 1  T G T C C A T T T T  A A C A C C A A G A  A T A G C G A A T G  A G G A A A A A G A  T T T G A G A T A A  R
3 0 1  A C T A T C T T T G  A G A A A C C A G A  C A C T A C A G T C  A A T A A A T G C T  A C A C T C A C T A
1 0 1  C C A A A C T A N G  A A N T G G C C C A  C A T G T C C A T C  A A T T G A T G G A  C A C A T A A G A A  F
1 5 1  A A T G T G A G A C  A G A C A C A C A C  A C A C A C A C A C  A C A C A C A G T G  G A G C A C T A C T
2 0 1  C A T A T G T A T G  A A G A A G G A T G  A T A T A T T C T A  T C A T T T A C A G  T A G A A A T G G A
F101
2 5 1  G G G A C T G G A G  GTCAGCATGC TGTGCTAAGT T C C A G T G C T C  A G A A G G A A A T  R
3 0 1  G C C C T G C A T G  T T C T T G C A T A  T G C A G A G G C C  A G G T G G T C A T  G A A A A G C A G C
1  A C T T G T C T G G  C T A T A G T G T C  A T T C A T C C T A  A C C A A T C T A G  G A A G T G G C C C  
5 1  A C A T G T C C A T  C A A T T G A T G G  A C A C A T A T A G  A A A A T G T G T A  G T A C A G A C A C  
1 0 1  A C A C A C A C A C  A C A C A C A C A C  A G T G G A G C A C  T A C T C A A T G A  T G A A A A A G G A  
1 5 1  T G A A C T T C T A  T C A T T T A C A G  A G A A A T G G A G  G G A C T G G A G G  T C A G C A T G C T  
2 0 1  G T G C T A A G T T  C C A G G C T C A G  A A G G A A A T G C  C C T G C A T G T T  C T T G C A T A T G  
2 5 1  C A G A G G C C A G  G T G G T C A T G A  A A G C A C C A C C  C G G G C T G T G T  G G G A T A T A A A
Figure 3.22 Microsatellite sequences generated from sub-clones of the P I  
clone F16, containing the gene encoding ferritin light chain. The
microsatellite sequences are underlined and the PCR primers designed to amplify them are 
shown in bold, the forward (F) and reverse primers (R) indicated.
R F110
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3.5 Discussion
The object of this work was the identification of new rat genetic markers to map the agu 
gene. Isolation and mapping of novel microsatellites within 10 cM of agu will provide a 
finer genetic map for the positional cloning of agu.
Data obtained with the primer pair GU10 forward and reverse allowed the mapping of the 
GRIK5 gene relative to agu and relative to published markers on this chromosome e.g. 
DlMgh7 and DIMitl. A recent paper by Szpirer et. al.,(1997) positioned GRIK5 to lq21 
on the rat chromosome by fluorescence in situ hybridisation (FISH) allowing the 
integration of the linkage and cytogenetic maps. This confirmed the mapping of GRIK 5 
to this region of rat chromosome 1 (Figure 3.23).
The methods used in the identification of new PI clones, containing genes of interest, 
were laborious and time consuming. The problems encountered with the isolation of PI 
clones may be due to the instability of certain PI clones or the rarity of others. Therefore, 
the screening for a PI clone containing the rat gene Atp4A was discontinued, as this gene 
mapped further centromere distal from the proposed site of agu on mouse maps, when 
compared to GRIK5.
Mapping of the marker defined by H31T forward and reverse, on the BN/AS/AGU 
backcross and from mapping on a somatic cell hybrid panel indicated that the gene 
encoding Atpl was actually contained on rat chromosome 4. This contradicted where this 
gene was expected to map in rat. However, Nezu et.al. (1992) who reported cloning of 
the cDNA for Atpl also reported that on genomic Southern blots there are three genes 
homologous to Atpl. It is not clear if these are functional genes or pseudogenes. Simkces 
et.al., (1996) reported that in mouse there also appeared to be three independent genes 
present on chromosomes 6, 7 and 17. Preliminary human mapping data identified at least 
two gene loci on chromosomes 3 and 16 (Hasebe et.al., 1992). It is possible therefore 
that we have cloned the Atpl gene not from chromosome 7 in the mouse (chromosome 1 in 
rat) but from another chromosome. In fact chromosome 4, to which a microsatellite from 
the Atpl PI clone mapped in rat, has a conserved region of syteny with mouse six which is 
syntenic to human chromosome 3 all of which are reported to contain a member of the Atpl 
gene family.
The marker F34 positioned the PI clone containing the ferritin light chain to 42.3 ±6.8 cM 
from agu, and indicated that either the gene was not contained within the conserved region 
of syteny on rat chromosome 1 or that an event had taken place during cloning which 
caused this PI clone to be chimaeric. Also the possibility exists that we have actually 
isolated another member of the ferritin light chain gene family. A recent study in mouse
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(Filie et.al., 1998) identified twelve family members; one expressed gene and eleven 
pseudogenes. The expressed gene in mouse corresponds to the ferritin light chain mapped 
to 19q 13.3-q 13.4 in man and mapped to the syntenic chromosome in mouse, chromosome 
7. Therefore, it is assumed that a number of rat ferritin light chain genes also exist and this 
is the one cloned in PI clone F. This would explain some of the results obtained from the 
somatic cell hybrid panel screen.
Human
19ql 3.2
L9ql 3.3
agu 
GRIK 5 (q21)
Calm 3 (q22)
9p24 I
Figure 3.23 Cytogenetic map of rat 
chromosome 1 with the position of 
GRIK 5 shown. The agu gene is just 
5cM centromere proximal to this 
marker.
5 cM
RNO 1
It would appear that in the case of Atpl and the ferritin light chain, I have in fact isolated a 
member of the gene family which does not map to the correct chromosome in rat. At the 
beginning of this work, only one rat gene encoding ferritin light chain had been identified. 
However, since this time genetic mapping earned out in mouse has identified 11 
pseudogenes contained on 11 different chromosomes in mouse (Filie et.al., 1998). It is 
possible, therefore, that I have isolated a pseudogene from rat.
Southern hybridisation of rat genomic DNA with a cDNA probe for Atpl had identified 
three distinct bands (Nezu et.al., 1992). However, the genes corresponding to these 
bands have not been isolated or sequenced. Therefore, when designing PCR primers to
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screen the PI library for Atpl, I specified them to an area of sequence which was not 
conserved between rat, mouse and man. This would hopefully be less well conserved and 
may not be present in other family members. However, this approach was not successful 
and another gene corresponding to one found on mouse chromosome six (rat chromosome 
4) was isolated.
The approach taken in the identification of these PI clones and microsatellites from them, 
is obviously flawed. More consideration should have been taken of gene families, which 
can lead to the problems detailed above. Therefore, if future work of this type is to be 
carried out either a probe specific for a particular family member must be used. Or once 
the genomic clones have been isolated, they should be used in a FISH analysis of a rat 
chromosome spread to confirm their presence on rat chromosome 1.
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Chapter 4
Alternative approaches to identifying new genetic markers
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4.1 Introduction
As very few markers or genes had been localised on genetic maps of the rat genome, new 
markers which would allow mapping of agu were a major requirement of this project. The 
mouse genome is extremely well characterised when compared to the rat genome, and has 
a greater number of markers and genes which have been accurately genetically mapped. 
Although microsatellites are widely regarded as anonymous sequences, it has been 
demonstrated that the location of (CA) repeats tends to be conserved between mammalian 
species (Hino et.al., 1993). The sequences immediately flanking the microsatellite motif, 
which serve as priming sites, are likely to diverge at a significant rate. Therefore, some 
microsatellite markers from the extensive syntenic mouse maps maybe be used for 
mapping within the rat (Kondo et.al., 1993; Hino et.al., 1993 and Sun and Kirkpatrick, 
1996). Hino and colleagues (Hino et.al., 1993) identified 14 universal mapping probes 
derived from human chromosome three that hybridised to rat, thus allowing transfer of 
information from a “map rich” organism to a “map poor”. Hindo and colleagues achieved 
the same objective from mouse to rat (Hindo et.al., 1993).
Microsatellites have become the genomic region routinely used for mapping in mammals 
and the region most commonly investigated for polymorphisms. However, this is not the 
only region of the genome where polymorphisms can be identified. Single-strand 
conformation polymorphism (SSCP) is a sensitive method for detecting single base 
differences in polymerase chain reaction (PCR) products (Orita et.al., 1989). The 
technique is based on the detection of a single-base substitution which alters the 
conformation of single-stranded DNA under non-denaturing conditions. SSCP has been 
utilised heavily in recent years for mapping in the mouse. A recent study carried out 
within our laboratory was able to detect a polymorphism in greater than 90% of PCR 
products tested from the 3’ UTR in the mouse strains Mus spretus and C57/BL6 
(A.S.McCallion, 1997). Therefore, SSCP was used to test various rat PCR products, in 
an attempt to identify strain differences between the three rat strains AS/AGU, BN and 
F344.
4.2 Results
4.2.1 SSCP analysis o f PCR products from the 3 ’ UTR o f rat genes.
The 3’ UTR region of genes has been preferentially used for SSCP analysis 
(Avramopoulos et.al., 1993), as this is region is less conserved when compared to other 
gene regions e.g. exons and introns, and therefore has a greater chance of containing a 
nucleotide difference. Three pairs of PCR primers (GU 101 forward (F) and reverse (R), 
102 F and R and 104 F and R) were designed to amplify a fragment of less than 300 bp
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from the 3’ UTR of the rat genes encoding Atp 4a, SCNIB and GRIK5 respectively, to 
allow SSCP analysis to be carried out between the rat strains. PCR products were 
resolved on 6% non-denaturing acrylamide gels at 4°C in the presence or absence of 
glycerol and with two different ratios of acrylamide to bis-acrylamide. The conditions for 
resolving SSCPs are discussed in A.S. McCallion (1997). No SSCP was observed 
between any of the PCR products from the rats strains AS/AGU, BN and F344 (an 
example is given in Figure 4.1). A summary of the PCR products tested for SSCPs is 
given in Table 4.1.
O
o
Figure 4.1 SSCP analysis carried out on the PCR product from GU104.
The gel conditions are as follows electrophoresised at 4°C for 4 hours at 30W. The gel 
was a 6% acrylamide non-denaturing gel containing 10% glycerol.
SSCP test Gene Location 
in gene
Product
size
Strain
difference
A ccession
num ber
GU 101 Atp 4a 3’ UTR 107 bp No J02649
GU 102 SCNIB 3’ UTR 276 bp No M91808
GU 104 GRIK5 3’ UTR 224 bp No U08258
Table 4.1 Summary of SSCP analysis carried out on PCR products from
the 3’ UTR of genes from rat.
4.2.2 SSCP analysis o f PCR products from  microsatellite markers.
SSCP analysis can also be carried out on PCR products from microsatellite markers which 
had proved to be non-informative after resolution on denaturing 6% acrylamide gels. A 
base change in the area surrounding the microsatellite or within the microsatellite motif
itself would be sufficient to display an SSCP. Many microsatellite markers previously
tested within our laboratory were non-informative on agarose or acrylamide gels. Eleven 
of these were tested by SSCP. Also three markers which had been isolated from the ends
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of the PI clone K (Chapter 6), presumably from unique sequence not derived from any 
gene were tested. All of these were tested for an SSCP under various conditions but again 
no strain difference was observed (Examples are given in Figure 4.2). A summary of the 
results obtained is given in Table 4.2.
ZCQ U-
D
O<
c /5<
—  i wmm
Calm 3 Cea 3 KT7
Figure 4.2 SSCP analysis carried out on microsatellite m arkers from rat.
The markers shown are Calm 3, Cea 3 and KT7. All three were tested on the rat strains 
BN, F344 and AS/AGU.
M arker Reference Strain  difference
DIMco 1 Gu et.al., (1996) No
R 94 Serikawa et.al., (1992) No
DIMgh 5 Jacob et.al., (1995) No
R 100 Serikawa et.al., (1992) No
Calm 3 Gu et.al., (1996) No
D 0G U  14 M.B. Duran Alonso, (1997) No
Atp la3 Gu et.al., (1996) No
D 1 Kyo 1 (M 105) Kondo et.al., (1993) No
Cea 3 M. Canham, (1997) No
CKM M.B. Duran Alonso, (1997) No
D8GU 18 M.B. Duran Alonso, (1997) No
KSP6 Chapter 6 No
KSP62 Chapter 6 No
KT7 Chapter 6 No
Table 4.2 Summary of SSCP analysis carried out on PCR products from  
microsatellite m arkers from rat.
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4.2.3 Utilising markers from  the mouse genome.
The mouse genome has been extensively mapped in recent years and the mouse genome 
therefore has a greater number of mapped genetic markers when compared to the rat 
genetic map (Chapter 1). It was postulated that some of these markers could be used for 
genetic mapping in the rat. The agu locus had been located to a genetic interval within 0.1 
cM of R158 (Chapter 5), therefore mouse genetic markers were selected within 2 cM 
(Figure 4.3) of the gene encoding PKC (Pkcc in mouse) which contains the microsatellite 
for the marker R158 in it’s 3 ’UTR. The markers were obtained from Research Genetics 
and their map position taken from the Mouse Genome Database (MGD).
Mouse chromosome 7
lc M  —
2 cM
3 cM
4 cM
Pkcc D7 Mit 75, D7 Mit 243, D7 Mit 152, D7 Mit 168, D7 Mit 244 
D7 Mit 153, D7 Mit 178, D7 Mit 190, D7 Mit 56.
D7 Mit 65, D7 Mit 191, D7 Mit 76
D7 Mit 216
Figure 4.3 Genetic map was taken from the Mouse Genome Database
(MGD) (June, 1996) showing the position of mouse markers used, in relation to Pkcc. 
The centromere is indicated by the black circle.
The mouse markers were initially tested on genomic DNA from different mouse strains to 
ascertain if the correct allele size for each strain was obtained. The markers were then used 
in a PCR reaction containing rat genomic DNA from the three rat strains used in this study. 
Of the thirteen markers tested, 4 produced single bands from rat DNA, however, none 
showed a polymorphism on 4% agarose gels (Figure 4.4). Tests carried out on 6%
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acrylamide gels also failed to display a polymorphism (Figure 4.5). Only three markers 
gave no PCR product on rat, the remaining six primer pairs produced multiple products.
D7Mit 243 
B F A M
D7Mit 153 
M B F A
D7Mit 178 
B F A
bp bp
396 344—
298 220—
220 134—
154
Figure 4.4 Example of mouse microsatellite m arkers used in PCR from rat 
genomic DNA from the three rat strains BN, F344 and AS/AGU. D7Mit 243 
and D7Mit 178 gave single products. D7Mit 153 produced no product. No strain 
difference was obtained on 4% Metaphor gels. The marker (M) was a 1 kb ladder.
■ ■ ■ I
D7Mit 178
D
a
Z  3  </5£Q UU <
D7Mit 243
Figure 4.5 Mouse prim ers D7Mit 243 and 178 tested on rat genomic DNA.
All three rat strains (BN, F344 and AS/AGU) were amplified and resolved on 6% 
acrylamide. Again no strain difference was obtained
The mouse markers D7Mit 178 and D7Mit 243 produced clear products of 150 and 250 bp 
when tested on rat DNA (Figure 4.4 and 4.5). SSCP analysis was carried out with both 
of these markers but again no strain difference was observed (Figure 4.6). The results 
obtained from tests of the mouse primers on rat genomic DNA are shown in Table 4.3.
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D7Mit 243
O
D7Mit 178
Figure 4.6 SSCP analysis carried out with the mouse prim ers D7Mit 243
and 178 on the three rat strains. No polymorphism was observed.
Mouse m arker PCR from rat Product size in rat S train
d ifference
D7Mit 75 No product - -
D7Mit 243 Single product 250 bp No
D7Mit 168 No product - -
D7Mit 152 Single product ~ 398 bp No
D7Mit 153 No product - -
D7Mit 178 Single product 150 bp No
D7Mit 76 Multiple products Major band 100 bp No
D7Mit 190 Two products ~ 135 bp No
D7Mit 56 Single product 130 bp No
D7Mit 65 Multiple products Major band 130 bp No
D7Mit 191 Multiple products No major product No
D7Mit 244 Multiple products No major product No
Table 4.3 Summary of PCR reactions carried out with mouse genetic 
m arkers on rat genomic DNA from the strains BN, F344 and AS/AGU
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The marker D7Mit 178 produced the strongest signal in a PCR reaction and this marker 
was used to screen the rat PI library in an attempt to isolate a PI clone containing this 
marker. A PCR product approximately 20 bp larger than the BN positive control was 
obtained from superpool 61 (Figure 4.7).
Figure 4.7 PCR carried out with the primers D7Mit 178 . PCR on rat genomic 
DNA (BN) and from PI library pool number 61 (S61) from the PI library. The gel shows 
the length polymorphism between the three products. The marker (M) was a 1 kb ladder.
Sequence analysis of the PCR products from mouse genomic DNA, BN genomic DNA 
and the product from superpool 61, all showed a (GT) microsatellite, with very little 
flanking unique sequence (Figure 4.8). This indicates that the mouse primers are indeed 
producing the same product in rat as in mouse, which unfortunately displays a strain 
difference between the rat strains SD (used to prepare the PI library) and BN, but not 
between the three rat strains currently under study.
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Figure 4.8 Sequence alignment of PCR products produced from D7M it 
178. Products from mouse genomic DNA (strain C57/BL6), rat genomic DNA (BN) and 
the PI superpool number 61 (SD). Dashes indicate a different or absent base.
4.3 Discussion
The object of much of this work was the identification of new genetic markers to map the 
agu gene. SSCP was utilised in this study, however, from the 17 markers tested no 
polymorphism was observed using this method. This is probably due to the fact that rat 
strains are quite homogeneous and do not display as many strain differences as is seen 
between Mus spretus and Mus musculus. Also the region tested for strain difference is 
very small, PCR products were generally smaller than 300 bp, and it was unlikely that a 
polymorphism would be detected in this small length of sequence. It would have been 
preferable to screen large areas of rat sequence for polymorphisms.
The mouse primers used to identify polymorphisms in rat also showed a low level of 
polymorphism. The fact that approximately 30% of the primers actually produced a PCR 
product from rat genomic DNA was promising and showed that in some cases mouse 
primers could be used for mapping in rat. Again the markers were non-polymorphic 
between our rat strains; however, only one PCR product was sequenced to confirm that 
the product contained microsatellite sequence. The mouse primer pair D7Mitl78 produced 
the correct sized PCR product from rat genomic DNA, which unfortunately was non- 
informative in our rat strains. This primer pair was used to screen the rat PI library and a 
product observed in library pool number 61. Sequence analysis showed that both the 
products from mouse and rat genomic DNA contained a (GT) microsatellite. 
Unfortunately the unique sequence surrounding the microsatellite was not long enough to
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determine absolutely if the two PCR products were the same. Approximately 400 colonies 
were screened from this superpool but a colony could not be identified which contained 
this marker. Unfortunately, there was not enough time to complete this work and further 
developments occurred which made it less important.
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Chapter 5 
Mapping the agu locus to within <1 cM
5.1 Introduction
Mapping of GU10 placed GRIK5 approximately 5 cM centromere distal from the agu 
gene. This work, along with other mapping studies defined a smaller genetic interval 
containing agu, defining an interval further centromere proximal (Szpirer et.al., 1997), 
than was originally thought. To date the marker mapped closest to agu was R191 
(Serikawa et. al., 1992), mapping approximately 4.9 ± 0.5 cM centromere proximal. The 
publication in 1996 of the Gu et.al. rat chromosome 1 map lead to the investigation of new 
markers mapped close to R191 e.g. D IM col, DlM co2 etc. and also markers previously 
thought to be further from agu e.g. R158 (Figure 5.1).
Data from Gu et al, 
1996.
Size in cM.
2.3
6.3
15.1
i
—  D lM co2
— R191
—  PKC/R158
D IM col, D lM co6 
GRIK5 —
agu '
—  Kal
Figure 5.1 Genetic map of rat chromosome 1 published by Gu e t .a l . ,  
1996. Only the top section is shown. The black circle represents the centromere.
5.2 Results
5.2.1 Establishing a defined genetic interval
It was clearly useful to establish a sub-set of backcross progeny which were recombinant 
within a defined interval containing agu. This would allow any new markers which were 
identified to be mapped quickly relative to agu on a smaller number of animals, rather than 
on the four thousand progeny constituting the two backcross (BN X AS/AGU and F344 X 
AS/AGU). This would also provide identification of cross-over events which had 
occurred within this region in some backcross progeny and would be of assistance in the 
future during physical mapping. Markers were identified from both backcrosses which 
spanned an interval containing agu. The marker DlM gh7 (Jacob et.al., 1995) PCR
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products display a strain difference, the AS/AGU allele is larger than the BN. DlM gh7 
was mapped in the BN X AS/AGU backcross (Figure 5.2).
bp
298
201
154
134
75
Figure 5.2 Example of genotyping carried out on backcross progeny from  
the BN X A S/A G U  backcross with m arker D lM gh7. The PCR products were 
resolved on 4% Metaphor gels at 125V for 4 hours. An example of a heterozygote and a 
homozygote animal are shown in the first two lanes. Numbers corresponding to each 
animal is given above. The marker (M) was a 1 kb ladder.
324 backcross progeny were genotyped with this marker and 70 proved to be recombinant 
between the agu and the DlM gh7 loci, placing the marker 23.1 ±2.3 cM from the agu 
mutation using the Kosambi estimate of map distance (Kosambi, 1944). A marker 
identified flanking agu on the other side (D lM itl; Jacob et.al., 1995)] had previously 
been mapped by M.B. Duran Alonso (Duran Alonso, 1998) to 5.5 ± 1.1 cM from agu. 
This defined a region of 30 cM in the BN X AS/AGU backcross in which recombinant 
progeny were selected (Figure 5.3). The two closest markers in the F344 backcross were 
GU10 (Chapter 3, Section 3.2.5) and R191 (Serikawa et.al., 1992). R191 was originally 
mapped by Mr. A. McCallion, 4.5 ± 0.5 cM from agu. Along with GU10, this gave a 
region for selection of recombinant animals of around 10 cM in the F344 backcross. Miss 
M.B. Duran Alonso (Duran Alonso, 1998) was responsible for identifying the 
recombinant panel of animals and showed that the markers R191 and GU10 and D lM itl 
and D lM gh7 could be multiplexed in the PCR reaction and the allelic products reliably 
resolved on agarose, allowing the fast and efficient identification of recombinant animals.
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o
5.5 cM ±1.1 |
i
20.25 cM ±2
DlMitl
agu
R158
DlM gh7
F344
R191
agu
R158
GU10
4.5 cM ±0.5
6.2 cM ±0.56
Figure 5.3 The region of genome selected to contain recom bination even ts .
The diagram illustrates the genetic markers used to establish panels of backcross progeny 
recombinant in the interval containing agu. The two backcrosses BN X AS/AGU and 
F344 X AS/AGU are labelled BN and F344.
5.2.2 Mapping R158
Further investigation of the genetic interval identified a new set of markers for study. One 
of these was R158 (Serikawa et.al., 1992). Gu and colleagues (Gu et.al., 1996) also 
described the mapping of this marker and reported a strain variation between AS and BN 
(AS<BN). When a test was carried out with R158, there proved to be a strain difference 
between the three strains used in the backcrosses, with the microsatellite being two bases 
(1 repeat unit) shorter in AS/AGU than in F344 and BN (Figure 5.4). The panels of 
recombinant animals which had been established from both backcrosses (Section 5.1) 
were genotyped with the marker R 158. (Table 5.1)
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F344 backcross BN backcross
Rec. panel
185
Total progeny
1800
Rec. panel Total progeny
102 400
Table 5.1 . Summary of backcross progeny contained within the 
recombinant panels (as of 21/2/98).
The 287 animals in the panels derived from 1800 F344 X AS/AGU and 400 BN X 
AS/AGU backcross progeny. Of all 287 animals recombinant within the selected interval, 
one animal from the BN X AS/AGU backcross was identified to be recombinant between 
R158 and agu (Animal number : 66-95). Another three animals from the F344 X 
AS/AGU backcross were found to have two recombination events between the flanking 
markers and also had a recombination event between the agu locus and R158 (Animal 
numbers : 280-96, 252-96 and F401-96).
D
Figure 5.4 An example of genotyping BN X AS/AGU backcross progeny 
with R158. The radio-actively-labelled PCR products were resolved on 6% acrylamide 
gels for 3 hours at 60 W. The parental strains are shown in the first three lanes and the 
backcross progeny in the remainder. The numbers above the gel correspond to individual 
animal numbers.
In total, from the two backcrosses, six animals were identified which appeared to have two 
recombination events between the flanking markers (Table 5.2). This was considered high 
for the small distances tested. Therefore, a PCR test was established to test if the DNA 
was derived from the correct animal. This test would be useful in establishing errors, 
either during DNA isolation or PCR.
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Animal no. BN 531- 
94
F 401-95 F 251-96 F252-96 F279-96 F 280-96
M arker 1 1 2 2 1 2 1
agu 2 1 1 2 1 2
R 158 2 2 1 1 1 1
M arker 2 1 2 2 1 2 1
Table 5.2 Haplotypes of animals identified to have two recom bination 
events in the interval selected. 1 = homozygote; 2 = heterozygote. Marker 1 is 
DIMit 1 in the BN X AS/AGU backcross and R191 in the F344 X AS/AGU backcross. 
Marker 2 is D lM gh7 in the BN X AS/AGU backcross and GU10 in the F344 X AS/AGU 
backcross.
Therefore, PCR primers were designed to specifically amplify the sex determining region 
Y gene (SRY) from the Y chromosome (Griffiths et.al., 1993). The sequence encoding 
the Rattus norvegicus SRY gene was retrieved from the database (Accession numbers: 
Z26907 and X89730) and PCR primers were designed to the sequence (Figure 5.5).
F ___________________________^
G A G A G G C A C A  A G T T G G C T C A  A C A G A A T C C C  A G C A T G C A G A  A T T C A G A G A T  
C A G C A A G C A G  C T G G G A T A T C  A G T G G A A A A G  C C T T A C A G A A  G C T G A A A A A A
S R Y
G G C C C T T T T T  C C A G G A G G C G  C A G A G A C T G A  A G A C C C T A C A  C A G A G A G A A A  o r v  A  
T A C C C A A A C T  A T A A A T A T C A  G C C T C A T C G A  A G G G T T A A A G  T G C C A C A G A G
— -------------------------------------  R
GAGTTATACT TTGCAGCGTG AAGTTGCCTC AACAAAACTG TACAACCTGC
Figure 5.5 PCR test for the SRY gene. PCR primers shown in bold were 
designed to amplify the rat Y chromosome to detect male-derived tissue.
The primers were firstly tested on a set of animals for which the sex was known and the 
primers were shown to be specific for the Y chromosome. The animals shown to be 
recombinant with R158 (Table 5.2) were tested using the primers and the sex of these 
animals was correct (Figure 5.6). However, the animals containing two cross-over events 
within the interval had sequential numbers and had therefore been maintained within the 
same cage. As only animals of the same sex were maintained in cages together it was 
unlikely that this test could establish errors during spleen and DNA isolation in these 
animals. One recombinant event between agu and R158 was identified in animal 66-95 
from the BN X AS/AGU backcross. This typing was verified by re-isolating DNA for 
this animal and repeating the genotyping with R158. The flanking markers also displayed
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the expected haplotype, and the position of the cross-over used to position agu, relative to 
R 158.
bp
506—
344—
201  —
154—
Figure 5.6 Animals recombinant for R158 typed with SRY to determ ine
the sex of each anim al. A -ve control containing DNA from a female F344 animal 
was included and a positive containing DNA from a male F344 animal. The marker (M) 
was a 1 kb ladder.
5.3 Discussion
The identification of backcross progeny which are recombinant within a defined interval 
provides a useful panel of animals which can be studied with new markers identified in 
future. This will reduce both the time and effort required for genotyping all backcross 
progeny. It will also establish a set of cross-over events which have occurred within this 
interval, which will be a useful tool in the fine genetic mapping of the region before the 
isolation of candidate cDNAs.
In total, six double recombination events and one single were detected between R158 and 
agu. Three animals from the F344 backcross appeared to be recombinant; however these 
animals were also recombinant for both markers flanking agu. The numbers of these 
animals were sequential which indicates the possibility of an error. Unfortunately the test 
devised to check for errors was unable to verify if these were correct, as animals of the 
same sex are maintained together in cages. Therefore, any mix up between these animals 
could not be established. As DNA was re-isolated from the spleens thought to correspond 
to these animals and the R158 typing was unchanged, it is thought that these animals 
represent errors which occurred during the removal of the animal’s spleen, possibly in the 
labelling of tubes; further work with new markers should determine this.
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Therefore, at this time only one animal, 66-95, was considered to show a true 
recombination event between R158 and agu, placing R158 less than 0.1 cM from agu. 
This small distance makes a chromosome walk from a genomic clone containing R158 a 
feasible option.
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Chapter 6
Establishing a genomic clone-based contig surrounding R158.
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6.1 Introduction
The new genetic marker R158 was identified by Serikawa et. al., (1992) during a 
sequence database search for microsatellites within the rat genome. The marker consists of 
an (AC)26 repeat contained within the 3' UTR of the gene encoding protein kinase C 
gamma (PKC type I/PKC-y) (Figure 6.1). This marker has been utilised by various 
groups for mapping purposes and was useful as an anchor point within our map, when 
comparing it to published genetic maps. It also displayed a strain difference in the length 
of the microsatellite between F344, BN and AS/AGU rat strains (F344=BN>AS/AGU) 
and was used for mapping the agu mutation in both backcrosses (Chapter 5).
The agu locus had been mapped to less than 0.1 cM (approximately 100 kb) from R158. 
There are no absolute cut-offs for determining what level of linkage is necessary before 
positional cloning is attempted. However, in general in mouse, linkage has been tighter 
than 1 cM. Therefore, it was reasonable to consider creating a clone-based physical map 
of a genetic interval which is larger than the distance estimated by linkage analysis. A 
contig of approximately 1 Mb would prove useful. This will take into account errors from 
genetic mapping and because the cM to megabase (Mb) ratio is not constant throughout the 
genome. To identify if a contig contains the agu locus, markers at each end of the contig 
would be isolated and used to map the position of the agu gene. This would be easily 
carried out on the panel of backcross progeny recombinant within this interval (Chapter 5, 
Section 5.1).
Construction of a physical map involves the identification of overlapping genomic clones 
within a given region, to form a contig. This involves isolation of a clone containing the 
closest marker, in this case R158, identifying the ends of the cloned insert in this clone and 
using this sequence to screen the genomic library from which the clone was originally 
isolated. This will identify further clones which hopefully overlap the original but extend 
further into novel regions. To achieve this both ends of the clone must be sequenced and 
used in a screen of the genomic library.
6.2 Results
6.2.1 Investigation o f  the PKCy gene.
As previously mentioned the marker R158 is contained within the 3' UTR of the gene 
encoding the y isoform of protein kinase C (PKCy or PKC type I). This isoform is 
expressed solely in the neurons of the brain and the spinal cord (Saito et.al, 1988). The 
rat PKCy cDNA was cloned in 1986 by Knopf et.al (1986). PCR primers were designed 
within the 3' and 5' UTRs (named K3 and K5, respectively) of the gene to amplify short
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probes for hybridisation, to enable assays to be carried out to detect both ends of the gene 
on genomic clones (Fig 6.1. and 6.2.). The PCR product from the marker R158 could not 
be used for probing as it was a microsatellite repeat and therefore not specific enough to 
allow probing. The PCR primers for both UTRs were designed using the computer 
programme MacVector. The primers from the 5’ UTR were designed to the sequence 
from Chen et.al., 1990 (Accession number: M55417 and J05664) and the 3 ’ UTR 
sequence was taken from Ono et.al., 1986 (Accession number: X07287).
6 9 7  V a l  H i s  P r o  A s p  A l a  A r g  S e r  P r o  T h r  S e r  P r o  V a l  P r o  V a l  P r o  V a l  M e t  
2 7 4 7  G T G  C A C  C C A  G A T  G C C  C G C  A G C  C C C  A C A  A G C  C C T  G T G  C C T  G T G  C C C  G T C  A T G
7 1 4  S t o p
►  K3-F
2 7 9 8  T A ^ T C T C A T C T G C T G C C G C T A G G T G T T C C C A G T G C T C C C T C C G C C A A G T T G G C T G T A A C T C C C A T C
2 8 6 4  C A C C C C C A T C C C C G C C T C T A G T C C G A A T T T T A G G T C T C T T A A A C C A C C C A A C C T T C T G G C C T C T T T C
2 9 3 1  A C G C G C C C C A A G T G G G T T C T A G A C G C T G T T C C C C A G C A T T G C T G G C A T T T T A A A C T T C A A A C A G T C T
2 9 9 8  C T A G G G C C T T T C T G T G T T C T A G G T T C G T T G T G C T G A G C C C T G G T T T T T C C C C A C C C C C A A C A T C T G G
3 0 6 5  A T G C T G T T C C A A C T C T T C C C A G A A A C C C C A C T C C G T G T G G G G T T C T A G A C T C T A T C T T G G T A G T T T T
3 1 3 2  A T G C C T T C T C T C T C C C T A G A C C A C G T T G G G A G A A A T A G T C T C A T G A G A T T G C C T G C T C C A G A C T A A G
3 1 9 9  A T T C C A G A T C A G C T C T C T G C A T C C T T C A A G G C C C C T C C T A C C T C C A C T T C A G T T G T A G A A T T A A G T G
_   K 3 . R
3 2 6 6  G G A G G C T G G G C T C C G T G T T C C A G G C C A C C T C C C T T C C A T G T T C T G G G G A T T C C T G G C A T G C A C G G A G
R158-F
3 3 3 3  G A T T C T C T C C C C G A C T T T T C T C A G T C A G C T T T T G T T C T A G A T T T G T T C C A G A A C C C T T C A C T G C T C A  
3 4 0 0  C C T G C C C C G T G C A T G G C T C C A G C C T T G G T C G G A A T C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A C A  
3 4 6 7  C A C A C A C A C A C A C A C A C A C A C C C C T T G T C C T C C G C A G T G C C T G C C A C T T T C T G G G A C T T T C T C A T C C
^ -------------------------  R158-R
3 5 3 4  C C C A C G C C C T T C C T T T A T C C T C T C C C A C C C A G A C A C A G C T G C T G G A G A A T A A A T T T G G A G C T C T C G A
Figure 6.1 PCR prim ers designed to the 3’ UTR of the rat PK C -y gene.
The PCR primers are shown in bold and are indicated by arrows. The stop codon for the 
gene is indicated by a vertical arrow. The PCR primers specifying the marker R158 are 
also shown in bold, with the microsatellite in italics.
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a )  - 1 6 1 2  GAATTCCAGA CGACCTCAGC AAAACCGCAA AGACTGAACA GACACCCGCA
- 1 5 6 2  TCACCGGAGC GGCCAGCCTG ATGCGCATTG CACGTCGGGA G C A G T A tS c
- 1 5 1 2  TCCGTTGCGT TCCAAGAATA GAGTACACGA GGGCCCCAAC TATAAGTCCC
- 1 4 6 2  AGAGTGCACT GAGCTTGACA GCCTCTGGGC GCCACAGCTC CCCAGAACGG
- 1 4 1 2  CTTCCTGCCA GAATGGACCC ATAGGAGGGC TGGAACTGGG AGAAAGGCGC
_________________________________  R
- 1 3 6 2  ATGGTGGGGC GTGACCTGGG GGAGGAACTC AAGAGAGGAA ACCTGGGCGT
Figure 6.2 Position of m arker K5. a) PCR primers for K5 (shown in bold and 
indicated by arrows) were designed to a region of the 5 ’ UTR of PKC-y to allow probing 
for this end of the gene. Co-ordinates are taken from a sequence alignment of the rat 
mRNA and exon 1. b) Schematic diagram indicating where the K5 PCR product lies 
within the PKC-y gene.
6.2.2 Investigation o f  the PI library.
The PI library was kindly provided by Dr.R.MacDonald of the University of Texas, and 
had been utilised extensively by our group in the isolation of microsatellite markers from 
the 10 cM region initially identified to contain agu. A summary is given in Table 6.1 of PI 
clones selected by PCR for containing genes or genetic markers from the interval of rat 
chromosome 1 thought to contain the agu locus. The table shows the 13 PI clones 
isolated to date, thus far there have been no cases of absent clones from the library. The 
PI library has shown good coverage of the rat genome, to date.
6.2.3 Screening the PI library fo r  overlapping PI clones.
A PI clone (clone K) was isolated by PCR from the PI library superpool 39, using the 
genetic marker R158, by Dr. P. Shiels. The clone ends of the PI clone were sequenced 
with both the SP6 and T7 primers. Sequence was obtained from the SP6 end of the 
cloning site and PCR primers (KSP6) specified to a region of this sequence. Dr. D. 
Donald sub-cloned the PI clone K, identified a sub-clone containing the T7 end of the 
cloning site and designed PCR primers (KT7) to this sequence.
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Marker/Gene 
used in screen
PI clone 
identified
Investigator Superpool
number
GRIK5 Yes Nicola Craig 49
ATPL Yes Nicola Craig 65
Ferritin light chain Yes Dr.P.Shiels 39
Cyp 2A3 Yes Dr.P.Shiels -
R158 Yes Paul Shiels 39
D7 Mit 178 Superpool identified Nicola Craig 61
D1 Mcol Yes Miss M.B. Duran Alonso 37
SCNIB Yes Miss M.B.Duran Alonso 56
Bgp2 Superpool identified Mrs.M.Gardiner 13
Cea 1 Yes Mr.M.Canhan 23
Cea 2 Yes Mr.M.Canhan 17
Cea 3 Yes Mr.M.Canhan 62
Cea 4 Yes Mr.M.Canhan 46
Table 6.1 Summary of PI clones isolated from the library to date.
The primers KSP6 and KT7 were used to screen the PI library to try to identify clones 
which overlap the original PI clone K, containing the marker R158. When primer pair 
KSP6 was used to screen lysates of the PI library pools, no product of the correct size 
(140 bp) was obtained from the library pool lysates. However a PCR product 20 bp larger 
was observed in certain superpools e.g. 11, 50 and 79 (Figure 6.3). This indicated the 
KSP6 primers were not sufficiently specific. The sequence obtained from the SP6 end of 
clone K was investigated using the RepeatMasker programme which screens DNA 
sequences for interspersed repeats known to exist in mammalian genomes and the forward 
primer from KSP6 was homologous to a Short Interspersed Repeat Element (SINE/Alu) 
repeat in rat (Figure 6.4) (Batzer et.al, 1996). This indicated that during the design of the 
primers, they were not sufficiently investigated for the presence,of line element sequence.
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M BN SD 11 79
Figure 6.3 PCR screen of the PI library with the prim ers specify ing  
KSP6. Lanes BN and SD are positive controls containing Brown Norway and Sprague 
Dawley rat genomic DNA. PCR signals from superpools 11 and 79 are shown. The 
marker (M) was a 1 kb ladder.
CTTGGGAGGC AGAAGCAATA GAATTTCTGG GAGTTTGATG CTAGCCTATT
F ____ ___  ____ j p -
A T A C A A A G T G A G T T C C A G G G A A G C C A T C A C T G T T A C A C A G A G A A A C C C T A
TCTC, VGGGGT GGGGGTGGAG GAAGCCATAT TCATTCAAGA GGCCTCTTTT
GGCCTTCTTT TCTGTTCTGA GTCTGGTCGT GGTAATGTTG CAAAGAGACC
2 01  A G G A T T G C C G  T G G A T T T A T G  G A T G A T G G G C  A G C C A C A C A A  G G A G A A G G A T
2 5 1  GCTGAGCTGA AGAGAGAGGA AGGATGCTAC CCATGGCAAG CTACAGGCAA
Figure 6.4 Sequence identified at the SP6 end of PI clone K. The SINE/Alu 
element is boxed. The primer pairs KSP6 and KSP62 are shown in bold and are indicated 
by dashed and plain arrows, respectively. The SINE/Alu sequence was a standard repeat 
element supplied by the RepeatMasker programme.
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1  CTTGGGAGGCAGAAGCAATAGAATTTCTGGGAGTTTGATGCTAGCCTATT 5 0
I I  l l l l l l l l l l  I I I  I M I N I  M i l l  I I  I I  M i l l  I
1  CTCGGGAGGCAGAGGCAGGCGGATTTCT. . GAGTTCGAGGCCAGCCTGGT 4 8  
5 1  A T A C A A A G T G A G T T C C A G G G A A G C C A T C A C T G T T A C A C A G A G A A A C C C T A  1 0 0
I I I  I I I I I I I I I I I I I I I I I I  I I  I I I I I  I I  I I I I  I I I  I I I
4 9  C T A C A A A G T G A G T T C C A G G A C A G C . . . C A G G G C T A C A C A G A G A A A C C C T G  9 5
1 0 1  T C T C  1 0 4
1111 
9 6  T C T C  9 9
Figure 6.5 Sequence alignment over 104 bp of sequence from the SP6 end of clone K 
(top line), aligned to a standard SINE/Alu repeat element from the RepeatMasker program 
(bottom line). The sequences are 81% homologous. Forward primers for KSP6 and 
KSP62 are indicated by dashed and plain lines, respectively.
A region of sequence from the SP6 end of K showed 81% homology with this repeat 
(Figure 6.5), therefore the PCR primers may be amplifying SINE/Alu repeat elements 
from elsewhere within the rat genome. Prior to receiving this data new primers were 
designed to another region of this sequence (Figure 6.4). This new primer pair (KSP62) 
also showed homology to the SINE/Alu element but was less homologous when compared 
to KSP6 (Figure 6.5). A PCR reaction with KSP62 showed only a single band from 
genomic DNA and the primers were used in a screen of 150 of the library pool lysates. 
However, no bands were observed.
6.2.4 Screening the PI library fo r  clones containing KSP6 and KT7.
No PCR signal was obtained from either the KSP6/KSP62 or KT7 PCR assays on the PI 
library. PCR assays had been carried out on lysates made from the library pools and these 
could at times produce faint PCR signals. Fysates were tested over a period of time by Dr. 
M.B. Duran Alonso (Duran Alonso, 1998) and the signal achieved from the PCR reaction 
was seen to reduce over time, presumably as the DNA in the lysates decayed. It was 
essential that a walk could be extended from PI clone K using the PI library and this 
required reliance on the negative results obtained so far from screens with KT7/KSP6. 
We reasoned that DNA isolated from the PI superpools would provide a more reliable 
template and would allow a greater confidence in the assay. Producing library pool DNA 
may also allow us to combine superpools into megapools to allow a reduction in time and 
reagents taken to screen the library.
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The 209 superpools from the library were therefore plated onto agar plates containing 
kanamycin and sucrose. Colonies were plated to achieve 95% confidence of including any 
particular sequence, using the formula derived by Clarke and Carbon (1976). Colonies 
were washed from the plates and DNA isolated from the bacterial cell pellet.
PCR tests were carried out for 8 genes and markers previously isolated from the PI 
library, to assess coverage of the DNA from the library and utility of the megapool system. 
The coverage of the library as far as could be tested appeared intact and the megapool 
system was successful. A PCR test was carried out for the PI clone containing the gene 
encoding ATPL (the isolation of which is described in Chapter 3). The DNA isolated from 
superpool 65 and a megapool of 10 superpools, containing superpool 65 were tested with 
the primer pair NCA, for the ATPL gene. Both tests showed PCR products of the correct 
size and the level of signal obtained from the library pool DNA was comparable to that 
seen for the positive control, genomic DNA (Figure 6.6). The megapool containing 
library pool 65 also produced a strong positive signal, with approximately 25% of the 
signal strength in a duplicate test. Another test was carried out with the primer pair 
GU103 for the gene GRIK5 on library pool 49 and the megapool containing it. A similar 
result was observed. Other tests were carried out for the gene encoding Cea 3 (for which 
PCR primers were provided by Mr.M. Canhan and the SSR marker G U M  (primers 
provided by Dr. M. Alonso) (Figure 6.6).
invO
o
£- M e g a p o o ls
M  I  j ?  8 2  >  M  M e g a p o o l s
M  + v e  5 2  - v e  M
bp
5 0 0
3 4 4
200
1 3 4
Figure 6.6 PCR assay for ATPL and GUM on DNA isolated from P I  
superpools, a) Superpool 65 was the pool from which ATPL was isolated. M egapool 8 
is made up of nine other superpools plus 65. Megapool 2 contains 10 other superpools, 
b) The megapools 5 and 2 both contain superpool 37, from which the PI clone was 
isolated, and both gave a strong positive signal. The marker (M) was a 1 kb ladder.
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DNA isolated from the PI superpools produced better quality, reproducible PCR results 
and coverage of the library as far as could be tested with 8 genes and markers was 
complete. The tests also showed that DNA isolated from the library pools, could be 
combined into groups of ten to produce megapools which will reduce screening time in 
future work.
The PI library megapools and the individual library pool DNAs were screened with 
KSP62 (Figure 6.7). Again no positive signal was obtained. Primer pair R158, originally 
used to isolate the PI clone K gave a positive result in megapool 15, containing positive 
library pool 39. A screen of the library megapool and library pool DNA carried out by Dr. 
D. Donald also produced no signals for the PCR primers KT7.
jyj > Megapools 9-15
bp
1, 000—
500 —
298 —j 
154
M Megapools 16-20 > M
1,000
500 
298 
154
Figure 6.7 Screen of the PI library megapools with the prim ers K S P 62 .
Megapools 9-20 are tested, no positive was observed. The positive control contains BN 
genomic DNA and the negative, no DNA. The marker (M) is 1 kb ladder.
The results of screening the PI library with KSP6, KT7 and R158 indicated that there 
were no PI clones within the library which overlap the original PI clone, K at these 
sequences. This indicates that there is a gap in the coverage of the PI library at this point, 
possibly indicating that DNA from this region is more difficult to clone, either because of 
sequence present or lack of restriction enzyme sites. The coverage of the library from 
other areas tested indicates that in general the coverage of the library is good. Work 
carried out by Southard-Smith (1994) suggested that the coverage of the rat genome by the 
library was at least two fold, therefore it appears that this region of DNA is not so well 
represented within this library.
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The isolation of DNA from the PI library superpools and subsequent screening allowed 
reliance on the negative results obtained in screening for ends of PI clone K. The DNA is 
now stored also as megapools to allow more efficient screening of the entire library which 
may prove useful in the future.
6.3 Investigation o f a new rat YAC library.
A rat Yeast Artificial Chromosome (YAC) library from Research Genetics became 
available in April, 1997. The construction of the YAC library was described in Cai et. al., 
(1997). The YAC library is contained within 67 superpools of DNA which are screened 
by PCR (Green and Olson, 1990). After the identification of positive superpools, the 
address of the clone within the superpool is determined by carrying out a further 28 PCR 
reactions, which identify a row and column within a particular library plate.
The YAC library was screened by PCR using the marker R158. From the sixty-seven 
superpools, seven positive signals were obtained (superpools 4, 14, 18, 23, 31, 45, and 
66) (Figure 6.8). The subsequent 28 PCR reactions were carried out for each superpool 
resulting in seven YAC clone addresses. The YAC clones (527 F9, 181 G12, 109 D l, 26 
F I, 355 E3, 143 G9 and 243 B6) were purchased from Research Genetics.
Superpools 1-12
Superpools 13-20 g
14 18
Figure 6.8 A PCR screen of the YAC superpools 1-20 with R158. The
negative control (-ve) contains no DNA, the other negative control (N l) contains yeast 
genomic DNA. The marker (M) was 1 kb ladder.
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The YAC clones were plated onto YPD plates (minimal medium) and single colonies 
dissolved in distilled water to make lysates, to allow identification of the correct YAC 
clone by PCR analysis with marker R 158. YAC clones were resolved on contour-clamped 
homogenous electric field (CHEF) gels and yeast DNA was isolated from cells in agarose 
plugs to reduce shearing (Schwartz and Cantor, 1984). YAC clones were grown in YPD 
culture media to produce agarose plugs and resolved on a CHEF gel (Figure 6.9). 
However, the yield of YAC DNA was low. It was difficult to observe on CHEF gels and 
a weak hybridisation signal was obtained (Figure 6.10). It was suggested that YAC 
clones produce better DNA when grown in the medium AHC, which is a complete 
medium for growing the yeast strain AB1380 while still selecting for the YAC clone 
(Brownstein et.al, 1989). The YAC clones were grown in AHC medium and a greater 
concentration of YAC clone DNA was observed (Figure 6.10).
2 26 
FI
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5 
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9 5 0 ------
6 9 0 ------
6 1 0 ------
4 5 0 ------
345------
2 7 0 ------
2 4 5 ------
Figure 6.9 Resolution of YAC clones on CHEF gels. The marker (M) is a 
yeast chromosome ladder from Promega. Bands corresponding to YAC clones 527 F9 
and 143 G9 are indicated by arrows, at 680 and 400 kb respectively. The remaining YAC 
clones are difficult to see because of the yeast chromosomes. Gels (1) and (2) were 
electrophoresised as follows; 1% Seaplaque GTG gels in 0.5X TBE at 14°C for 20 and 22 
hours respectively, with switch times of 30-30 secs and 20-84 secs. The gels were 
electrophoresised at 6V/cm.
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Following electrophoresis of the YAC clones on CHEF gels, the DNA was transferred 
from the gel to nitrocellulose by Southern blotting. These filters were then probed with the 
PCR probes K5 and K3 (Figure 6.1 and 6.2) from the 5' and 3' UTR of the rat PKCy 
gene, respectively (Section 6.1). This allowed estimation of the size of each YAC clone 
(Table 6.2) and also allowed identification of overlaps between YAC clones and the 
original PI clone, K. The average size of YAC clones reported in the library was 700 kb; 
the average for the 5 YAC clones tested was 626 kb, very similar to that reported for the 
library.
Figure 6.10 Southern blots of YAC clones resolved on CHEF gels.
The blots (a) and (b) were probed concurrently to allow comparison between YPD and 
AHC medium, (a) YAC clones from cultures grown in AHC medium, blotted and probed 
with the K3 probe, (b) YAC clones from cultures grown in YPD medium, blotted and 
probed with the K3 probe, (c) YAC clones from cultures grown in YPD medium, blotted 
and probed with the K5 probe.
Clone 181 G12 109 D1 26 FI 243 B6 355 E3 527 F9 143 G9
Size ? 500 kb 800 kb 9 750 kb 680 kb 400 kb
Table 6.2 Summary of YAC clone sizes (in kb) as estimated from Southern  
blots probed with K5 and K3 probes. The size of 181 G12 could not be 
determined as this clone was shown not to contain either the K3 or the K5 sequence by 
PCR.
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PCR tests were earned out on all of the YAC clones for the presence of sequence 
identified from the original PI clone K. These tests involved the ends of the PI clone 
(KT7 and KSP6) and SSR markers isolated from K (K100, K106 and K66). This 
allowed elucidation of the overlap between clones and provided information on the overlap 
of the YAC clones and the PI clone K. DNA can be isolated easily for this purpose from 
the YAC clones by lysing the cells and precipitating the DNA, as shearing of the DNA is 
not a consideration. Figure 6.11 shows an example of one of these tests.
Figure 6.11 Example of a PCR test carried out on YAC DNA, using the 
m arker KT7. The negative control contains no DNA. The YAC clones 527 F9, 355 E3 
and 26 FI are positive and clone 109 D1 is negative. The marker (M) was a 1 kb ladder.
The PCR and hybridisation allowed a putative contig to be established with the YAC 
clones and PI clone K (a summary of the results are given in Table 6.3 and Figure 6.12). 
The grouping of markers on the YAC clones allowed an orientation for markers within 
clone K.
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YAC K SP62 K100 K 106 K3 R 158 K5 K66 KT7
109 D1 - - - + + - - -
181 G12 - - - - + - - -
26 FI - - - + + + + +
243 B6 + + + - + - - -
527 F9 + + + + + + + +
355 E3 + + + + + + + +
143 G9 + + - + + - - -
Table 6.3 PCR results from YAC clones tested with m arkers from P I clone 
K.
PI clone K
KSP6 K100/K106 R158 K5 KT7
|  t M 1- - - - 1- - - - - - - - 1
K3 K66
  109 D1
  181 G12
243 B6----------------------------------
143 G 9 %-
26 FI
527 F9 
355 E3
❖ Indicates a deletion of the marker K106 from the YAC clone 143 G9. 
i f  Indicates a deletion of the marker K3 from the clones 243 B6 and 181 G 12.
Figure 6.12 Establishing a putative contig of YAC clones using m arkers 
from the PI clone K.
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6.4. Identification o f  overlappin g  genomic clones from  a PAC library.
Contigs containing YAC clones are often difficult to construct because of problems 
associated with YAC cloning e.g. chimaerism, difficulty in isolating DNA and deletions of 
inserts. A more popular approach is to screen genomic libraries of clones containing 
smaller inserts (PI, BACs, PACs and cosmids) and to order and characterise these. A 
new rat PI artificial chromosome (PAC) library (Ioannou et.al., 1994) became available in 
April 1997, which was ideal for our purposes. It combines all of the advantages of the PI 
library; large insert size, between 100-300 kb, easy preparation of clone DNA, clone 
stability and high cloning efficiency with a convenient screening system. The library has 
been arrayed into 384 well microtiter plates and placed onto nylon high density 
hybridisation filters for screening by probe hybridisation. This allows a quick and easy 
identification of a clone address. The PAC library from BAC/PAC (Roswell Park Center, 
www site: http://bacpac.med.buffalo.edu.) resources was gridded, as a set of duplicate 
clones, on filters for probing by hybridisation.
The PCR product, K5 (from the 5’ UTR of the rat gene encoding PKCy), was band 
isolated, radioactively-labelled by random-priming and used as a probe on a genomic 
Southern blot of rat DNA. This allowed me to check for the presence of any repetitive 
element within the probe. The probe produced one band and was used to screen the PAC 
library filters. E.coli DNA was also radioactively-labelled to the same specific activity as 
K5 and added at 1/10 the activity of the K5 probe to allow background grid colonies to be 
lightly labelled. An adequate image of the background grid of colonies was essential to 
orientate filters and identify the address of positive clones (some examples are given in 
Fig. 6.13). Five positive PAC clones were identified from the library with the K5 probe: 
603 C15, 542 G19, 365 J2, 437 C18 and 539 G6 (Figure 6.13).
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603 C15
Figure 6.13 Identification of PAC clones from the library probed with the 
K5 probe. The background grid is lightly labelled with E.coli DNA. Five positive 
clones were identified from this screen. Duplicate signals were seen for each colony (as 
shown above).
DNA was isolated from each of the PAC clones using phenol/chloroform extraction, as for 
the PI clones. The PAC DNA was partially digested using Sau 3A and ligated into pUC 
18. The resulting colonies were screened with SP6 and T7 radioactively labelled 
oligonucleotides to identify the sub-clones containing the end fragments of the PAC 
clones. Sub-clone 106 contained the T7 end of PAC clone 542 G19 and was used as a 
probe to isolate overlapping PAC clones and extend a contig.
DNA isolated from sub-clone 106 was digested to excise PAC vector sequence and a 0.9 
kb band (Figure 6.14) was identified from 106 which produced a single band in genomic 
Southern blots. The PAC library was screened with this fragment ; three new positive 
clones in addition to the original PAC clones identified which had been identified with the 
K5 probe. The new PAC clones were: 582 G16, 462 P14 and 419 M14. They were 
confirmed to overlap 542 G19 by probing with the 0.9 kb band digested from sub-clone 
106 used to screen the library and an independent probe using another fragment of 1.1 kb 
digested from sub-clone 106.
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pUC 18 vector
Fragment used to screen library
Figure 6.14 Restriction analysis of subclone 106. The large arrow indicates the 
fragment identified for screening the PAC library. The smaller arrow indicates the pUC18 
vector band. The other band shown (1.1 kb) was used to confirm that the clones identified 
were correct.
A 2.3 kb Bgl 11 fragment identified from PAC 542 G19 contained the SP6 end of this 
clone. This was sub-cloned into pUC 18 and sequenced using the SP6 primer. The 2.3 
kb Bgl 11 fragment also contained a dinucleotide (CA) repeat unit of 22 repeats and PCR 
primers were designed to amplify this repeat (GU20 Forward and Reverse) (Figure 6.15). 
Rat strains BN, F344 and AS/AGU were screened for a strain variation in the size of the 
PCR product from GU20 by Miss M.B. Duran Alonso; no length variation was observed 
between the rat strains BN, F344 and AS/AGU. A strain difference was observed 
between the rat strains DA and AS/AGU.
Another region of presumably unique sequence within the clone was amplified with the 
PAC 542 G19 SP6 F and R primers to enable screening of the PAC library (542 G19 SP6 
F and R) (Figure 6.15). A radioactively-labelled PCR product from the 542 G19 SP6 
forward and reverse primers gave a single band on a genomic Southern blot (Figure 6.16) 
which identified 4 new PAC clones from the library ; 429 0 2 , 434 L2, 372 C17 and 399 
G7. Only PAC 542 G19, of those previously isolated, hybridised with this probe.
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GU 20JF_____________
1  T G G G C A G T T C  C T A A A G A T A G  C C T C T A G C C C  C C A G T G C A T A  T G T A A A C A T A
5 1  T A C A T A C A T G  C C A G C T T A C A  CACACACACA CACACACACA CACACACACA
542 SP6 F ----------------------------
1 0 1  CACACACACA C A T T T A A A G T  C A T T A A A G G A  A G A G C G G T G T  T T A T C C C C T C
^ ---------------------GU 20 R
1 5 1  A C C T G A C T G A  A G G C C A G A A T  G T G G G T C A T C  T C A G T G T G G A  T T G G C T C A G G
2 0 1  A G C T G T G T G A  T G T C C T G A A A  A C T G C A G T C A  A T C A A T C G C T  T G C A T T T A T T
2 5 1  T C T C C C T T G C  C C T G G A A T T C  C C C A T A T T T T  T T T G T A A T C A  G C C C A G T A T A
^ -----------  542 SP6 R
3 0 1  T A C A C A A A A C  C A G A A A C T G A  G T C T C T A T G C  T G C C T T T T A T  T C A A
Figure 6.15 Sequence obtained from the SP6 end of the PAC clone 542 
G19. The repeat unit is shown in italics. The primers designed are shown in bold and 
indicated by arrows.
Figure 6.16 Rat genomic Southern blot probed with the PAC 542 G19 SP6 
end PCR product. Only one band is seen in each restriction digest on the blot.
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6.5 Discussion
To date one PI, twelve PAC and seven YAC clones have been isolated using markers 
identified close to R158. These genomic clones were assayed by PCR and hybridisation 
to determine clone overlap and to create a contig (Craig et.al., 1997). The YAC clones 
were previously tested with the SSR markers from PI clone K, and the ends of PAC clone 
542 G19 were used to probe the YAC clones, and markers from the PI clone K were also 
tested on the PAC clones (Table 6.4). The degree of shared DNA markers between the 
PAC and YAC clones has been established (Figure 6.17).
K SP6 K100 K106 K3 R158 K5 K66 KT7
YAC Clones
109 D1 - - - +* + - - -
181 G12 - - - _ * + - - -
243 B6 + + + _ * + _ * - -
143 G9 + + - +* + _ * - -
26 FI - - - +* + +* + +
355 E3 + + + +* + +* + +
527 F9 + + + +* + +* + +
PAC Clones
542 G12 +* +* + n.t. + +* + +*
365 J2 _* +* + n.t. + +* + +*
603 C15 +* + + n.t. + +* . + +*
582 G16 - + + - - - - -
462 P14 - - - - - - - -
419 M14 - + + - - - - -
372 C17 - - - - - - - -
429 0 2 + + + + + + + +
Table 6.4 Summary of tests with markers from the genomic region  
containing R158 on the YAC and PAC genomic clones, indicates the test 
carried out was by hybridisation, n.t. indicates where a test was not carried out. PCR test 
on the PAC clones for markers from K were carried out by Dr. M.B. Duran Alonso.
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There are a few anomalies within the contig construct:
(1) The YAC clone 26 FI is approximately 800 kb in length by Southern blotting (Table 
6.2) but does not appear to contain either the SP6 or T7 ends of the PAC clone 542 G12 
indicating that this YAC clone may be chimaeric, as the distance from R158 to these two 
markers is probably less than 200 kb.
(2) The YAC clone 243 B6 has a deletion of the sequence for marker K3 and contains the 
sequence for SP6 end of the PAC 542 G19 when it is expected to contain the T7 end. 
(The orientation of the 542 G19 clone was established because of markers K100 and K106 
found in PAC clones isolated using the T7 end of the clone (582 G16 and 419 M14).
(3) YAC clone 143 G9 appears to have deletions not only for K106 but also the SP6 end 
of 542 G19.
YAC clones 355 E3 and 527 F9, however, appear to contain most of the markers tested 
and do not appear to contain any rearrangements or deletions, thus far. These YAC clones 
are also 750 and 680 kb in length, respectively and will cover a large area of contig 
established using PAC clones. At present these YAC clones are the most interesting for 
study and should be tested further to assay clone stability and integrity.
One of the YAC clones 181 G12 appeared only to contain the DNA containing the marker 
R158 for which the library was screened. This YAC clone may have been a false positive, 
an error which may have arisen during either screening of the YAC library or during 
selection for positive YAC clones from plates, possibly because of PCR contamination. 
The YAC clone 109 D1 contained only markers R158 and K3, approximately 70 kb apart, 
but this YAC clone is 500 kb in size as estimated by probing with the K3 probe. This 
indicated that this clone may be a chimera which probably arose by co-cloning of DNA 
fragments from two disparate genomic locations. The level of chimearism within this 
library was estimated at 20-30% by Cai et.al., 1997 and to date our evidence for 
chimearism is one clone from six, giving an estimate of 16% for the clones isolated with 
R158. However, this was not an exhaustive study of the clones and if further work is to 
be carried out on these clones this will have to be investigated in detail.
The YAC clones 143 G9 and 243 B6 appear to lack DNA corresponding to the markers 
K106 and K3 respectively. These may reflect small deletions of sequence from the YAC 
clones. This is the case for YAC 243 B6; marker K3 is approximately 70 kb from R158, 
the marker used to isolate the YAC clones, yet this clone has the DNA sequence 
corresponding to R 158 but not K3. This may indicate that these clones are unstable, a 
problem estimated to occur in 1-2% of YAC clones (Wada et.al., 1994). The YAC clones
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26 FI, 527 F9 and 355 E3 however, appear to have an intact insert for the markers tested 
so far.
Twenty genomic clones have been isolated to have markers close to the agu locus and have 
been used to establish a genomic contig spanning at least 750 kb. A contig of PAC clones 
extending in both directions from the original PI clone (K) has been established. New 
microsatellite markers are currently being isolated by Dr.M.B. Duran Alonso to establish 
the orientation of agu with respect to R158 within the contig. Mapping of the new markers 
will also establish the genetic distance “walked” from R158. The physical distance can 
also be determined by restriction mapping.
At this time no further work was carried out on the YAC clones isolated. The problems 
associated with YAC clones have been well documented e.g. chimaerism, instability and 
rearrangements, particular problems for physical mapping. Therefore the YAC clones will 
only be used should a problem occur with PAC clones e.g. chimaerism or in the absence 
of PAC clones. However, results so far obtained from the PAC library indicate that 
coverage of the library is good. The YAC clones isolated in this study have not been 
tested exhaustively for chimearism etc. but appear to show between 30-40% chimaerism. 
The level reported by Cai et.al (1997) for the library was 20-30% so the level we observe 
is slightly higher than expected. PAC clones are now being routinely used within this 
study. DNA can be easily isolated from clones and thus far no problems have been 
encountered with instability. The levels of chimaerism in these clones is so far untested 
but there have been no reports of this occurring.
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Chapter 7 
D iscussion
7.1 Progress Review
The goals of my research as outlined in Section 1.8 were the identification of new genetic 
markers to allow fine mapping of the agu gene in a genetic interval and the establishment 
of a genomic clone based contig of this region. The identification of new genetic markers 
from PI clones was carried out and in the case of D1GU10 produced a marker which has 
been useful in the fine mapping of the region containing agu and in the establishment of a 
panel of recombinant backcross progeny. These backcross progeny will prove to be 
useful in the investigation of cross-over events which have occurred within this region 
which should further define the interval for investigation. It is unfortunate that some of the 
other markers identified proved to be non-informative within the rat strain AS/AGU, F344 
and BN, but this problem has been addressed (Section 7.4.3.1). A genomic contig of 
twenty genomic clones spanning approximately 750 kb has been established which will 
hopefully contain the agu gene. However, further investigation of this contig must be 
carried out to establish the coverage of these clones and rule out any problems e.g. 
chimaeric clones and deletions. Therefore, the two major goal have been achieved.
7.2 Utilisation of rat genomic libraries
Three rat genomic libraries were utilised during the positional cloning phase of this project; 
a PI library (Southard-Smith et.al., 1994), a PAC library and a YAC library (Cai et.al.,
1997). Initial work involving the isolation of clones carried out with the PI library was 
difficult and the system of work established is not ideal. Isolation of PI clones from 
superpools was time consuming and not always successful. Also when a walk was 
attempted from the original PI clone, K, no overlapping clones were identified (Chapter 
6). Therefore it was fortuitous that within a short space of time after this was confirmed 
two new genomic rat libraries became available. Work carried out using the YAC library 
has been important, seven YAC clones were isolated using the marker R158. However, 
working with YAC clones presents some problems, the major one being the difficulty in 
isolating intact DNA not containing any host DNA. YACs also present problems 
involving rearrangements and chimaerism (Green et.al., 1991). However, the YAC 
clones isolated still have a role to play in the construction of a contig containing agu. Their 
large insert size makes them ideal for cloning large segments of genome. In future studies, 
they will be confirmed as being non-chimaeric and then used as a frame-work against 
which all new clones can be confirmed to be contained within the contig.
The library most heavily utilised was the PAC library, the major reason being that the 
cloned DNA within the PAC clones is large but isolation of DNA from PAC clones is still 
simple, quick and inexpensive. This allows a far greater range of investigations on the 
clones to be carried out. This resulted in the PAC library being used to walk in either
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direction from one of the original PAC clones isolated. The method of screening the 
library is fast and efficient, allowing a rapid pace of walking, even though smaller steps 
are being taken when compared to YAC clones. For these reasons the PAC library is now 
being used to construct a contig across the region thought to contain agu, and it is hoped 
that once this region has been mapped both physically and genetically, the PAC clones will 
eventually be used to isolate cDNAs encoded by genes contained on the PACs.
7.3 Evidence for the role of the agu gene from phenotypic analysis
The number of possible candidate proteins which could contain the agu mutation are huge 
and range from enzymes involved in dopamine synthesis and metabolism e.g. MAO-B, 
tyrosine hydroxylase and the dopamine receptor, to proteins involved in oxidative stress 
e.g. ferritin light chain, glutathione and SOD. However, a number of candidate genes 
which could contain the mutation are suggested by the altered pharmacology produced in 
the AS/AGU rat. In a previous study, dopamine levels in striatal micropunch samples 
from AS/AGU rats, deficits only occurred after 6 months of age (Campbell et.al., 1997), 
when there was a 30% loss, compared with controls. However, in further studies, carried 
out using microdialysis and HPLC analysis (Campbell et.al., 1998), extracellular levels of 
dopamine in the dorsal caudate-putamen of conscious animals were markedly reduced to 
only 10-20% of control levels at all three ages selected (3, 6 and 9 months). Conversely, 
levels of DOPAC were 2-4 times higher in AS/AGU than in AS animals (Campbell et.al.,
1998).
It is unclear if this loss in extracellular dopamine is due to the loss of dopaminergic 
neurons in these animals. For example, at 6 months of age the AS/AGU rat displays no 
detectable loss of whole tissue dopamine when compared to controls (Campbell et.al., 
1997). However, when extracellular levels of dopamine are measured there is a massive 
decrease at 3 months of age (Campbell et.al., 1998), in the absence of a detectable loss of 
whole tissue dopamine. This could be a result of over compensation by cells which are 
still functioning for their non-functioning neighbours. It is likely, therefore, that the loss 
of extracellular dopamine is not simply the result of the loss of dopaminergic neurons.
The high extracellular concentration of the metabolite DOPAC relative to that of dopamine 
is normally observed in studies of rats and is thought to reflect the high re-uptake and 
metabolic capacity of nerve terminals. As this was also the case in tests on the AS/AGU 
rat, it indicates that there is no major deficit in uptake and metabolism of dopamine in these 
animals (Campbell et.al., 1998). However, the elevated levels of the metabolite DOPAC 
(2.5 - 5 fold) in AS/AGU animals, when compared to controls, are very interesting. This 
evidence may indicate that the primary defect is in dopamine release in the AS/AGU 
animal.
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Suggestions that the agu mutation leads to a defect in the release of dopamine from 
presynaptic nerve terminals provides many other considerations. As discussed previously 
(Chapter 1, Section 1.1.3) the number of proteins which appear to be involved in the 
release of neurotransmitters is huge. Therefore, the number of possible candidate genes is 
large (Section 7.4.2.2).
Not only does the suggestion of a defect in the release of dopamine in the AS/AGU rat 
suggest candidate genes, it may also indicate a mechanism by which cell death within the 
substantia nigra occurs. If dopamine produced by a neuron is not released, what are the 
consequences? Although the cause of PD is still unknown, oxidative stress has been 
implicated as a pathogenic factor. According to this so called "free radical hypothesis", the 
degeneration of the nigro-striatal system in PD is related to the relatively high exposure of 
these neurons to reactive oxygen species (ROS).
Oxidative stress in PD may arise from the metabolism of dopamine itself by both chemical 
and enzymatic mechanisms. The autoxidation of dopamine leads to the production of 
semiquinones, which are themselves toxic and may also lead to the generation of reactive 
oxygen species (Olanow, 1990). The semiquinone cascade leads to polymerisation and 
the formation of neuromelanin which may also act as a ROS, although there is no evidence 
that increased dopamine oxidation or melanin formation occurs in individuals who develop 
PD.
Perhaps more important is the enzymatic metabolism of dopamine, which leads not only to 
the deaminated metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic 
(DOPAC) but also to the generation of hydrogen peroxide (H2O2 ). Every dopamine 
molecule deaminated produces one molecule of hydrogen peroxide (H2O2 ). Based on this 
observation, a theoretical scheme for the excess formation of the oxidant species, H2 O2 , 
and OH* formation has been devised (Jenner and Olanow, 1996). Increased dopamine 
turnover in the early stages of PD might generate excessive H2O2 , which would normally 
be inactivated by glutathione (GSH) in a reaction catalysed by glutathione peroxidase. 
However, if the GSH system were impaired or deficient, H2O2 might be converted by the 
iron-mediating Fenton reaction to form highly reactive OH*, so initiating lipid peroxidation 
and cell death (Jenner and Olanow, 1996). Indeed, the experimental elevation of 
dopamine turnover can lead to increased oxidative stress as determined by a rise in the 
formation of oxidised glutathione (Spina and Cohen, 1989).
To prevent breakdown of dopamine before it's release from presynaptic endings, the 
transmitter is taken up and stored in presynaptic granules (vesicles). Excessive dopamine 
within the cell may not be packaged into vesicles due to the fact that this packaging is 
carried out by a receptor (VMAT) and is thus limited by the numbers of receptors available
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at any given time. Excessive dopamine in the presynaptic neuron may lead to an increased 
turnover of dopamine being deaminated by monoamine oxidase, a by-product of which is 
hydrogen peroxide, which can produce free radicals and can contribute to oxidative stress. 
To evoke increased presynaptic turnover of dopamine, Spina and Cohen (1989) used the 
drug reserpine, which prevents the storage of dopamine in neuronal transmitter vesicles by 
interfering with the transport of dopamine into the vesicles (through VMAT). As a result, 
the metabolism of dopamine by mitochondrial MAO-A is increased. Levels of glutathione 
disulphide (GSSG) were greatly increased, indicating that the rate of production of 
hydrogen peroxide evoked by reserpine was sufficient to override the cellular mechanism 
for reducing GSSG. Therefore, an increased amount of presynaptic metabolism of 
dopamine can lead to a detectable alteration in the redox status of dopamine terminals 
(Spina and Cohen, 1989). A persistent oxidative stress, coupled to significant loss of 
GSH, may promote a faster than normal rate of neuronal senescence.
Another piece of evidence which substantiates this theory is the injection of L-Dopa into 
AS/AGU rats. Injection of L-Dopa appears to reduce the severity of the phenotype 
produced by the agu mutation, as displayed by an increase in performance in the 
locomotion and balance tests (A.Payne, personal communication). Dopamine (DA) 
synthesised from L-Dopa is not packaged into synaptic vesicles, different to native 
dopamine. Studies suggest that most of the DA formed from L-Dopa remains in the 
cytoplasm and is not stored in the vesicles (Melamed, 1992). The DA produced from L- 
Dopa is then not released by the classical transmitter release pathway, but is probably 
released from the cell by diffusion. Likewise, the normal negative feedback mechanisms 
regulating DA synthesis and release appear to be absent in the case of L-Dopa derived 
dopamine (Melamed 1992; Ponzio et.al., 1983). As the injection of L-Dopa is seen to 
reduce the severity of the AS/AGU phenotype, the dopamine produced may be overriding 
the reduction of released dopamine from the neuron.
The agu mutation may lead to a reduction in the amount of dopamine released from 
neurons in the caudate putamen. This would have several consequences; increased 
dopamine turnover within the cell would lead to the production of free radicals which 
could lead to cell death. Another consequence of reduction of released dopamine would be 
on the negative feedback loop which regulates the synthesis of dopamine. If reduced 
amounts dopamine are being released this will not signal to the cell to limit the synthesis of 
new dopamine. The cell will then be producing larger amounts of dopamine than would 
be normal which would then have to be metabolised leading to further production of free 
radicals. Also as the dopamine producing cells die, the neighbouring surviving cells will 
increase their production of dopamine to compensate for the loss, leading to the production 
of excess free radicals within these cells.
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7.4 Identification of the agu gene
7.4.1 Strategies involved in gene identification
There a many ways of identifying the gene which contains the agu mutation but the 
following strategies appear to be the most likely approach. The first stage of the 
investigation is to rule out any candidate genes. These can be divided into two categories; 
those implicated by their genetic map location and those implicated by clues derived from 
the phenotype analysis. These candidate genes can be eliminated in many ways e.g. 
Northern blot analysis of RNA transcripts, probing of genomic clones with probes derived 
from these genes and if they are present, direct sequencing within the AS and AS/AGU rat 
strains.
If this approach does not identify a gene containing the agu mutation the next step would 
involve the fine mapping of the interval containing the gene to identify the smallest genetic 
region, defined by cross-over events, which contains the gene. This region can then be 
investigated for expressed genes by various methods (Section 7.4.3.2).
7.4.2 Identification of genes which are candidates to contain the agu mutation
As previously detailed (Section 7.4.1) there are two approaches to identifying candidate 
genes for this project; candidates based on genetic data and from phenotypic analysis.
7.4.2.1 Candidates based on genetic data
Genetic mapping of the marker R158 (Section 5.2) very close to agu allowed a small 
interval of the rat genome to be investigated in detail. Investigation of this interval can 
therefore be carried out to identify novel genes within this genomic region. Also genes 
which have previously been mapped to this genetic interval in rat could be considered 
candidate genes and must be excluded from future study.
A major candidate gene suggested by the current mapping data, was the gene encoding 
protein kinase C type 1 (PKC-y). The marker R158 (Serikawa et.al., 1992) was 
contained within the 3' UTR of the gene encoding PKC-y (Section 6.1), and mapping of 
this marker positioned it to within 100 kb of the agu locus. However, this figure is only a 
very crude estimation from genetic mapping, as only one definite recombinant animal has 
been identified between the marker and agu. Also the exact size of the gene encoding 
PKC-y in rat is unknown, it is a possibility therefore that this gene could contain the agu 
mutation. PKC is present in high concentrations in neuronal tissues and has been 
implicated in a variety of neuronal functions including signal transduction, modulation of
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ion channel activity and synaptic transmission. The y-subspecies of PKC appears to be 
expressed solely in the brain and spinal cord, and is particularly concentrated in the rat 
brain in the hippocampus, cerebellum, cerebral cortex and amygdaloid complex (Ono 
et.a l, 1988 and Yoshihara et.al., 1991)). Subcellular localisation studies indicate that 
PKC-y is present primarily in the soma and dendritic processes of neurons (Huang et.al., 
1988).
PKC-y deficient mice were created in 1993 (Abeliovich et.al, 1993a) and have been used 
in the study of memory and long-term potentiation. It is interesting to compare the 
phenotype of these mice to the AS/AGU rat, if the gene encoding PKC-y is considered as 
a candidate gene. These mice were reported to show no gross anatomical abnormalities of 
the brain, and as this work was focused on the hippocampus and cerebellum (Abeliovich 
et.al, 1993b) it is unlikely that fine anatomical studies were carried out e.g. investigation of 
the substantia nigra. The mutant mice were mildly ataxic and showed a decreased effect of 
ethanol on behaviours and they were demonstrated to be defective in motor co-ordination 
but were fully capable of motor learning (Chen et.al., 1995). However, as these mice 
displayed unusual, persistent multiple innervation of Purkinje cells by climbing fibres 
(Kano et.al., 1995), the authors proposed this as the primary cause of the motor 
discoordination (Chen et.al., 1995). It is difficult to compare these mice to the AS/AGU 
rat as similar tests and investigations have not been carried out, however, there is one 
similarity e.g. mild ataxia. The authors do not detail the progression of this ataxia or 
indeed when it becomes observable.
Evidence suggests that phosphorylation of the dopamine transporter (DAT) is controlled 
by PKC, and reduction in DAT phosphorylation leads to increased dopamine transport 
(Vaughan et.al., 1997). If the agu mutation is contained within PKC-y, then it is feasible 
that a reduction in PKC-y brought about by the mutation could lead to reduced 
phosphorylation of DAT, producing increased dopamine transport from the synaptic cleft 
into the cell This may lead to decreased extracellular dopamine and increased metabolites 
of dopamine, after the action of MAO, as observed in the AS/AGU rat.
However, the y isoform of PKC seems to be localised in the postsynaptic side of the 
glutamatergic synapse (Kose et.al., 1988) but has not been localised within the dopamine 
synapse. PKC-y may be involved in long-term potentiation (LTP) and long-term 
depression (LTD), possibly involved in storage of information in the brain (Tanaka and 
Nishizuka, 1994). The y isoform is therefore thought of as a likely candidate for 
involvement in postsynaptic regulation of glutamate receptors (Tanaka and Nishizuka, 
1994). However, PKC-y may still have a role to play in presynaptic processes. PKC-y 
therefore still proves a very interesting candidate gene and one which must be ruled out 
before a thorough investigation of novel candidate genes is carried out.
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Another major candidate gene identified by work carried out by Polymeropoulos and 
colleagues (Polymeropoulos et.al., 1997) was the gene encoding oc-synuclein. As 
discussed in Chapter 1 the gene encoding a-synuclein was shown to contain a missense 
mutation that segregated with PD in the large Contursi kindred (Polymeropoulos et.al., 
1997) and was also found in three additional PD families of Greek origin. The mechanism 
by which this mutation leads to PD is largely unknown and there is relatively little known 
about the protein itself. However, a-synuclein immunostaining can be observed in Lewy 
bodies of idiopathic PD and diffuse Lewy body disease patients and it is thought that the 
mutation within the protein may promote the aggregation of a-synuclein into filaments, 
resulting in the formation of Lewy bodies (Spillantini et.al., 1997).
Synuclein was first isolated by an expression screen of a Torpedo electric lobe cDNA 
library using an anti-serum against purified synaptic vesicles (Maroteaux et.al., 1988). In 
Torpedo and rat the gene encodes a protein comprised largely of 11 amino acid repeat 
units, and is expressed only in neurons with immunoreactivity localised to synaptic 
vesicles within the presynaptic nerve terminal and a region of the nuclear envelope. Two 
observations gave rise to the hypothesis that synuclein was associated with synaptic 
vesicles: the first, that the gene was initially identified in an expression screen using a 
serum antibody generated against purified cholinergic synaptic vesicles. The second, EM 
localisation of synuclein fusion protein antibody staining in the vicinity of synaptic vesicles 
(Maroteaux et.al., 1988). Experiments also suggest that one form of the synuclein protein 
appears to be associated with the synaptosomal membrane (Maroteaux and Scheller, 1991) 
and may be inserted into the membrane after post translational modification.
Since the protein structure predicted from the analysis of cDNA clones most likely ruled 
out an enzymatic role for synuclein in nerve cells, it was postulated that the function of the 
protein was a functional or structural one (Maroteaux et.al., 1988). The repeats within the 
protein contain a conserved core which is also found in the rho gene family (Maroteaux 
et.al, 1988) which may indicate a role in cell signalling. Also the localisation of synuclein 
to the synaptic vesicles could indicate a role in the trafficking, docking and membrane 
fusion of synaptic vesicles. Synuclein expression co-localises with neurons using 
phosphoinositol (PI) and phospholipase C (PLC) as second messengers, and the form of 
synuclein associated with the synaptosomal membrane can be induced to return to the 
soluble form by phosphotidylinositol specific PLC. It is possible that activation of PLC 
after neuronal stimulation leads to solubilisation of synucleins, thus implicating synucleins 
in synaptic vesicles release and/or recycling (Maroteaux and Scheller, 1991). It is 
interesting that NCAP, a peptide fragment of a-synuclein, is an unusual protein in that it 
adopts an extended, non-globular conformation known as a "natively unfolded" random 
coil, in vitro. Such random coil domains promote protein-protein interactions and make
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the protein amyloidogenic in vitro (Weinreb et.al., 1996). As previously detailed Chapter 
1 the synaptic vesicle release system is comprised of many protein-protein interactions.
The discovery that a-synuclein, when mutated, predisposes with high probability to the 
development of PD in families with autosomal dominant disease, suggest that a structural 
abnormality of this protein, either by changing conformation or altering normal proteolytic 
processing, may be the initiating event for protein aggregation. Why this mutation gives 
rise to nerve cell death primarily within the substantia nigra is a question which remains 
unanswered.
a-synuclein represents a strong candidate for the gene containing the agu mutation. 
Synuclein is localised to the presynaptic nerve terminal, the area of the cell where the agu 
protein is thought to act (Section 7.3). Synuclein is associated with synaptic vesicles and 
is thought to play a role in trafficking, docking or membrane fusion of vesicles. There is, 
however, one major piece of evidence to suggest that a-synuclein is not the gene 
containing the agu mutation. The region of human chromosome thought to contain the agu 
mutation, by synteny with rat is chromosome 19ql3.4 and a-synuclein was shown to map 
to chromosome 4q21-q23 (Polymeropoulos et.al, 1996). However, there is a possibility 
that rearrangements have occurred within the human genome to breakdown the region of 
synteny. Also there may be as yet unidentified/un-mapped members of the synuclein gene 
family which may be contained in the correct region of rat chromosome 1. In fact, 
Southern blot analysis of rat genomic DNA indicated that there are at least three rat 
synuclein family members (Maroteaux and Scheller, 1991).
Another strong candidate gene suggested by genetic mapping data is synaptotagmin 3 
(Syt3) which maps to within 1.2 cM of the gene encoding PKCy on mouse chromosome 7 
(Stubbs et.al., 1996), the region syntenic to rat chromosome 1 which contains the agu 
gene. As detailed in Section 1.2.2 synaptotagmins are likely to function as Ca2+ sensors at 
the site of neurotransmitter exocytosis and are likely to trigger the final stage of the fusion 
of vesicles to the synaptic membrane. Therefore, the genetic location of synaptotagmin 3 
and the action of the protein makes this a strong candidate gene (Section 7.4.2.2).
PKC-y, a-synuclein and synaptotagmin 3 are all good candidates for the agu gene and will 
have to be eliminated before future studies are carried out.
7.4.2.2 Candidate genes identified from phenotypic analysis
The pharmacology presented in the AS/AGU rat (Section 7.3) suggests that the agu 
mutation leads to a reduction in the amount of dopamine being released from the 
presynaptic membrane. Neurosecretion is a complex, multistep process involving vesicle
149
biogenesis, neurotransmitter packaging, vesicle translocation and Ca2+ dependent vesicle 
fusion with the plasma membrane (Section 1.2.2). Proteins which are involved at any one 
of these steps could be considered a candidate to contain the agu mutation. As anticipated 
for a highly regulated, multistep pathway, the concerted action of a large number of gene 
products is required for neurosecretion. Genetic screens in C.elegans identified 
approximately 30 genes with presynaptic functions (Miller et.al., 1996). There are at least 
50 proteins currently known to be essential for trafficking in the exocytotic pathway in 
neurons (Martin, 1997) (Table 7.1). They could all be considered candidates to contain 
the agu mutation.
Translocatio Vesicle Unknown C . ATP- Late stages
n , proteins site o f elegans dependent prior to
cytoskeletal with action genes priming fusion
anchorage, uncharacteri
recruitment sed roles
of vesicles
kinesins,rab3s synaptophysin Rab3s, ric-1, ric-6 Ptdlns synaptobrevi
14-3-3s,actin, synaptoporin rabphillin, ric-7, ric-8 transfer ns,
myosin II SV2s, RabGDI, unc-10, proteins syntaxins,
,myosin light SCAMPs, MSS4, Doc- unc-26, (PEP3), SNAP-25s,
chain kinase, synaptogyrin, 2, Hrs-2, unc-7 Ptdlns 4- synaptotagmi
scinderin, pp60src, unc-41p, kinase, ns, CAPs.
synapsins, cysteine string unc-18p PtdIns4P-
CaM kinase II, proteins (muncl8, kinase
rabphillin nSecl, rop),
unc-13p, aex-
3p, rSec6,
annexins,
GAP-43,
neurexins,
VAP-33
(PEP1),
NSFs,
a/p/y-
SNAP
Table 7.1 Proteins involved in regulated exocytosis in the neuron. The
protein types are given as a heading to each column. Many of these proteins, indicated by 
plurals, are encoded by multiple genes. Ptdlns = phosphatidylinositol phosphate. 
Adapted from Miller (1997).
Both a-synuclein and synaptotagmin 3 fall into this category of candidate genes as well as 
those from genetic mapping, as they are also suggested by the phenotype of the AS/AGU 
rat (Section 7.3). a-synuclein represents a strong candidate for the gene containing the
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agu mutation. Synuclein is localised to the presynaptic nerve terminal, the area of the cell 
where the agu protein is thought to act (Section 7.3). Synuclein is associated with 
synaptic vesicles and is thought to play a role in protein interactions in trafficking, docking 
or membrane fusion of vesicles (Maroteaux and Scheller, 1991). Another good example is 
syntaxin; Drosophila with mutations in syntaxin reveal a complete absence of both evoked 
and spontaneous neurotransmitter release. Ultrastructural studies of syntaxin mutants 
show that vesicles appear normally docked at the active zone and that there is a significant 
increase in the number of docked vesicles (Broadie et.al., 1995). This suggests that in 
syntaxin mutants the absence of syntaxin impairs the ability of vesicles to undergo fusion.
7.4.3 Identification of the agu gene by genetic and physical mapping
If the above strategies do not identify the agu gene, then the conventional process of 
positional cloning will be instigated. There are two distinct steps within this final process; 
they are the definition of a precise genetic region containing the agu mutation, followed by 
investigation of genes expressed in this region.
The precise definition of the genetic region contained on a contig involves the detailed 
mapping of that contig with closely-linked genetic markers. To achieve this aim new 
microsatellite markers will be isolated from clones contained in the contig (as detailed in 
Chapter 3). Once these markers have been identified they can be used to map cross-over 
events which have occurred within the recombinant panel of backcross progeny 
established in Section 5.2.2. This will further refine the region for investigation. This 
will also allow the determination of the direction in which the chromosome walk should be 
carried out i.e. towards agu, by positioning agu on one side of the contig.
7.4.3.1 Establishing a new backcross with AS/AGU and DA
To achieve the fine mapping of a genetic interval a number of informative microsatellite 
markers must be identified. Some problems have been encountered in identifying 
informative markers in the rat strains used in this study (F344, BN and AS/AGU). 
Genetic map construction is significantly more difficult in the rat, than in the mouse in one 
important respect: genetic mapping in the mouse can exploit artificial laboratory crosses 
with different species that have SSLP polymorphism rates with laboratory strains of about 
90%, rather than intraspecific crosses in which the polymorphism rate is only about 50% 
(Jacobs et.al., 1995). An excellent example, is in the case of the interspecific backcross 
generated using M.musculus and M.spretus, utilised in our laboratory for mapping SSCPs 
(McCallion, 1997), where strain variations were found in > 90% of PCR products tested 
from the 3' UTR of mouse genes. A complete barrier to gene flow existed between the 
house mouse {M.musculus) and the aboriginal strain {M.spretus), two populations with
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overlapping ranges which do not breed - the definition of a species. However, in 1978, 
Bonhomme and his colleagues (Bonhomme et.al., 1978) reported the finding that 
M.spretus males and laboratory strain females could be bred in captivity to produce viable 
offspring of both sexes. Because similarly genetically unrelated rat strains are not 
available, only about half of the SSRs isolated are informative in any given mapping cross.
Initial analysis of polymorphism rates between the strains BN and F344 indicated an 
average of 68% across the genome (Shiels et.al, 1995), and AS/AGU differed from BN, 
F344 and PVG at 62%, 47% and 43% respectively. Strain BN has previously been 
shown to have the highest genetic divergence from all other inbred strains (Canzian, 
1997). However, there was concern with the low rates of strain variation in PCR products 
containing novel SSR markers identified from PI clones; no strain differences were 
observed in PCR products from eight SSR markers from the region surrounding PI clone 
K (Section 6.3, markers K100, K106 etc.). To allow fine mapping of the interval 
surrounding agu, contained in the genomic contig, a large number of informative markers 
must be identified from this region.
A project mapping markers on rat chromosome 1 was carried out by Ding and colleagues 
(Ding et.al., 1996) which utilised a rat cross between the inbred rat strains DA/Bkl and 
F344/Hsd. Polymorphism rates for SSR markers between the strains F344, LEW, BN 
and DA were assessed and polymorphism rates between F344/DA and BN/DA were 
72.5% and 77.5%, respectively for 40 markers tested. Markers reported by Ding and 
colleagues within the interval thought to contain agu were tested and proved to be non- 
informative between our rat strains (Canham, 1997). Three markers from 11 tested which 
were not polymorphic between the rat strains AS/AGU, F344 and BN, showed a 
polymorphism between DA and AS/AGU (DlArb33 = Ceal, Cgm4 = Cea4, Ding et.al, 
1996). However, strain DA was not informative when compared to AS/AGU for markers 
D1GU10 (Chapter 3) and DlMgh7 (Chapter 5 and Jacobs et.al., 1995) which were 
utilised in the present study.
A new backcross has been initiated between the strains DA and AS/AGU with progeny 
expected in February 1998. Although this backcross may not necessarily produce a higher 
polymorphism rate when compared to AS/AGU, it will still provide another rat strain in 
which microsatellite markers can be investigated for strain variation. It is hoped that this 
backcross will prove useful in fine mapping of the <1 cM region thought to contain agu, 
which entails the isolation and mapping of a large number of informative SSR markers 
from the interval.
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7.4.3.2 Expressed gene identification
Once this fine genetic mapping of the interval has been achieved and the agu gene has been 
identified to be contained on as few clones as possible then the process of expressed gene 
identification can be carried out. This can be carried out by two main processes; cDNA 
hybrid selection and exon trapping.
Once a region of genomic DNA cloned has been shown to contain the agu locus by fine 
mapping of the interval, an investigation will be carried out to identify candidate genes 
contained within this interval. Many techniques have been utilised to aid in the 
identification of transcribed sequences from particular genomic regions e.g. identification 
of CpG islands, zoo blots, screening cDNA libraries with genomic clones, direct 
sequencing and using genomic clones to identify a transcript in RNA on a Northern blot.
However, in recent years two techniques have become established as the most efficient and 
simple ways of identifying transcribed sequences from genomic regions. The first strategy 
was devised by Duyk e t.a l, (1990) and further developed by Buckler et.al. (1991) and 
involves the identification of exons from random pieces of genomic DNA and is known as 
exon trapping. In summary, genomic DNA is cloned into a vector that contains functional 
splice donor and acceptor sites and the clones are then propagated in E.coli and then 
transfected into COS cells. When the cloned DNA contains an exon, splicing occurs 
between the vector and the genomic DNA, RNA is then isolated from the cells, cDNA is 
synthesised and amplified using primers to the vector. A unique DNA fragment is 
therefore obtained where correct splicing has occurred. Theoretically this procedure 
should identify all internal exons from a region of interest and has been applied with good 
results (Chen et.al., 1996). However, it is technically complex and as it simply requires 
the presence of splice donor and acceptor sites, false positives can be encountered.
Recently, techniques which involve direct cDNA selection or "hybrid selection" have been 
devised. These methods employ the sensitivity of PCR with the specific selection of 
cDNAs by hybridisation to large genomic regions. This was first devised by Lovett et.al. 
(1991) and involves the hybridisation of an entire cDNA pool to an immobilised genomic 
clone. Genomic clone DNA was isolated, digested and immobilised onto nylon filter 
discs. cDNA inserts were amplified from an oligo d(T) cDNA library using primers 
designed to the library vector. The amplified inserts were preblocked with sheared total 
human DNA, yeast DNA and pBR322 DNA, this reduced non-specific hybridisation of 
repetitive elements, yeast and vector sequences. The blocked cDNA was then hybridised 
in solution with the filter containing the genomic DNA. Non-specific hybrids were 
removed, selected cDNAs were eluted, amplified with the primers used to amplify the
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cDNA at the onset and either cloned into a phage vector or subjected to further selection. 
More recently the technique has been improved by introducing better blocking efficiency, 
hybridisation in solution to better control hybridisation conditions and biotin/streptavidin 
capture on magnetic beads (Parimoo et.al., 1991, Korn et.al., 1992 and Morgan et.al., 
1994). The initial experiments were carried out using YAC genomic clones but the 
technique has been adapted to the use of PI, PAC, BAC and cosmid clones.
There are several advantages to hybrid selection: first it is rapidly carried out, second this 
method tends to normalise the frequency of the transcripts encoded by the genomic clone 
and has greater enrichment factors for rare transcripts than abundant ones. The abundant 
cDNAs will quickly saturate their genomic target, leaving the majority of cDNAs in 
solution. Thus the net result should be an approximate normalisation of the abundant 
cDNAs downwards and the low abundance transcripts upwards. Since the isolation of 
rare cDNAs is as important as the isolation of abundant ones, enrichment of these is a great 
advantage of this technique, as opposed to screening conventional libraries which may not 
even contain these transcripts. Third, it is more robust than screening with labelled probes 
and has a much higher signal to noise ratio mainly because it is easier to quench sequences 
by blocking to prevent non-specific hybridisation. Finally, it is also less sensitive to the 
size of the clone used for selection. Cosmid, BAC or PI DNA is better than YAC DNA 
because it is less prone to deletions, chimaerism and is readily separated from E.coli DNA.
There are a few limitations to hybrid selection: firstly, it is not suitable for retrieving 
complete coding sequences for genes, rather it provides a route to finding expressed 
sequence tags (ESTs) which can be used as probes to isolate the gene. Thus, screening a 
library is probably a second step in the process. Secondly, there is a problem with the co­
selection of pseudogenes, either transcribed or non-transcribed. Thirdly, it is limited when 
the transcription pattern of the gene of interest is unknown; cDNA from many different 
tissues or developmental stages may have to be tested.
The improvements in the cDNA hybrid selection method make this technique a rapid and 
feasible way of isolating transcribed sequences from genomic clones thought to contain the 
agu locus. This could be carried out with PAC clones currently under investigation. The 
sequencing of cDNAs encoded by the genomic interval under investigation would allow 
the identification of candidate genes for agu, which could then be sequenced in the rat 
strains AS and AS/AGU and the gene sequence compared to identify the mutation in 
AS/AGU.
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7.5 Future work - Do mutations in the agu gene lead to PD in man?
The obvious goal of the project is the identification of the gene containing the agu 
mutation. Once this has been established it is important to ascertain if this gene has any 
involvement in human Parkinson's disease. This is vital because not only could it provide 
an insight into susceptibility to PD, but could also validate the AS/AGU rat as a genetic 
model of human PD, a tool currently lacking in this field of research.
An assessment will have to be carried out if the agu gene is implicated in human PD. This 
should be a relatively simple task with probably no need for complicated linkage studies. 
Once the gene sequence has been identified in rat and then in man, the gene can be 
sequenced in many of the PD families identified (for example; Maragnore et.al., 1991, 
Golbe et.al., 1996, Denson et.al, 1997) to ascertain if any mutation is present in the 
affected individuals in these families.
Preliminary work has already been carried out on the involvement of the agu gene in 
human PD. When a region of human chromosome 19 was identified to contain the agu 
gene by nature of synteny with rat, genetic markers flanking this region were tested for 
linkage to PD in the large Contursi kindred, the kindred which was recently identified to 
contain a mutation in the a-synuclein gene thought to contribute to PD. No linkage was 
found between the markers and PD in this family (R.G. Sutcliffe, personal 
communication). However, this family is seen as a good example of early-onset families 
with PD characterised by a highly penetrant, autosomal dominant inheritance. These 
families account for only a small proportion of familial cases of PD and the majority of 
cases of PD are sporadic. Therefore, the agu gene may not be involved in PD within this 
family but may prove to be important in other PD families and sporadic cases. Also the 
protein produced from the agu gene may not itself produce human PD but may 
nevertheless, still be involved in the pathological process and is therefore still important. 
In either case the AS/AGU rat still provides a good model in which to study the pathology 
of neurodegeneration.
7.6 Concluding remarks
There still remains much work to be carried out before the gene containing the agu 
mutation can be identified, although many candidate genes have been suggested. Future 
work would involve the exclusion of these candidate genes as the agu gene. If this is 
successful and all candidates have been eliminated, then identification of transcribed 
sequences from cloned DNA will be carried out, presumably using cDNA hybrid 
selection. The cDNAs can then be sequenced to again identify candidate genes, which can
155
be sequenced in AS and AS/AGU to identify the agu mutation. To ascertain that the gene 
thought to contain the mutation is in fact the one mutated in AS/AGU, the gene can be 
introduced back into these rats to "rescue" the phenotype.
When the mutation has been identified sequencing can be carried out in man to ascertain 
the involvement of the agu gene in human PD. If this is confirmed then the AS/AGU rat 
could be used a model of human PD, and could be utilised in the elucidation of new 
treatment procedures and novel drugs to reduce the effects of Parkinson's disease.
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Appendices
Appendix 1 - Genotyping of F344 X AS/AGU backcross progeny with the marker 
GU10.
Animal number Phenotype Genotyping with 
marker GU10 
primers
Genotype at the 
GU10 locus
FI 15-95 W 2 P
FI 16-95 W 2 P
F127-95 w 2 P
F143-95 n 2 Recombinant
FI 54-95 w 2 P
F163-95 n 1 P
F179-95 w 2 P
F193-95 n 1 P
F197-95 ,U 1 P
FI 99-95 w 1 Recombinant
F200-95 1 P
F256-95 n 2 Recombinant
F257-95 n 1 P
F258-95 w 2 P
F259-95 n 1 P
F262-95 n 1 P
F277-95 M- 1 P
F297-95 w 2 P
F302-95 n 1 P
F310-95 n 2 Recombinant
F322-95 1 P
F331-95 n 1 P
F333-95 w 2 P
F344-95 w 2 P
F343-95 w 2 P
F344-95 w 2 P
F348-95 w 2 P
F367-95 n 1 P
F374-95 w 1 Recombinant
F383-95 n 2 Recombinant
178
F384-95 1 P
F387-95 W 2 P
F389-95 W 2 P
F390-95 1 P
F394-95 w 2 P
F397-95 w 2 P
F438-95 n 1 P
F440-95 V 1 P
F441-95 n 1 P
F442-95 n 1 P
F443-95 n 1 P
F444-95 1 P
F446-95 n 1 P
F448-95 w 2 P
F449-95 w 2 P
F450-95 w 2 P
F451-95 1 P
F453-95 w 2 P
F454-95 w 2 P
F455-95 1 P
F456-95 1 P
F457-95 w 1 Recombinant
F458-95 1 P
F459-95 1 P
F460-95 IA 1 P
F465-95 w P
F466-95 n 1 P
F469-95 1 P
F472-95 w 2 P
F485-95 w 2 P
F486-95 w 2 P
F487-95 w 2 P
F489-95 w 2 P
F490-95 w 2 P
F493-95 w 2 P
F494-95 |LA 1 P
F495-95 w 2 P
F498-95 w 2 P
179
F499-95 1 P
F500-95 W 2 P
F501-95 V 1 P
F511-95 M- 1 P
F512-95 1 P
F513-95 W 2 P
F514-95 4 1 P
F515-95 V 1 P
F516-95 W 2 P
F517-95 W 2 P
F518-95 4 1 P
F519-95 1 P
F520-95 W 2 P
F525-95 w 2 P
F526-95 w 2 P
F655-95 n 1 P
F656-95 w 2 P
F657-95 w 2 P
F660-95 w 2 P
F661-95 n 1 P
F663-95 w 2 P
F664-95 w 2 P
F666-95 w 2 P
F667-95 w 2 P
F668-95 w 2 P
F669-95 w 2 P
F671-95 M- 2 Recombinant
F672-95 4 1 P
F673-95 1 P
F674-95 2 Recombinant
F675-95 w 2 P
F676-95 4 1 P
F677-95 W 2 P
F678-95 n 1 P
F679-95 w 2 P
F680-95 n 1 P
F682-95 w 2 P
F683-95 11 1 P
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F684-95 W 2 P
F685-95 n 1 P
F686-95 w 2 P
F687-95 w 2 P
F692-95 w 2 P
F693-95 w 2 P
F694-95 n 1 P
F695-95 w 2 P
F696-95 w 2 P
F697-95 w 2 P
F698-95 n 1 P
F699-95 n 1 P
F700-95 M- 1 P
F701-95 1 P
F702-95 w 2 P
F703-95 w 2 P
F704-95 w 2 P
F705-95 w 2 P
F706-95 w 2 P
F707-95 1 P
F708-95 w 2 P
F709-95 w 2 P
F710-95 n 1 P
F711-95 n 1 P
F712-95 n 1 P
F729-95 w 2 P
F730-95 w 2 P
F732-95 1 P
F733-95 w 2 P
F734-95 w 2 P
F735-95 w 2 P
F736-95 w 2 P
F738-95 w 2 P
F748-95 w 2 P
F749-95 n 1 P
F750-95 1 P
F751-95 M- 1 P
F752-95 w 2 P
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F753-95 W 2 P
F754-95 W 2 P
F756-95 n 1 P
F757-95 w 2 P
F774-95 w 2 P
F775-95 w 2 P
F776-95 w 2 P
F777-95 w 2 P
F778-95 w 2 P
F779-95 w 1 Recombinant
F781-95 w 1 Recombinant
F782-95 w P
F783-95 n 1 P
F785-95 1 P
F786-95 w P
F795-95 n 1 P
F796-95 V 1 P
F797-95 w 2 P
F801-95 w 2 P
F802-95 w 2 P
F803-95 w 2 P
F804-95 w 2 P
F805-95 w 2 P
F806-95 w 2 P
F810-95 M- 2 Recombinant
F811-95 n 1 P
F812-95 w 2 P
F815-95 w 2 P
F822-95 n 1 P
F823-95 n 1 P
F824-95 w P
F825-95 n 1 P
F826-95 M- 1 P
F827-95 w P
F830-95 n 1 P
F831-95 n 1 P
F851-95 w 2 P
F852-95 w 2 P
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F853-95 W 2 P
F854-95 P 1 P
F855-95 W 2 P
F857-95 P 1 P
F859-95 P 1 P
F860-95 P 1 P
F862-95 P 1 P
F863-95 w 2 P
F864-95 w 2 P
F865-95 w 2 P
F866-95 w 2 P
F881-95 w 2 P
F882-95 p 1 P
F883-95 p 1 P
F885-95 p 1 P
F886-95 p 1 P
F887-95 p 1 P
F889-95 p 1 P
F890-95 p 1 P
F892-95 w 2 P
Table A .l  Genotyping data from m arker GU10 with progeny from the 
F344 X AS/AGU backcross. The first column indicates the animal number, the 
second the animal phenotype; W = wild type phenotype, p = indicates the mutant 
phenotype. The third column indicates the genotyping data from the primers specifiying 
the GU10 locus; with 2 indicating heterozygote (2 bands) and 1 indicating homozygote (1 
band). The final column indicates the genotype of the animal at the GU10 locus with P = 
parental allele at the locus (no cross-over between the agu and the GU10 locus) and 
Recombinant = indicating a recombinant allele (a cross-over event between the agu and the 
GU10 locus).
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Appendix 2 - Genotyping of BN X AS/AGU backcross progeny with the marker 
DlMgh7.
Anim al
num ber
Phenotype Genotype at 
D lM gh7 
locus
G enotype
127-94 W 1 Recom binant
128-94 W 1 Recom binant
129-94 n 1 P
130-94 \i 1 P
131-94 n 1 P
138-94 w 1 Recom binant
142-94 w 2 P
143-94 p 1 P
144-94 w 2 P
145-94 M- 1 P
146-94 n 2 Recom binant
147-94 w 2 P
149-94 w 2 P
150-94 p 1 P
181-94 w 2 P
183-94 w 2 P
184-94 w 2 P
185-94 w 2 P
186-94 w 2 P
187-94 n 1 P
188-94 n 1 P
189-94 w 2 P
190-94 n 1 P
191-94 w 2 P
193-94 w 2 P
195-94 w 2 P
196-94 w 1 R ecom binant
197-94 w 2 P
198-94 w 1 Recom binant
199-94 w 2 P
200-94 w 1 Recom binant
201-94 w 1 Recom binant
184
202-94 1 P
203-94 W 2 P
204-94 1 P
205-95 M- 2 Recom binant
206-94 2 Recom binant
207-94 M- 1 P
208-94 2 Recom binant
209-94 H 2 Recom binant
210-94 w 2 P
212-94 n 1 P
213-94 u 1 P
214-94 w 2 P
215-94 w 2 P
216-94 w 1 Recom binant
217-94 w 1 Recom binant
218-94 w 2 P
219-94 w 2 P
220-94 \l 2 Recom binant
222-94 2 Recom binant
223-94 u 1 P
232-94 w 2 P
239-94 n 1 P
240-94 w 2 P
241-94 w 1 Recom binant
242-94 n 2 Recom binant
243-94 w 1 Recom binant
244-94 n 2 Recom binant
245-94 u 2 Recom binant
246-94 w 2 P
247-94 11 2 Recom binant
248-94 M- 1 P
249-94 2 Recom binant
250-94 1 P
251-94 w 1 Recom binant
252-94 w 2 P
253-94 1 P
254-94 U 1 P
255-94 w 2 P
256-94 W 2 P
257-94 W 2 P
258-94 w 2 P
306-94 1* 1 P
309-94 w 2 P
314-94 1 P
317-94 II 1 P
325-95 n 1 P
329-94 M- 1 P
335-94 n 2 Recom binant
336-94 11 1 P
337-94 n 1 P
338-94 1 P
339-94 w 2 P
340-94 w 2 P
341-94 n 1 P
342-94 w 2 P
343-94 w 2 P
344-94 w 2 P
354-94 w 2 P
346-94 w 2 P
347-94 w 2 P
348-94 u 1 P
349-94 w 2 P
350-94 u 1 P
351-94 II 1 P
352-94 w 1 Recom binant
364-94 11 1 P
366-94 II 2 Recom binant
367-94 w 2 P
368-94 II 1 P
369-94 II 1 P
370-94 w 2 P
371-94 w 2 P
372-94 w 2 P
373-94 u 1 P
374-94 n 1 P
375-94 w 2 P
376-94 W 2 P
377-94 li 1 P
378-94 w 2 P
379-94 V- 1 P
380-94 w 2 P
381-94 11 2 Recom binant
382-94 n 1 P
383-94 11 1 P
384-94 11 1 P
385-94 n 1 P
386-94 w 2 P
387-94 w 2 P
388-94 ii 2 Recom binant
389-94 w 2 P
418-94 w 2 P
419-94 11 1 P
420-94 11 1 P
421-94 w 2 P
422-94 n 1 P
423-94 li 2 R ecom binant
424-94 w 2 P
425-94 w 2 P
426-94 n 2 Recom binant
427-94 ii 1 P
428-94 w 2 P
429-94 w 2 P
430-94 w 2 P
431-94 w 2 P
432-94 11 2 Recom binant
433-94 w 2 P
434-94 w 2 P
436-94 u 2 Recom binant
437-94 w 2 P
438-94 w 2 P
439-94 w 1 Recom binant
440-94 w 1 Recom binant
441-94 n 1 P
442-94 11 1 P
443-94 W 1 Recom binant
447-94 n 2 Recom binant
451-94 W 2 P
453-94 li 1 P
454-94 w 2 P
455-94 w 1 Recom binant
456-94 w 2 P
457-94 11 1 P
458-94 w 2 P
460-94 11 2 Recom binant
461-94 11 2 Recom binant
462-94 11 1 P
463-94 11 2 Recom binant
464-94 11 2 Recom binant
465-94 11 1 P
467-94 11 1 P
469-94 u 2 Recom binant
470-94 li 1 P
471-94 li 2 Recom binant
473-94 w 2 P
474-94 w 2 P
476-94 w 1 Recom binant
511-94 w 2 P
512-94 n 1 P
513-94 n 1 P
514-94 n 1 P
515-94 H 1 P
516-94 w 1 Recom binant
517-94 w 2 P
518-94 w 2 P
519-94 w 2 P
520-94 w 1 Recom binant
527-94 w 2 P
528-94 w 2 P
529-94 w 2 P
530-94 w 1 Recom binant
531-94 w 1 Recom binant
532-94 w 2 P
533-94 li 1 P
534-94 W 1 Recom binant
535-94 W 2 P
536-94 w 2 P
537-94 w 2 P
538-94 w 1 Recom binant
539-94 w 2 P
540-94 w 2 P
541-94 w 1 Recom binant
542-94 w 2 P
543-94 w 2 P
544-94 11 1 P
545-95 w 2 P
546-94 w 2 P
547-94 w 2 P
548-94 w 2 P
549-94 11 1 P
550-94 11 2 Recom binant
551-94 w 2 P
553-94 n 1 P
554-94 11 1 P
555-94 w 2 P
556-94 w 2 P
557-94 n 2 Recom binant
558-94 n 1 P
559-94 11 1 P
560-94 w 2 P
561-94 11 2 Recom binant
562-94 11 1 P
563-94 n 1 P
564-94 II 1 P
565-94 w 2 P
566-94 w 2 P
567-94 w 2 P
568-94 w 1 Recom binant
578-94 w 2 P
579-94 11 2 Recom binant
580-94 w 2 P
581-94 n 1 P
582-94 n 2 Recom binant
583-94 li 2 Recom binant
584-94 n 1 P
585-94 W 2 P
586-94 W 2 P
587-94 li 1 P
588-94 w 1 Recom binant
589-94 w 2 P
1-95 w 2 P
3-95 w 2 P
4-95 w 2 P
5-95 w 1 Recom binant
6-95 w 1 Recom binant
7-95 11 1 P
8-95 w 2 P
9-95 n 1 P
10-95 w 2 P
11-95 w 2 P
12-95 11 1 P
13-95 w 2 P
14-95 w 2 P
15-95 11 1 P
16-95 w 1 Recom binant
17-95 n 1 P
18-95 11 1 P
19-95 II 1 P
22-95 w 2 P
23-95 w 2 P
24-95 11 1 P
25-95 w 2 P
26-95 11 1 P
29-95 w 2 P
30-95 n 1 P
31-95 n 1 P
32-95 II 1 P
33-95 11 1 P
34-95 u 1 P
35-95 W 2 P
36-95 n 1 P
37-95 W 2 P
40-95 w 2 P
41-95 w 1 Recom binant
49-95 n 1 P
50-95 u 1 P
51-95 II 1 P
52-95 n 1 P
53-95 n 1 P
65-95 u 1 P
66-95 w 1 Recom binant
67-95 II 1 P
68-95 w 2 P
69-95 w 2 P
70-95 n 1 P
71-95 w 2 P
72-95 w 1 Recom binant
80-95 w 2 P
81-95 II 1 P
82-95 11 1 P
83-95 n 1 P
84-95 w 2 P
85-95 w 2 P
86-95 w 2 P
88-95 w 2 P
89-95 11 1 P
90-95 11 1 P
91-95 w 2 P
92-95 w 2 P
94-95 w 2 P
209-95 w 2 P
211-95 w 2 P
213-95 11 1 P
214-95 w 1 Recom binant
219-95 w 2 P
220-95 11 1 P
221-95 u 1 P
222-95 W 1 Recom binant
223-95 W 2 P
224-95 w 1 Recom binant
225-95 p 1 P
226-95 u 1 P
227-95 w 2 P
228-95 P 2 Recom binant
229-95 p 1 P
232-95 p 1 P
234-95 p 1 P
237-95 p 1 P
253-95 w 2 P
255-95 p 1 P
Table A .2 Genotyping data from m arker DlM gh7 with progeny from  the 
BN X AS/AGU backcross. The first column indicates the animal number, the second 
the animal phenotype; W = wild type phenotype, p = indicates the mutant phenotype. The 
third column indicates the genotyping data from the primers specifiying theDlMgh7 locus; 
with 2 indicating heterozygote (2 bands) and 1 indicating homozygote (1 band). The final 
column indicates the genotype of the animal at the DlMgh7 locus with P = parental allele at 
the locus (no cross-over between the agu and the DlMgh7 locus) and Recombinant = 
indicating a recombinant allele (a cross-over event between the agu and the DlMgh7 
locus).
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Appendix 3 - Genotyping of BN X AS/AGU backcross progeny with the marker F34.
Animal
num ber
Phenotype Genotype at 
F34 locus
G enotype
186-94 W 2 P
216-94 W 2 P
218-94 w 1 Recom binant
309-94 w 2 P
317-94 n 1 P
325-94 IT 2 Recom binant
329-94 IT 1 P
339-94 w 2 P
341-94 V 1 P
342-94 w 2 P
344-94 w 2 P
351-94 n 2 Recom binant
369-94 w 2 P
378-94 w 1 Recom binant
380-94 w 1 Recom binant
385-94 w 2 P
422-94 2 Recom binant
424-94 w 2 P
425-94 w 2 P
427-94 IT 1 P
428-94 w 1 Recom binant
430-94 w 1 Recom binant
431-94 w 1 Recom binant
432-94 I* 2 Recom binant
433-94 w 2 P
434-95 w 1 Recom binant
436-94 n 2 Recom binant
439-94 w 2 P
440-94 w 2 P
443-94 w 1 Recom binant
537-94 w 2 P
540-94 w 1 Recom binant
80-95 w 2 P
193
86-95 W 1 Recom binant
88-95 W P
90-95 p 1 P
209-95 W P
211-95 w 1 Recom binant
223-95 w 1 Recom binant
224-95 w 1 Recom binant
226-95 p 1 P
228-95 IT 1 P
232-95 P Recom binant
237-95 P 1 P
306-95 P 1 P
377-95 P Recom binant
383-95 P 1 P
548-95 w 1 Recom binant
Table A.3 Genotyping data from m arker F34 with progeny from  the BN X 
AS/AGU backcross. The first column indicates the animal number, the second the 
animal phenotype; W = wild type phenotype, ji = indicates the mutant phenotype. The 
third column indicates the genotyping data from the primers specifying the F34 locus; 
with 2 indicating heterozygote (2 bands) and 1 indicating homozygote (1 band). The final 
column indicates the genotype of the animal at the F34 locus with P = parental allele at the 
locus (no cross-over between the agu and the F34 locus) and Recombinant = indicating a 
recombinant allele (a cross-over event between the agu and the F34 locus).
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